[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Mercury Enterprises, Inc. dba Mercury Medical\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":386},{"warningLetters":4,"total":385},[5,30,54,73,93,113,133,155,177,201,220,238,253,271,287,305,325,348,367],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":29,"medical_device_id":19,"response_letter_date":19},812,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2025-06-24T04:00:00Z\">06\u002F24\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-04-22T04:00:00Z\">04\u002F22\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmom-enterprises-llc-698651-04222025\">M.O.M. Enterprises, LLC\u003C\u002Fa>","Human Foods Program","CGMP\u002FDietary Supplement\u002FAdulterated\u002FMisbranded","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Yasmin S. Kaderali\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner and CEO \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>M.O.M. Enterprises, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1001 Canal Boulevard, Suite C\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Richmond\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>94804\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Ykaderali@mommysbliss.com\"> Ykaderali@mommysbliss.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Human Foods Program\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>April 22, 2025&nbsp;\u003C\u002Fp>\u003Cp>RE: CMS 698651\u003C\u002Fp>\u003Cp>Dear Ms. Kaderali:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) conducted an inspection of your dietary supplement facility located at 1001 Canal Boulevard, Suite C, Richmond, California 94804, from August 19 through September 27, 2024. Based on inspectional findings and a review of your product labels collected during the inspection, as well as a review of your firm’s website, www.mommysbliss.com, we identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You may find the Act and FDA regulations through links on FDA's home page at www.fda.gov.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection on September 27, 2024, our investigator provided your firm with a Form FDA 483, Inspectional Observations (FDA 483). We acknowledge receipt of your responses dated October 17 and November 22, 2024, and January 10, 2025; we address your responses below.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Adulterated Dietary Supplements\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The inspection of your facility from August 19 through September 27, 2024, identified serious violations of FDA’s regulations for current Good Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, under Title 21 of the Code of Federal Regulations, Part 111 (21 CFR 111). These violations cause your dietary supplement products Gripe Water Original, Gripe Water Night Time, Kids Cough Syrup &amp; Mucus + Immunity Support, and Kids Cough Syrup &amp; Mucus Night Time (including such product in the Day + Night Combo Packs) to be adulterated within the meaning of section 402(g)(1) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 342(g)(1)] because they have been prepared, packed, or held under conditions that do not meet cGMP requirements for dietary supplements.\u003C\u002Fp>\u003Cp>Your significant violations of the cGMP requirements are as follows:\u003C\u002Fp>\u003Cp>1. You failed to extend the review and investigation of a product complaint to all relevant batchesand records, as required by 21 CFR 111.560(c).\u003C\u002Fp>\u003Cp>You initiated a market withdrawal of eight lots of Kids Cough Syrup &amp; Mucus + ImmunitySupport, Kids Cough Syrup &amp; Mucus Night Time, Baby Cough Syrup &amp; Mucus + ImmunitySupport, and Baby Cough Syrup &amp; Mucus Nighttime, including those in the Day + Night Combo Packs, on April 19, 2023, after your contract manufacturer notified you of early spoilage in these products. You reformulated the product to include the addition of glycerin to lower the water activity and also lowered the pH of the products, but your investigation did not extend to all relevant batches and records. After your firm initiated the market withdrawal, you received at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> complaints from September 2023 through May 2024, in which complainants described bulging bottles of product and product where the lids popped off, including \u003Cstrong>(b)(4)\u003C\u002Fstrong> complaints for Kids Cough Syrup &amp; Mucus Night Time, Lot Number \u003Cstrong>(b)(4)\u003C\u002Fstrong>, EXP 03\u002F25, which lot was not included in your market withdrawal. For example, complaint #\u003Cstrong>(b)(4)\u003C\u002Fstrong>, received on December 1, 2023, for Kids Cough Syrup &amp; Mucus Night Time, lot number \u003Cstrong>(b)(4)\u003C\u002Fstrong>, stated that “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and described “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” Relating to this complaint, your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” states, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>. The product has since reformulated the product [\u003Cem>sic\u003C\u002Fem>].” Your investigation, however, does not explain how such reformulation would have addressed the issue relating to bulging product bottles and product packaging that popped open, nor did it address the concerns relating to this specific lot that had not been withdrawn from the market.\u003C\u002Fp>\u003Cp>In your October 17, 2024, response, you indicate the mold complaints were not new problems and were part of a previously investigated issue. However, your response does not explain how you determined that the issues were connected to complaints you received subsequent to the market withdrawal. You did not conduct additional investigations of these complaints to determine whether additional lots of product were affected by the known spoilage issue to determine if additional corrective actions were needed, even though your complaint records correlate these complaints to your market withdrawal.\u003C\u002Fp>\u003Cp>2. You failed to follow written procedures for the requirements to review and investigate all product complaints, as required by 21 CFR 111.553. Your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” procedure, revision date March 14, 2019, SOP #\u003Cstrong>(b)(4)\u003C\u002Fstrong>, and your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” procedure, effective date July 1, 2022, QA-1009, both require your quality control manager to review complaints to determine whether the complaint involves a possible failure of a dietary supplement to meet any of its specifications, and to review and approve decisions to investigate complaints and any findings and follow up actions, in accordance with 21 CFR 111.560(a) and 21 CFR 111.560(b). However, a review of complaints you received from December 2019 through August 2024 revealed complaints that were not investigated. For example:\u003C\u002Fp>\u003Cp>a. Complaints received for your Gripe Water Original and Gripe Water Night Time under the category “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” revealed there were \u003Cstrong>(b)(4)\u003C\u002Fstrong> complaints that were not investigated, \u003Cstrong>(b)(4)\u003C\u002Fstrong> of which met the criteria for a serious adverse event.\u003C\u002Fp>\u003Cp>b. Complaints received for your Gripe Water Original and Gripe Water Night Time under the category “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” revealed at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> complaints that were not investigated. Of these \u003Cstrong>(b)(4)\u003C\u002Fstrong> complaints, \u003Cstrong>(b)(4)\u003C\u002Fstrong> were resolved as “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” with no further action documented.\u003C\u002Fp>\u003Cp>In your October 17, 2024, response, you committed to updating your \u003Cstrong>(b)(4)\u003C\u002Fstrong> procedure and conducting a retrospective review of all complaints received from 2019-2024 to ensure all are fully investigated and completely documented. You also indicated that any complaints that are determined to be a serious adverse event will be reported per your revised \u003Cstrong>(b)(4)\u003C\u002Fstrong> procedure, and that you will conduct retraining of your employees on the revised procedure, as well as perform monthly monitoring of your firm’s compliance with the revised procedure.\u003C\u002Fp>\u003Cp>In your response dated November 22, 2024, you provided a copy of your revised \u003Cstrong>(b)(4)\u003C\u002Fstrong> procedure and stated that your employee retraining was completed on November 20, 2024. You also indicated your retrospective review of complaints is in-progress. As your corrective actions are still in progress, we cannot evaluate the adequacy of your corrections at this time.\u003C\u002Fp>\u003Cp>3. You failed to comply with the requirements for records of product complaints in 21 CFR111.570. Specifically, written records of product complaints that are related to good manufacturing practice must include the findings of the investigation and follow-up action taken when an investigation is performed [21 CFR 111.570(b)(2)(ii)(F)]. However, a review of your electronic consumer complaint records revealed your complaint records, in which your Quality Manager stated that \u003Cstrong>(b)(4)\u003C\u002Fstrong>. For example, complaint #\u003Cstrong>(b)(4)\u003C\u002Fstrong>, received October 4, 2021, in which the complainant described their baby turning blue after administering Gripe Water Night Time, your electronic record indicates the quality investigation is completed. However, you were unable to provide documentation pertaining to the quality review and investigation of this complaint.\u003C\u002Fp>\u003Cp>In your initial response, you committed to revising your \u003Cstrong>(b)(4)\u003C\u002Fstrong> procedure and including a detailed template which will be designed to capture all required steps and follow-up actions for complaint investigations. You provided FDA with this revised procedure and the consumer complaint investigation form. We will evaluate the adequacy of this corrective action during our next inspection of your firm.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Failure to Submit a Serious Adverse Event Report\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to submit a Serious Adverse Event Report (SAER) for a dietary supplement within 15 business days after receiving a report about the adverse event, as required by section 761(c) of the Act [21 U.S.C. 379aa-1(c)]. Specifically, you received reports of at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> serious adverse events between December 2019 and August 2024, but did not submit a SAER as required. For example, our inspection found you received reports of infants choking, infants that stopped breathing, and infants that were admitted to the hospital after being administered your Gripe Water Original products. For example:\u003C\u002Fp>\u003Cp>a. On January 19, 2021, you received a complaint (#\u003Cstrong>(b)(4)\u003C\u002Fstrong>) in which the complainant described giving their two-month-old baby Gripe Water Original on January 12, 2021, and a second dose on January 13, 2021, when they noticed he had a fever of 101.8 degrees. The complainant explained they called the local emergency room which advised the complainant to bring the baby to the hospital. The complainant explained their baby was sent to a bigger hospital where additional tests, including blood work and a spinal tap were performed and he was admitted to the hospital where he stayed until January 17, 2021. Per the complainant, the tests were positive for E. coli, although the complainant reported the hospital could not tell them what caused the infection.\u003C\u002Fp>\u003Cp>b. On October 7, 2021, you received a complaint (#\u003Cstrong>(b)(4)\u003C\u002Fstrong>) in which the complainant described their daughter was born prematurely, they used Gripe Water Original and the infant vomited and was taken to the emergency room. The complainant further explained the infant “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.”\u003C\u002Fp>\u003Cp>c. On October 15, 2021, you received a complaint (#\u003Cstrong>(b)(4)\u003C\u002Fstrong>) in which the complainant described their six-week-old infant choked on Gripe Water Original. Per your complaint record, the complainant explained their infant “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” Your complaint record further explains the complainant attempted cardiopulmonary resuscitation (CPR) multiple times until the infant began breathing again. The complainant also reported that paramedics were called and looked over their infant.\u003C\u002Fp>\u003Cp>d. On March 30, 2022, you received a complaint (#\u003Cstrong>(b)(4)\u003C\u002Fstrong>) in which the complainant gave their baby Gripe Water Original and the baby “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” The complainant further explained they were “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.”\u003C\u002Fp>\u003Cp>e. On May 4, 2023, you received a complaint (#\u003Cstrong>(b)(4)\u003C\u002Fstrong>) in which the complainant described giving their baby Gripe Water Original and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.”\u003C\u002Fp>\u003Cp>f. On July 30, 2024, you received a complaint (#\u003Cstrong>(b)(4)\u003C\u002Fstrong>) in which the complainant described their child choking on Gripe Water Original on two different occasions. The complainant explained they gave their two-month-old some Gripe Water Original, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.”\u003C\u002Fp>\u003Cp>Under section 761(c) of the Act, you must submit a report of a serious adverse event associated with any of your dietary supplements no later than fifteen (15) business days after a report of the event is received through the address or phone number provided on your dietary supplement products.\u003C\u002Fp>\u003Cp>Because prompt submission of such serious adverse event reports is important for public health reasons, the agency recommends that all serious adverse events be reported to FDA within fifteen (15) business days of receipt regardless of the means by which you receive the initial report. These serious adverse event reports should be submitted under the MedWatch Form 3500A. More information on adverse event reporting can be found on FDA’s website at www.fda.gov, in the publication “Questions and Answers Regarding Adverse Event Reporting and Recordkeeping for Dietary Supplements as required by the Dietary Supplement and Nonprescription Drug Consumer Protection Act.”\u003C\u002Fp>\u003Cp>In your written response letters, with respect to the observation relating to serious adverse event reporting, you provided a revised \u003Cstrong>(b)(4)\u003C\u002Fstrong> procedure and complaint investigation form that appear to provide adequate details for assessing the severity of the adverse events. You also committed to conducting a retrospective review of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> complaints identified during our inspection as reportable events using your revised \u003Cstrong>(b)(4)\u003C\u002Fstrong> procedure and reporting any complaints that are deemed reportable.\u003C\u002Fp>\u003Cp>In your October 17, 2024, response, you quote from the guidance “Questions and Answers Regarding Adverse Event Reporting and Recordkeeping for Dietary Supplements as required by the Dietary Supplement and Nonprescription Drug Consumer Protection Act” and explain that you interpreted the FDA guidance as stating the details of the event come from the perspective of trained health care professionals. However, FDA’s guidance clearly states, as quoted in your response, “[W]e encourage responsible persons to use trained health care practitioners to elicit information from reporters, computer-assisted interview technology, targeted questionnaires, and\u002For other appropriate methods that help focus the line of questioning.” It does not appear that your firm was using either trained healthcare professionals, computer-assisted interview technology, targeted questionnaires, or other methods that would help focus the line of questioning; your \u003Cstrong>(b)(4)\u003C\u002Fstrong> procedure required customer service representatives to determine whether a complaint required escalation as an adverse event or serious adverse event. It is not a requirement that the details of events come from trained healthcare professionals; it does not require “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” as stated in your response. In fact, the guidance defines an initial reporter as the person who first notifies the responsible person about the serious adverse event and “can be the patient, a family member, or some other person (e.g., doctor, pharmacist).”\u003C\u002Fp>\u003Cp>According to your November 22, 2024, response, as a result of your retrospective review of the complaints identified during our inspection, you are in the process of reporting \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the complaints to FDA as SAERs, and are re-opening the remaining complaints for one year in order to try and gather additional information needed for reporting the SAERs. Per your response, you have concluded these remaining complaints are also qualifying events per your procedure, but do not have complete data elements.\u003C\u002Fp>\u003Cp>Of the remaining complaints that you identified as qualifying events, the missing data element for many of these complaints is listed as “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” However, per the complaint records reviewed during our inspection, the product name is identified as Gripe Water Original for each of these complaints. It is unclear why the complaint records reviewed during our inspection identified the product as “Gripe Water Original” for each of these complaints, but your retrospective review has now determined the complainant didn’t specify the product.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Misbranded Dietary Supplements\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>1. Your Gripe Water, Gripe Water Night Time, and Kids Cough Syrup &amp; Mucus Day + Night Combo Pack products are misbranded within the meaning of section 403(q)(5)(F) [21 U.S.C. 343(q)(5)(F)] in that the presentation of the nutrition information on the labeling of your products does not comply with 21 CFR 101.9, 21 CFR 101.36, and 21 CFR 101.2. For example:\u003C\u002Fp>\u003Cp>a. The product’s inner bottle labels do not bear nutrition information, as required by 21 CFR 101.36. The unit container is exempted from these requirements if the unit container bears the statement “This Unit Not Labeled for Retail Sale” [21 CFR 1.24(a)(24)].\u003C\u002Fp>\u003Cp>b. The dosage guide and\u002For directions for use are placed above the Supplement Facts label, which is not in accordance with 21 CFR 101.2(a) and (e). Nutrition information should appear on the principal display panel (PDP) or directly to the right of the PDP with no intervening material in between.\u003C\u002Fp>\u003Cp>c. For your Gripe Water Night Time and Kids Cough Syrup &amp; Mucus Day + Night Combo Pack, the serving size in the Supplement Facts labels fails to be declared as required by 21 CFR 101.36(b)(1)(i). Serving size must be expressed in common household measures as set forth in 21 CFR 101.9(b) and must be followed by the equivalent metric quantity in parenthesis (fluids in milliliters and all other foods in grams).\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved New Drug\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA reviewed your website at the internet address www.mommysbliss.com in December 2024 and determined that you take orders there for your Gripe Water Original. The claims on your website establish that your product Gripe Water Original is a drug under section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)] because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act. Thus, in addition to being an adulterated and misbranded dietary supplement, your Gripe Water Original is also an unapproved new drug under section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)].\u003C\u002Fp>\u003Cp>Examples of some of the claims that provide evidence that your Gripe Water Original product is intended for use as a drug include:\u003C\u002Fp>\u003Cp>From the blog post on your website: Acid Reflux = The Pits – Mommy's Bliss\u003C\u002Fp>\u003Cp>• &nbsp;“Acid reflux, also known as gastroesophageal reflux or GER, is when acids and content of the stomach come back up into the baby’s esophagus. It happens because the lower esophageal sphincter isn’t fully developed. . . .[I]f [a baby’s esophageal sphincter] fails to develop correctly or becomes weak, a baby may develop GERD (gastroesophageal reflux disease) which has more severe complications. . . .\u003C\u002Fp>\u003Cp>How do you know if your baby has acid reflux?&nbsp;&nbsp;\u003Cbr>The symptoms of acid reflux are typically clear and easy to read….&nbsp;\u003C\u002Fp>\u003Cp>1. Frequent Vomiting….2. Irritability….The acid of the digestive juices irritates the stomach and esophagus….3. Persistent Coughing or Wheezing….There is a link between acid reflux, wheezing, coughing, and even asthma….5. Colic The persistent crying of a colicky baby could be a symptom of reflux. The irritation of the stomach and the esophagus from all those digestive juices may trigger your baby into colic….How do you help a baby with acid reflux?....&nbsp;\u003C\u002Fp>\u003Cp>Try Gripe Water&nbsp;\u003C\u002Fp>\u003Cp>Gripe water can also be a great way to ease symptoms of acid reflux in infants. It is a natural approach to help reduce the stomach acid that causes pain. . . .&nbsp;\u003C\u002Fp>\u003Cp>Mommy’s Bliss Gripe Water is a safe and gentle way to help ease your baby’s stomach discomfort. The organic ginger and fennel relieve the irritation and prevent the stomach acid from flowing up into the esophagus. Fennel is known for its ability to reduce inflammation and acid in the stomach while ginger’s phenolic compounds help relieve irritation and reduce gastric contractions.”\u003C\u002Fp>\u003Cp>Additionally, your blog post titled “Acid Reflux = The Pits,” in discussing the “link between acid reflex, wheezing, and coughing,” links to an article from the Mayo Clinic article entitled “Asthma and acid reflux: Are they linked?” (Asthma and acid reflux: Are they linked? - Mayo Clinic). This link from your blog further suggests that your Mommy’s Bliss Gripe Water Original is intended for the cure, mitigation, treatment, or prevention of GERD and asthma.\u003C\u002Fp>\u003Cp>Your product is not generally recognized as safe and effective for the above referenced uses and, therefore, the product is a “new drug” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Misbranded Drug\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safety and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\u003Cp>Your Gripe Water Original is intended for treatment or prevention of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purpose. Accordingly, Gripe Water Original fails to bear adequate directions for its intended use and, therefore, the product is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. 331(a)].\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within fifteen (15) working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Your written response should be sent to Jamie M. Bumpas, Compliance Officer, U.S. Food and Drug Administration, Human Foods Program, Office of Enforcement, 5001 Campus Drive, College Park, Maryland 20740-3835, or via email at HFP-OCE-DietarySupplements@fda.hhs.gov. If you have any questions, you may email us at HFP-OCE-DietarySupplements@fda.hhs.gov. Please reference CMS #698651 on any submissions and within the subject line of any \u003Ca>emails.\u003C\u002Fa>\u003C\u002Fp>\u003Cp>Sincerely,&nbsp;\u003C\u002Fp>\u003Cp>\u002FS\u002F&nbsp;\u003Cbr>Laura Akowuah, JD, MPH&nbsp;&nbsp;\u003Cbr>Acting Director, Office of Enforcement&nbsp;&nbsp;\u003Cbr>Office of Compliance and Enforcement&nbsp;&nbsp;\u003Cbr>Human Foods Program&nbsp;&nbsp;\u003Cbr>U.S. Food and Drug Administration\u003Cbr>&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nYasmin S. Kaderali\n\nRecipient Title\n\nOwner and CEO\n\nM.O.M. Enterprises, LLC\n\n1001 Canal Boulevard, Suite C\n\nRichmond, CA 94804\n\nUnited States\n\nYkaderali@mommysbliss.com\n\nIssuing Office:\n\nHuman Foods Program\n\nUnited States\n\nWARNING LETTER\nApril 22, 2025\nRE: CMS 698651\nDear Ms. Kaderali:\nThe U.S. Food and Drug Administration (FDA) conducted an inspection of your dietary supplement facility located at 1001 Canal Boulevard, Suite C, Richmond, California 94804, from August 19 through September 27, 2024. Based on inspectional findings and a review of your product labels collected during the inspection, as well as a review of your firm’s website, www.mommysbliss.com, we identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You may find the Act and FDA regulations through links on FDA's home page at www.fda.gov.\nAt the conclusion of the inspection on September 27, 2024, our investigator provided your firm with a Form FDA 483, Inspectional Observations (FDA 483). We acknowledge receipt of your responses dated October 17 and November 22, 2024, and January 10, 2025; we address your responses below.\nAdulterated Dietary Supplements\nThe inspection of your facility from August 19 through September 27, 2024, identified serious violations of FDA’s regulations for current Good Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, under Title 21 of the Code of Federal Regulations, Part 111 (21 CFR 111). These violations cause your dietary supplement products Gripe Water Original, Gripe Water Night Time, Kids Cough Syrup & Mucus + Immunity Support, and Kids Cough Syrup & Mucus Night Time (including such product in the Day + Night Combo Packs) to be adulterated within the meaning of section 402(g)(1) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 342(g)(1)] because they have been prepared, packed, or held under conditions that do not meet cGMP requirements for dietary supplements.\nYour significant violations of the cGMP requirements are as follows:\n1. You failed to extend the review and investigation of a product complaint to all relevant batchesand records, as required by 21 CFR 111.560(c).\nYou initiated a market withdrawal of eight lots of Kids Cough Syrup & Mucus + ImmunitySupport, Kids Cough Syrup & Mucus Night Time, Baby Cough Syrup & Mucus + ImmunitySupport, and Baby Cough Syrup & Mucus Nighttime, including those in the Day + Night Combo Packs, on April 19, 2023, after your contract manufacturer notified you of early spoilage in these products. You reformulated the product to include the addition of glycerin to lower the water activity and also lowered the pH of the products, but your investigation did not extend to all relevant batches and records. After your firm initiated the market withdrawal, you received at least (b)(4) complaints from September 2023 through May 2024, in which complainants described bulging bottles of product and product where the lids popped off, including (b)(4) complaints for Kids Cough Syrup & Mucus Night Time, Lot Number (b)(4), EXP 03\u002F25, which lot was not included in your market withdrawal. For example, complaint #(b)(4), received on December 1, 2023, for Kids Cough Syrup & Mucus Night Time, lot number (b)(4), stated that “(b)(4)” and described “(b)(4).” Relating to this complaint, your “(b)(4)” states, “(b)(4). The product has since reformulated the product [sic].” Your investigation, however, does not explain how such reformulation would have addressed the issue relating to bulging product bottles and product packaging that popped open, nor did it address the concerns relating to this specific lot that had not been withdrawn from the market.\nIn your October 17, 2024, response, you indicate the mold complaints were not new problems and were part of a previously investigated issue. However, your response does not explain how you determined that the issues were connected to complaints you received subsequent to the market withdrawal. You did not conduct additional investigations of these complaints to determine whether additional lots of product were affected by the known spoilage issue to determine if additional corrective actions were needed, even though your complaint records correlate these complaints to your market withdrawal.\n2. You failed to follow written procedures for the requirements to review and investigate all product complaints, as required by 21 CFR 111.553. Your “(b)(4)” procedure, revision date March 14, 2019, SOP #(b)(4), and your “(b)(4)” procedure, effective date July 1, 2022, QA-1009, both require your quality control manager to review complaints to determine whether the complaint involves a possible failure of a dietary supplement to meet any of its specifications, and to review and approve decisions to investigate complaints and any findings and follow up actions, in accordance with 21 CFR 111.560(a) and 21 CFR 111.560(b). However, a review of complaints you received from December 2019 through August 2024 revealed complaints that were not investigated. For example:\na. Complaints received for your Gripe Water Original and Gripe Water Night Time under the category “(b)(4)” revealed there were (b)(4) complaints that were not investigated, (b)(4) of which met the criteria for a serious adverse event.\nb. Complaints received for your Gripe Water Original and Gripe Water Night Time under the category “(b)(4),” “(b)(4),” and “(b)(4)” revealed at least (b)(4) complaints that were not investigated. Of these (b)(4) complaints, (b)(4) were resolved as “(b)(4)” with no further action documented.\nIn your October 17, 2024, response, you committed to updating your (b)(4) procedure and conducting a retrospective review of all complaints received from 2019-2024 to ensure all are fully investigated and completely documented. You also indicated that any complaints that are determined to be a serious adverse event will be reported per your revised (b)(4) procedure, and that you will conduct retraining of your employees on the revised procedure, as well as perform monthly monitoring of your firm’s compliance with the revised procedure.\nIn your response dated November 22, 2024, you provided a copy of your revised (b)(4) procedure and stated that your employee retraining was completed on November 20, 2024. You also indicated your retrospective review of complaints is in-progress. As your corrective actions are still in progress, we cannot evaluate the adequacy of your corrections at this time.\n3. You failed to comply with the requirements for records of product complaints in 21 CFR111.570. Specifically, written records of product complaints that are related to good manufacturing practice must include the findings of the investigation and follow-up action taken when an investigation is performed [21 CFR 111.570(b)(2)(ii)(F)]. However, a review of your electronic consumer complaint records revealed your complaint records, in which your Quality Manager stated that (b)(4). For example, complaint #(b)(4), received October 4, 2021, in which the complainant described their baby turning blue after administering Gripe Water Night Time, your electronic record indicates the quality investigation is completed. However, you were unable to provide documentation pertaining to the quality review and investigation of this complaint.\nIn your initial response, you committed to revising your (b)(4) procedure and including a detailed template which will be designed to capture all required steps and follow-up actions for complaint investigations. You provided FDA with this revised procedure and the consumer complaint investigation form. We will evaluate the adequacy of this corrective action during our next inspection of your firm.\nFailure to Submit a Serious Adverse Event Report\nYou failed to submit a Serious Adverse Event Report (SAER) for a dietary supplement within 15 business days after receiving a report about the adverse event, as required by section 761(c) of the Act [21 U.S.C. 379aa-1(c)]. Specifically, you received reports of at least (b)(4) serious adverse events between December 2019 and August 2024, but did not submit a SAER as required. For example, our inspection found you received reports of infants choking, infants that stopped breathing, and infants that were admitted to the hospital after being administered your Gripe Water Original products. For example:\na. On January 19, 2021, you received a complaint (#(b)(4)) in which the complainant described giving their two-month-old baby Gripe Water Original on January 12, 2021, and a second dose on January 13, 2021, when they noticed he had a fever of 101.8 degrees. The complainant explained they called the local emergency room which advised the complainant to bring the baby to the hospital. The complainant explained their baby was sent to a bigger hospital where additional tests, including blood work and a spinal tap were performed and he was admitted to the hospital where he stayed until January 17, 2021. Per the complainant, the tests were positive for E. coli, although the complainant reported the hospital could not tell them what caused the infection.\nb. On October 7, 2021, you received a complaint (#(b)(4)) in which the complainant described their daughter was born prematurely, they used Gripe Water Original and the infant vomited and was taken to the emergency room. The complainant further explained the infant “(b)(4).”\nc. On October 15, 2021, you received a complaint (#(b)(4)) in which the complainant described their six-week-old infant choked on Gripe Water Original. Per your complaint record, the complainant explained their infant “(b)(4).” Your complaint record further explains the complainant attempted cardiopulmonary resuscitation (CPR) multiple times until the infant began breathing again. The complainant also reported that paramedics were called and looked over their infant.\nd. On March 30, 2022, you received a complaint (#(b)(4)) in which the complainant gave their baby Gripe Water Original and the baby “(b)(4).” The complainant further explained they were “(b)(4).”\ne. On May 4, 2023, you received a complaint (#(b)(4)) in which the complainant described giving their baby Gripe Water Original and “(b)(4).”\nf. On July 30, 2024, you received a complaint (#(b)(4)) in which the complainant described their child choking on Gripe Water Original on two different occasions. The complainant explained they gave their two-month-old some Gripe Water Original, “(b)(4).”\nUnder section 761(c) of the Act, you must submit a report of a serious adverse event associated with any of your dietary supplements no later than fifteen (15) business days after a report of the event is received through the address or phone number provided on your dietary supplement products.\nBecause prompt submission of such serious adverse event reports is important for public health reasons, the agency recommends that all serious adverse events be reported to FDA within fifteen (15) business days of receipt regardless of the means by which you receive the initial report. These serious adverse event reports should be submitted under the MedWatch Form 3500A. More information on adverse event reporting can be found on FDA’s website at www.fda.gov, in the publication “Questions and Answers Regarding Adverse Event Reporting and Recordkeeping for Dietary Supplements as required by the Dietary Supplement and Nonprescription Drug Consumer Protection Act.”\nIn your written response letters, with respect to the observation relating to serious adverse event reporting, you provided a revised (b)(4) procedure and complaint investigation form that appear to provide adequate details for assessing the severity of the adverse events. You also committed to conducting a retrospective review of the (b)(4) complaints identified during our inspection as reportable events using your revised (b)(4) procedure and reporting any complaints that are deemed reportable.\nIn your October 17, 2024, response, you quote from the guidance “Questions and Answers Regarding Adverse Event Reporting and Recordkeeping for Dietary Supplements as required by the Dietary Supplement and Nonprescription Drug Consumer Protection Act” and explain that you interpreted the FDA guidance as stating the details of the event come from the perspective of trained health care professionals. However, FDA’s guidance clearly states, as quoted in your response, “[W]e encourage responsible persons to use trained health care practitioners to elicit information from reporters, computer-assisted interview technology, targeted questionnaires, and\u002For other appropriate methods that help focus the line of questioning.” It does not appear that your firm was using either trained healthcare professionals, computer-assisted interview technology, targeted questionnaires, or other methods that would help focus the line of questioning; your (b)(4) procedure required customer service representatives to determine whether a complaint required escalation as an adverse event or serious adverse event. It is not a requirement that the details of events come from trained healthcare professionals; it does not require “(b)(4)” as stated in your response. In fact, the guidance defines an initial reporter as the person who first notifies the responsible person about the serious adverse event and “can be the patient, a family member, or some other person (e.g., doctor, pharmacist).”\nAccording to your November 22, 2024, response, as a result of your retrospective review of the complaints identified during our inspection, you are in the process of reporting (b)(4) of the complaints to FDA as SAERs, and are re-opening the remaining complaints for one year in order to try and gather additional information needed for reporting the SAERs. Per your response, you have concluded these remaining complaints are also qualifying events per your procedure, but do not have complete data elements.\nOf the remaining complaints that you identified as qualifying events, the missing data element for many of these complaints is listed as “(b)(4).” However, per the complaint records reviewed during our inspection, the product name is identified as Gripe Water Original for each of these complaints. It is unclear why the complaint records reviewed during our inspection identified the product as “Gripe Water Original” for each of these complaints, but your retrospective review has now determined the complainant didn’t specify the product.\nMisbranded Dietary Supplements\n1. Your Gripe Water, Gripe Water Night Time, and Kids Cough Syrup & Mucus Day + Night Combo Pack products are misbranded within the meaning of section 403(q)(5)(F) [21 U.S.C. 343(q)(5)(F)] in that the presentation of the nutrition information on the labeling of your products does not comply with 21 CFR 101.9, 21 CFR 101.36, and 21 CFR 101.2. For example:\na. The product’s inner bottle labels do not bear nutrition information, as required by 21 CFR 101.36. The unit container is exempted from these requirements if the unit container bears the statement “This Unit Not Labeled for Retail Sale” [21 CFR 1.24(a)(24)].\nb. The dosage guide and\u002For directions for use are placed above the Supplement Facts label, which is not in accordance with 21 CFR 101.2(a) and (e). Nutrition information should appear on the principal display panel (PDP) or directly to the right of the PDP with no intervening material in between.\nc. For your Gripe Water Night Time and Kids Cough Syrup & Mucus Day + Night Combo Pack, the serving size in the Supplement Facts labels fails to be declared as required by 21 CFR 101.36(b)(1)(i). Serving size must be expressed in common household measures as set forth in 21 CFR 101.9(b) and must be followed by the equivalent metric quantity in parenthesis (fluids in milliliters and all other foods in grams).\nUnapproved New Drug\nFDA reviewed your website at the internet address www.mommysbliss.com in December 2024 and determined that you take orders there for your Gripe Water Original. The claims on your website establish that your product Gripe Water Original is a drug under section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)] because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act. Thus, in addition to being an adulterated and misbranded dietary supplement, your Gripe Water Original is also an unapproved new drug under section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)].\nExamples of some of the claims that provide evidence that your Gripe Water Original product is intended for use as a drug include:\nFrom the blog post on your website: Acid Reflux = The Pits – Mommy's Bliss\n• “Acid reflux, also known as gastroesophageal reflux or GER, is when acids and content of the stomach come back up into the baby’s esophagus. It happens because the lower esophageal sphincter isn’t fully developed. . . .[I]f [a baby’s esophageal sphincter] fails to develop correctly or becomes weak, a baby may develop GERD (gastroesophageal reflux disease) which has more severe complications. . . .\nHow do you know if your baby has acid reflux?\nThe symptoms of acid reflux are typically clear and easy to read….\n1. Frequent Vomiting….2. Irritability….The acid of the digestive juices irritates the stomach and esophagus….3. Persistent Coughing or Wheezing….There is a link between acid reflux, wheezing, coughing, and even asthma….5. Colic The persistent crying of a colicky baby could be a symptom of reflux. The irritation of the stomach and the esophagus from all those digestive juices may trigger your baby into colic….How do you help a baby with acid reflux?....\nTry Gripe Water\nGripe water can also be a great way to ease symptoms of acid reflux in infants. It is a natural approach to help reduce the stomach acid that causes pain. . . .\nMommy’s Bliss Gripe Water is a safe and gentle way to help ease your baby’s stomach discomfort. The organic ginger and fennel relieve the irritation and prevent the stomach acid from flowing up into the esophagus. Fennel is known for its ability to reduce inflammation and acid in the stomach while ginger’s phenolic compounds help relieve irritation and reduce gastric contractions.”\nAdditionally, your blog post titled “Acid Reflux = The Pits,” in discussing the “link between acid reflex, wheezing, and coughing,” links to an article from the Mayo Clinic article entitled “Asthma and acid reflux: Are they linked?” (Asthma and acid reflux: Are they linked? - Mayo Clinic). This link from your blog further suggests that your Mommy’s Bliss Gripe Water Original is intended for the cure, mitigation, treatment, or prevention of GERD and asthma.\nYour product is not generally recognized as safe and effective for the above referenced uses and, therefore, the product is a “new drug” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\nMisbranded Drug\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safety and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\nYour Gripe Water Original is intended for treatment or prevention of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purpose. Accordingly, Gripe Water Original fails to bear adequate directions for its intended use and, therefore, the product is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. 331(a)].\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within fifteen (15) working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\nYour written response should be sent to Jamie M. Bumpas, Compliance Officer, U.S. Food and Drug Administration, Human Foods Program, Office of Enforcement, 5001 Campus Drive, College Park, Maryland 20740-3835, or via email at HFP-OCE-DietarySupplements@fda.hhs.gov. If you have any questions, you may email us at HFP-OCE-DietarySupplements@fda.hhs.gov. Please reference CMS #698651 on any submissions and within the subject line of any emails.\nSincerely,\n\u002FS\u002F\nLaura Akowuah, JD, MPH\nActing Director, Office of Enforcement\nOffice of Compliance and Enforcement\nHuman Foods Program\nU.S. Food and Drug Administration","M.O.M. Enterprises, LLC","mom-enterprises-llc-698651-04222025","2026-08-18T06:42:28.676509+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmom-enterprises-llc-698651-04222025","2026-10-26T08:09:27.535097+00:00","Warning Letter","Issued","2025-06-24","698651","Food & Beverages","Yasmin S. Kaderali","2026-08-19T16:39:01.029+00:00","2025-04-22",{"id":31,"raw":32,"subject":37,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":43,"fei_number":19,"letter_url":44,"updated_at":45,"action_type":22,"case_status":46,"posted_date":47,"marcs_cms_no":48,"product_type":49,"closeout_date":50,"issuing_office":36,"recipient_name":51,"body_fetched_at":52,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":53,"medical_device_id":19,"response_letter_date":19},1508,[33,34,35,36,37,13,38,13],"\u003Ctime datetime=\"2024-04-23T13:20:00Z\">04\u002F23\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-04-18T04:00:00Z\">04\u002F18\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fzen-enterprises-llc-678407-04182024\">Zen Enterprises LLC\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Failure to Register and List","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fzen-enterprises-llc-678407-09112024\">\u003Ctime datetime=\"2024-09-17T04:00:00Z\">09\u002F17\u002F2024\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>David Makima\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Zen Enterprises LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>9061 W. Sahara Ste 105\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Las Vegas\u003C\u002Fspan>, \u003Cspan>NV\u003C\u002Fspan> \u003Cspan>98117-5797\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Registration@fdaimports.com\"> Registration@fdaimports.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>April 18, 2024\u003Cbr>\n\u003Cbr>\nRE: WL 2644\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Makima:\u003C\u002Fp>\n\n\u003Cp>This letter concerns your firm’s drug listing information provided to FDA’s electronic Drug Registration and Listing System (eDRLS) for your drug products, Zen Sports Balm, NDC 73048-000, Zen Hemp Balm, NDC 73048-001, Zen Hand Sanitizer, NDC 73048-002, and Sycuan Casino Resort Hand Sanitizer, NDC 73048-003.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Your firm has not fulfilled its listing obligations under section 510(j) of the Federal Food Drug and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 360(j), which is a prohibited act under section 301(p) of the FD&amp;C Act, 21 U.S.C. 331(p). In addition, the drugs stated above are not properly listed with FDA, causing them to be misbranded drugs under section 502(o) of the FD&amp;C Act, 21 U.S.C. 352(o). Introduction or delivery for introduction of such misbranded drugs into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Registration and Drug Listing Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Section 510(j) of the FD&amp;C Act, 21 U.S.C 360(j), and 21 CFR Part 207 outline the requirements for registration and listing of drug products. Drug listing submissions must include the name and Unique Facility Identifier of the establishment where the registrant who lists the drug manufactures it and the type of operation performed on the drug at that establishment as required under section 510(j)(1)(c) of the FD&amp;C Act, 21 U.S.C. 360(j)(1)(c), and 21 CFR 207.49(a)(12)(i). Furthermore, in accordance with 21 CFR 207.49(a)(12)(ii), the listing file must include the name and Unique Facility Identifier of every other establishment where manufacturing is performed for the drug and the type of operation performed at each such establishment. In the listing files submitted to FDA for Zen Sports Balm, NDC 73048-000, Zen Hemp Balm, NDC 73048-001, Zen Hand Sanitizer, NDC 73048-002, and Sycuan Casino Resort Hand Sanitizer, NDC 73048-003, the manufacturer referenced under the establishment section of the listing SPL files is identified as Dr. Sankunni’s Ayurvedic Research Foundation Private Ltd., (DUNS 650517704). However, in accordance with the response provided on December 15, 2022 to the Office of Quality Surveillance (OQS) in the Office of Pharmaceutical Quality (OPQ) to their 704(a)(4) records request, it was confirmed that Dr. Sankunni’s Ayurvedic Research Foundation Private Ltd. is not currently involved in the manufacturing of the drugs mentioned above. Thus, Dr. Sankunni’s Ayurvedic Research Foundation Private Ltd. should not be registered with FDA as a manufacturer, nor should this firm be included as the manufacturer under the establishment sections of any drug listing files. To date, no updates have been made to the listing files to correct the manufacturer that is referenced.\u003C\u002Fp>\n\n\u003Cp>Therefore, your firm has not fulfilled its listing obligations under section 510(j) of the FD&amp;C Act, 21 U.S.C. 360(j), which is a prohibited act under section 301(p) of the FD&amp;C Act, 21 U.S.C. 331(p). In addition, the drugs Zen Sports Balm, NDC 73048-000, Zen Hemp Balm, NDC 73048-001, Zen Hand Sanitizer, NDC 73048-002, and Sycuan Casino Resort Hand Sanitizer, NDC 73048-003 are not properly listed with FDA, causing them to be misbranded drugs under section 502(o) of the FD&amp;C Act, 21 U.S.C. 352(o). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>Complete, accurate and up-to-date establishment registration and drug listing information is essential to promote and protect patient safety. FDA relies on establishment registration and drug listing information for several key programs, including drug establishment inspections, supply chain security, and post-market surveillance. Drug registration and listing information is also widely used outside FDA for purposes such as electronic prescribing and electronic health records, insurance reimbursement, and patient education.\u003C\u002Fp>\n\n\u003Cp>We note that this warning letter only addresses registration and listing issues associated with your products included above. It is not intended to be an all-inclusive statement of violations that may exist in connection with your products. Your firm should investigate and determine the causes of any violations and take prompt actions to correct the violations and bring the products into compliance. It is also your responsibility to correct any listing deficiencies with all other products distributed by your firm.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.\u003Cbr>\n\u003Cbr>\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. In absence of a corrective action, the deficient listing data will not be available for certification under 21 CFR 207.57(b)(2) requirements and will be ultimately inactivated by FDA. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to U.S. Food and Drug Administration, Center for Drug Evaluation and Research\u002FOffice of Compliance\u002FOffice of Unapproved Drugs and Labeling Compliance by e-mail to eDRLS@fda.hhs.gov. Please be aware that a manual override may be required for certain types of revisions made to an existing drug listing file. If you receive a validation error or have any questions regarding the contents of this letter, please contact us at eDRLS@fda.hhs.gov. for further assistance. Include the case identification number 2644 on all correspondence.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Tina Smith, M.S.\u003Cbr>\nCaptain, U.S. Public Health Service\u003Cbr>\nDirector\u003Cbr>\nOffice of Unapproved Drugs &amp; Labeling Compliance\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nU.S. Food and Drug Administration\u003C\u002Fp>\n\n\u003Cp>_________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> On December 4, 2023, we sent you a drug listing deficiency letter notification describing the observed listing deficiencies in the information you submitted. On January 18, 2024, we sent you a data removal email notification informing you of a data removal action. As stated in this email, the continued deficiencies resulted in your product’s data removal from FDA’s Online NDC Directory. FDA sends data deficiency letters and data removal notifications to the contact person found in the labeler code SPL submitted by your firm to FDA. If this information has changed, it is your responsibility to update this within 30 days of any change, under 21 CFR 207.33(c).\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nDavid Makima\n\nZen Enterprises LLC\n\n9061 W. Sahara Ste 105\n\nLas Vegas, NV 98117-5797\n\nUnited States\n\nRegistration@fdaimports.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWARNING LETTER\n\nApril 18, 2024\n\nRE: WL 2644\n\nDear Mr. Makima:\n\nThis letter concerns your firm’s drug listing information provided to FDA’s electronic Drug Registration and Listing System (eDRLS) for your drug products, Zen Sports Balm, NDC 73048-000, Zen Hemp Balm, NDC 73048-001, Zen Hand Sanitizer, NDC 73048-002, and Sycuan Casino Resort Hand Sanitizer, NDC 73048-003.1 Your firm has not fulfilled its listing obligations under section 510(j) of the Federal Food Drug and Cosmetic Act (FD&C Act), 21 U.S.C. 360(j), which is a prohibited act under section 301(p) of the FD&C Act, 21 U.S.C. 331(p). In addition, the drugs stated above are not properly listed with FDA, causing them to be misbranded drugs under section 502(o) of the FD&C Act, 21 U.S.C. 352(o). Introduction or delivery for introduction of such misbranded drugs into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a). These violations are described in more detail below.\n\nRegistration and Drug Listing Violations\n\nSection 510(j) of the FD&C Act, 21 U.S.C 360(j), and 21 CFR Part 207 outline the requirements for registration and listing of drug products. Drug listing submissions must include the name and Unique Facility Identifier of the establishment where the registrant who lists the drug manufactures it and the type of operation performed on the drug at that establishment as required under section 510(j)(1)(c) of the FD&C Act, 21 U.S.C. 360(j)(1)(c), and 21 CFR 207.49(a)(12)(i). Furthermore, in accordance with 21 CFR 207.49(a)(12)(ii), the listing file must include the name and Unique Facility Identifier of every other establishment where manufacturing is performed for the drug and the type of operation performed at each such establishment. In the listing files submitted to FDA for Zen Sports Balm, NDC 73048-000, Zen Hemp Balm, NDC 73048-001, Zen Hand Sanitizer, NDC 73048-002, and Sycuan Casino Resort Hand Sanitizer, NDC 73048-003, the manufacturer referenced under the establishment section of the listing SPL files is identified as Dr. Sankunni’s Ayurvedic Research Foundation Private Ltd., (DUNS 650517704). However, in accordance with the response provided on December 15, 2022 to the Office of Quality Surveillance (OQS) in the Office of Pharmaceutical Quality (OPQ) to their 704(a)(4) records request, it was confirmed that Dr. Sankunni’s Ayurvedic Research Foundation Private Ltd. is not currently involved in the manufacturing of the drugs mentioned above. Thus, Dr. Sankunni’s Ayurvedic Research Foundation Private Ltd. should not be registered with FDA as a manufacturer, nor should this firm be included as the manufacturer under the establishment sections of any drug listing files. To date, no updates have been made to the listing files to correct the manufacturer that is referenced.\n\nTherefore, your firm has not fulfilled its listing obligations under section 510(j) of the FD&C Act, 21 U.S.C. 360(j), which is a prohibited act under section 301(p) of the FD&C Act, 21 U.S.C. 331(p). In addition, the drugs Zen Sports Balm, NDC 73048-000, Zen Hemp Balm, NDC 73048-001, Zen Hand Sanitizer, NDC 73048-002, and Sycuan Casino Resort Hand Sanitizer, NDC 73048-003 are not properly listed with FDA, causing them to be misbranded drugs under section 502(o) of the FD&C Act, 21 U.S.C. 352(o). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nComplete, accurate and up-to-date establishment registration and drug listing information is essential to promote and protect patient safety. FDA relies on establishment registration and drug listing information for several key programs, including drug establishment inspections, supply chain security, and post-market surveillance. Drug registration and listing information is also widely used outside FDA for purposes such as electronic prescribing and electronic health records, insurance reimbursement, and patient education.\n\nWe note that this warning letter only addresses registration and listing issues associated with your products included above. It is not intended to be an all-inclusive statement of violations that may exist in connection with your products. Your firm should investigate and determine the causes of any violations and take prompt actions to correct the violations and bring the products into compliance. It is also your responsibility to correct any listing deficiencies with all other products distributed by your firm.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. In absence of a corrective action, the deficient listing data will not be available for certification under 21 CFR 207.57(b)(2) requirements and will be ultimately inactivated by FDA. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nYour response should be sent to U.S. Food and Drug Administration, Center for Drug Evaluation and Research\u002FOffice of Compliance\u002FOffice of Unapproved Drugs and Labeling Compliance by e-mail to eDRLS@fda.hhs.gov. Please be aware that a manual override may be required for certain types of revisions made to an existing drug listing file. If you receive a validation error or have any questions regarding the contents of this letter, please contact us at eDRLS@fda.hhs.gov. for further assistance. Include the case identification number 2644 on all correspondence.\n\nSincerely,\n\n\u002FS\u002F\n\nTina Smith, M.S.\n\nCaptain, U.S. Public Health Service\n\nDirector\n\nOffice of Unapproved Drugs & Labeling Compliance\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nU.S. Food and Drug Administration\n\n_________________________\n\n1 On December 4, 2023, we sent you a drug listing deficiency letter notification describing the observed listing deficiencies in the information you submitted. On January 18, 2024, we sent you a data removal email notification informing you of a data removal action. As stated in this email, the continued deficiencies resulted in your product’s data removal from FDA’s Online NDC Directory. FDA sends data deficiency letters and data removal notifications to the contact person found in the labeler code SPL submitted by your firm to FDA. If this information has changed, it is your responsibility to update this within 30 days of any change, under 21 CFR 207.33(c).","Zen Enterprises LLC","zen-enterprises-llc-678407-04182024","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fzen-enterprises-llc-678407-04182024","2026-10-26T08:10:38.406573+00:00","Closed Out","2024-04-23","678407","Drugs","2024-09-17","David Makima","2026-08-20T00:10:11.347+00:00","2024-04-18",{"id":55,"raw":56,"subject":60,"body_html":61,"body_text":62,"firm_name":63,"letter_id":64,"created_at":65,"fei_number":19,"letter_url":66,"updated_at":67,"action_type":22,"case_status":23,"posted_date":68,"marcs_cms_no":69,"product_type":49,"closeout_date":19,"issuing_office":36,"recipient_name":70,"body_fetched_at":71,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":72,"medical_device_id":19,"response_letter_date":19},2728,[57,58,59,36,60,13,13,13],"\u003Ctime datetime=\"2022-04-19T13:20:00Z\">04\u002F19\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-04-13T04:00:00Z\">04\u002F13\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fambi-enterprises-llc-628367-04132022\">AMBI Enterprises LLC \u003C\u002Fa>","Finished Pharmaceuticals\u002FUnapproved New Drug\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>David Lennarz \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>AMBI Enterprises LLC \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>10411 Motor City Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Bethesda\u003C\u002Fspan>, \u003Cspan>MD\u003C\u002Fspan> \u003Cspan>20817-1008\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:consumercare@ambi.com\"> consumercare@ambi.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Date: April 13, 2022\u003Cbr>\n\u003Cbr>\nDear Mr. Lennarz:\u003C\u002Fp>\n\n\u003Cp>This letter concerns your firm’s distribution of drug products to bleach and\u002For lighten the skin. AMBI® SKINCARE Fade Cream OILY SKIN and AMBI® SKINCARE Fade Cream NORMAL SKIN drug products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the Federal Food Drug &amp; Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a), and are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranded Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>AMBI® SKINCARE Fade Cream OILY SKIN and AMBI® SKINCARE Fade Cream NORMAL SKIN are drugs as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body. Specifically, these products are intended for use as skin bleaching products.\u003C\u002Fp>\n\n\u003Cp>Examples of the claims observed on your product labels and labeling from your website https:\u002F\u002Fambi.com, where products are available for purchase, that provide evidence of the intended use(s) (as defined in 21 CFR 201.128) of your products include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>AMBI® SKINCARE Fade Cream OILY SKIN\u003Cbr>\n“Fades dark spots for even, natural skin tone . . . \u003Cstrong>Drug Facts\u003C\u002Fstrong> . . . Hydroquinone 2% . . . \u003Cstrong>Purpose\u003C\u002Fstrong> . . . Skin Bleaching Agent . . . \u003Cstrong>Uses\u003C\u002Fstrong> . . . For the gradual fading of dark (brownish) skin discolorations such as freckles, age and liver spots or pigment that may occur in pregnancy or from the use of oral contraceptives . . . An advanced formula that effectively fades dark spots and skin discolorations to help restore your natural skin tone. You will begin to see results in as little as 2 weeks and results improve with continued use. This targeted treatment contains a unique triple-action formula, which combines the following: . . . \u003Cstrong>Hydroquinone\u003C\u002Fstrong> . . . a dermatologist recommended ingredient to safely fade dark spots” [from your “AMBI Fade Cream OILY Skin” product label]\u003C\u002Fp>\n\n\u003Cp>“AMBI® Fade Cream Oily Skin effectively and safely fades unwanted dark marks without changing your natural skin tone. You will begin to see results in as little as two weeks and results will improve with continued use. . . . This targeted treatment contains . . . \u003Cstrong>Hydroquinone-\u003C\u002Fstrong> a dermatologist-recommended ingredient to safely fade dark spots” [from your website https:\u002F\u002Fambi.com\u002Fcollections\u002Fbest-sellers\u002Fproducts\u002Fambi-fade-cream-for-oily-skin]\u003C\u002Fp>\n\n\u003Cp>AMBI® SKINCARE Fade Cream NORMAL SKIN\u003Cbr>\n“Fade Cream . . . \u003Cstrong>Drug Facts\u003C\u002Fstrong> . . . Hydroquinone 2% . . . \u003Cstrong>Purpose\u003C\u002Fstrong> . . . Skin Bleaching Agent . . . \u003Cstrong>Uses\u003C\u002Fstrong> . . . For the gradual fading of dark (brownish) skin discolorations such as freckles, age and liver spots or uneven pigment that may occur in pregnancy or from the use of oral contraceptives . . . An advanced formula that visibly fades dark spots and skin discolorations for an even, natural skin tone. You will begin to see results in as little as 2 weeks and results improve with continued use. This targeted treatment contains a unique triple-action formula, which combines the following: . . . \u003Cstrong>Hydroquinone\u003C\u002Fstrong> . . . a dermatologist recommended ingredient to safely fade dark spots” [from your “AMBI Fade Cream NORMAL SKIN” product label]\u003C\u002Fp>\n\n\u003Cp>“AMBI® Fade Cream Normal Skin effectively and safely fades unwanted dark marks without changing your natural skin tone. You will begin to see results in as little as two weeks and results will improve with continued use. . . . This targeted treatment contains . . . \u003Cstrong>Hydroquinone-\u003C\u002Fstrong> a dermatologist-recommended ingredient to safely fade dark spots” [from your website https:\u002F\u002Fambi.com\u002Fcollections\u002Fbest-sellers\u002Fproducts\u002Fambi-fade-cream-for-normal-skin]\u003C\u002Fp>\n\n\u003Cp>AMBI® SKINCARE Fade Cream OILY SKIN and AMBI® SKINCARE Fade Cream NORMAL SKIN are skin bleaching drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Specifically, these skin bleaching products fall under section 505G(a)(4) of the FD&amp;C Act, 21 U.S.C. 355h(a)(4), as added on March 27, 2020 with the enactment of the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), because they are subject to a determination to be not generally recognized as safe and effective (GRASE) in a proposed rule that is the most recently applicable proposal issued under 21 CFR part 330.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Thus, AMBI® SKINCARE Fade Cream OILY SKIN and AMBI® SKINCARE Fade Cream NORMAL SKIN are deemed to be new drugs under section 201(p)(1) of the FD&amp;C Act and subject to the requirement to have an approved new drug application for marketing under section 505 of the FD&amp;C Act, 21 U.S.C. 355, beginning on September 23, 2020.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for AMBI® SKINCARE Fade Cream OILY SKIN and AMBI® SKINCARE Fade Cream NORMAL SKIN. Accordingly, these skin bleaching drug products are unapproved new drugs and their introduction or delivery for introduction into interstate commerce violates section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a).\u003C\u002Fp>\n\n\u003Cp>Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) of the FD&amp;C Act, 21 U.S.C. 331(d).\u003C\u002Fp>\n\n\u003Cp>Moreover, AMBI® SKINCARE Fade Cream OILY SKIN and AMBI® SKINCARE Fade Cream NORMAL SKIN are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because they are deemed as such under section 505G(a)(4) of the FD&amp;C Act, 21 U.S.C. 355h(a)(4), and because they are nonprescription drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but are not the subject of applications approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355, and do not comply with the requirements under section 505G of the FD&amp;C Act, 21 U.S.C. 355h.\u003C\u002Fp>\n\n\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations regarding your products nor are the skin bleaching\u002Fskin lightening drug products named in this letter intended to be an all-inclusive list of products you have manufactured, registered, and\u002For listed in FDA’s electronic drug registration and listing system (eDRLS), or introduced into interstate commerce. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence and the occurrence of other violations. It is your responsibility to assure that your firm complies with all requirements of federal law and FDA regulations. You should take prompt action to correct the violations cited in this letter. Failure to promptly correct any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations of the FD&amp;C Act may be cause for FDA to withhold approval of requests for export certificates and approval of pending new drug applications or supplements listing your facility as a supplier or manufacturer.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot completely address violations within 15 working days, state your reasons for delay and schedule for completion.\u003C\u002Fp>\n\n\u003Cp>If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please direct your email response to Office of Unapproved Drugs and Labeling Compliance at the following email address to FDAADVISORY@fda.hhs.gov and include your firm name in the subject line of your email.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Carolyn E. Becker\u003Cbr>\nDirector\u003Cbr>\nOffice of Unapproved Drugs and Labeling Compliance\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>_________________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> On August 29, 2006, FDA issued a proposed rule (71 FR 51146) setting forth a determination that OTC skin bleaching drug products, including but not limited to those that contain hydroquinone as an active ingredient, are not generally recognized as safe and effective.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Section 505G(a)(4) of the FD&amp;C Act, 21 U.S.C. 355h(a)(4), authorized FDA to take action before September 23, 2020, to extend the period during which a drug subject to that section may be marketed without an approved new drug application if the Agency determined that such an extension is in the interest of public health. However, FDA did not make such a determination for skin bleaching products.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nDavid Lennarz\n\nAMBI Enterprises LLC\n\n10411 Motor City Drive\n\nBethesda, MD 20817-1008\n\nUnited States\n\nconsumercare@ambi.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWARNING LETTER\n\nDate: April 13, 2022\n\nDear Mr. Lennarz:\n\nThis letter concerns your firm’s distribution of drug products to bleach and\u002For lighten the skin. AMBI® SKINCARE Fade Cream OILY SKIN and AMBI® SKINCARE Fade Cream NORMAL SKIN drug products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the Federal Food Drug & Cosmetic Act (FD&C Act), 21 U.S.C. 355(a), and are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\n\nUnapproved New Drug and Misbranded Drug Violations\n\nAMBI® SKINCARE Fade Cream OILY SKIN and AMBI® SKINCARE Fade Cream NORMAL SKIN are drugs as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body. Specifically, these products are intended for use as skin bleaching products.\n\nExamples of the claims observed on your product labels and labeling from your website https:\u002F\u002Fambi.com, where products are available for purchase, that provide evidence of the intended use(s) (as defined in 21 CFR 201.128) of your products include, but may not be limited to, the following:\n\nAMBI® SKINCARE Fade Cream OILY SKIN\n\n“Fades dark spots for even, natural skin tone . . . Drug Facts . . . Hydroquinone 2% . . . Purpose . . . Skin Bleaching Agent . . . Uses . . . For the gradual fading of dark (brownish) skin discolorations such as freckles, age and liver spots or pigment that may occur in pregnancy or from the use of oral contraceptives . . . An advanced formula that effectively fades dark spots and skin discolorations to help restore your natural skin tone. You will begin to see results in as little as 2 weeks and results improve with continued use. This targeted treatment contains a unique triple-action formula, which combines the following: . . . Hydroquinone . . . a dermatologist recommended ingredient to safely fade dark spots” [from your “AMBI Fade Cream OILY Skin” product label]\n\n“AMBI® Fade Cream Oily Skin effectively and safely fades unwanted dark marks without changing your natural skin tone. You will begin to see results in as little as two weeks and results will improve with continued use. . . . This targeted treatment contains . . . Hydroquinone- a dermatologist-recommended ingredient to safely fade dark spots” [from your website https:\u002F\u002Fambi.com\u002Fcollections\u002Fbest-sellers\u002Fproducts\u002Fambi-fade-cream-for-oily-skin]\n\nAMBI® SKINCARE Fade Cream NORMAL SKIN\n\n“Fade Cream . . . Drug Facts . . . Hydroquinone 2% . . . Purpose . . . Skin Bleaching Agent . . . Uses . . . For the gradual fading of dark (brownish) skin discolorations such as freckles, age and liver spots or uneven pigment that may occur in pregnancy or from the use of oral contraceptives . . . An advanced formula that visibly fades dark spots and skin discolorations for an even, natural skin tone. You will begin to see results in as little as 2 weeks and results improve with continued use. This targeted treatment contains a unique triple-action formula, which combines the following: . . . Hydroquinone . . . a dermatologist recommended ingredient to safely fade dark spots” [from your “AMBI Fade Cream NORMAL SKIN” product label]\n\n“AMBI® Fade Cream Normal Skin effectively and safely fades unwanted dark marks without changing your natural skin tone. You will begin to see results in as little as two weeks and results will improve with continued use. . . . This targeted treatment contains . . . Hydroquinone- a dermatologist-recommended ingredient to safely fade dark spots” [from your website https:\u002F\u002Fambi.com\u002Fcollections\u002Fbest-sellers\u002Fproducts\u002Fambi-fade-cream-for-normal-skin]\n\nAMBI® SKINCARE Fade Cream OILY SKIN and AMBI® SKINCARE Fade Cream NORMAL SKIN are skin bleaching drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Specifically, these skin bleaching products fall under section 505G(a)(4) of the FD&C Act, 21 U.S.C. 355h(a)(4), as added on March 27, 2020 with the enactment of the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), because they are subject to a determination to be not generally recognized as safe and effective (GRASE) in a proposed rule that is the most recently applicable proposal issued under 21 CFR part 330.1 Thus, AMBI® SKINCARE Fade Cream OILY SKIN and AMBI® SKINCARE Fade Cream NORMAL SKIN are deemed to be new drugs under section 201(p)(1) of the FD&C Act and subject to the requirement to have an approved new drug application for marketing under section 505 of the FD&C Act, 21 U.S.C. 355, beginning on September 23, 2020.2\n\nNo FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for AMBI® SKINCARE Fade Cream OILY SKIN and AMBI® SKINCARE Fade Cream NORMAL SKIN. Accordingly, these skin bleaching drug products are unapproved new drugs and their introduction or delivery for introduction into interstate commerce violates section 505(a) of the FD&C Act, 21 U.S.C. 355(a).\n\nIntroduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. 331(d).\n\nMoreover, AMBI® SKINCARE Fade Cream OILY SKIN and AMBI® SKINCARE Fade Cream NORMAL SKIN are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because they are deemed as such under section 505G(a)(4) of the FD&C Act, 21 U.S.C. 355h(a)(4), and because they are nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but are not the subject of applications approved under section 505 of the FD&C Act, 21 U.S.C. 355, and do not comply with the requirements under section 505G of the FD&C Act, 21 U.S.C. 355h.\n\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations regarding your products nor are the skin bleaching\u002Fskin lightening drug products named in this letter intended to be an all-inclusive list of products you have manufactured, registered, and\u002For listed in FDA’s electronic drug registration and listing system (eDRLS), or introduced into interstate commerce. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence and the occurrence of other violations. It is your responsibility to assure that your firm complies with all requirements of federal law and FDA regulations. You should take prompt action to correct the violations cited in this letter. Failure to promptly correct any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\n\nFailure to address violations of the FD&C Act may be cause for FDA to withhold approval of requests for export certificates and approval of pending new drug applications or supplements listing your facility as a supplier or manufacturer.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot completely address violations within 15 working days, state your reasons for delay and schedule for completion.\n\nIf you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nPlease direct your email response to Office of Unapproved Drugs and Labeling Compliance at the following email address to FDAADVISORY@fda.hhs.gov and include your firm name in the subject line of your email.\n\nSincerely,\n\n\u002FS\u002F\n\nCarolyn E. Becker\n\nDirector\n\nOffice of Unapproved Drugs and Labeling Compliance\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\n_________________________________\n\n1 On August 29, 2006, FDA issued a proposed rule (71 FR 51146) setting forth a determination that OTC skin bleaching drug products, including but not limited to those that contain hydroquinone as an active ingredient, are not generally recognized as safe and effective.\n\n2 Section 505G(a)(4) of the FD&C Act, 21 U.S.C. 355h(a)(4), authorized FDA to take action before September 23, 2020, to extend the period during which a drug subject to that section may be marketed without an approved new drug application if the Agency determined that such an extension is in the interest of public health. However, FDA did not make such a determination for skin bleaching products.","AMBI Enterprises LLC","ambi-enterprises-llc-628367-04132022","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fambi-enterprises-llc-628367-04132022","2026-10-26T08:07:54.399692+00:00","2022-04-19","628367","David Lennarz","2026-08-20T01:59:07.789+00:00","2022-04-13",{"id":74,"raw":75,"subject":80,"body_html":81,"body_text":82,"firm_name":83,"letter_id":84,"created_at":65,"fei_number":19,"letter_url":85,"updated_at":86,"action_type":22,"case_status":23,"posted_date":87,"marcs_cms_no":88,"product_type":89,"closeout_date":19,"issuing_office":79,"recipient_name":90,"body_fetched_at":91,"delivery_method":92,"recipient_title":19,"reference_number":19,"action_taken_date":87,"medical_device_id":19,"response_letter_date":19},2860,[76,77,78,79,80,13,13,13],"\u003Ctime datetime=\"2022-02-17T20:00:00Z\">02\u002F17\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-02-17T05:00:00Z\">02\u002F17\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flecig-enterprises-inc-624574-02172022\">Lecig Enterprises Inc\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Michael Elias\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Lecig Enterprises Inc\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>810 West Collin Raye Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>De Queen\u003C\u002Fspan>, \u003Cspan>AR\u003C\u002Fspan> \u003Cspan>71832\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:me@lecig.com\"> me@lecig.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>February 17, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Elias:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that LeCig Enterprises, Inc manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)) these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>The FD&amp;C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>A New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States LeCig Cinnamon Roll 36mg 30ml e-liquid product without a marketing authorization order.\u003C\u002Fp>\n\n\u003Cp>The tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&amp;C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm is a registered manufacturer with over 600 products listed with FDA. FDA received your Premarket Tobacco Product Application (PMTA), assigned STN PM0003586, on September 9, 2020. However, FDA issued a negative action for STN PM0003586 in the form of a Marketing Denial Order determination on September 15, 2021, which covers 85 products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your ENDS products covered by STN PM0003586 that resulted in a Marketing Denial Order determination, are adulterated and misbranded. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For more information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2200418, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nMichael Elias\n\nRecipient Title\n\nOwner\n\nLecig Enterprises Inc\n\n810 West Collin Raye Drive\n\nDe Queen, AR 71832\n\nUnited States\n\nme@lecig.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nFebruary 17, 2022\n\nWARNING LETTER\n\nDear Mr. Elias:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that LeCig Enterprises, Inc manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)) these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nThe FD&C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nA New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\n\nFDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States LeCig Cinnamon Roll 36mg 30ml e-liquid product without a marketing authorization order.\n\nThe tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with over 600 products listed with FDA. FDA received your Premarket Tobacco Product Application (PMTA), assigned STN PM0003586, on September 9, 2020. However, FDA issued a negative action for STN PM0003586 in the form of a Marketing Denial Order determination on September 15, 2021, which covers 85 products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your ENDS products covered by STN PM0003586 that resulted in a Marketing Denial Order determination, are adulterated and misbranded. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For more information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market.\n\nIt is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2200418, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products","Lecig Enterprises Inc","lecig-enterprises-inc-624574-02172022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flecig-enterprises-inc-624574-02172022","2026-10-26T08:09:13.233972+00:00","2022-02-17","624574","Tobacco","Michael Elias","2026-08-20T02:10:13.7+00:00","VIA UPS and Electronic Mail",{"id":94,"raw":95,"subject":100,"body_html":101,"body_text":102,"firm_name":103,"letter_id":104,"created_at":65,"fei_number":19,"letter_url":105,"updated_at":106,"action_type":22,"case_status":23,"posted_date":107,"marcs_cms_no":108,"product_type":26,"closeout_date":19,"issuing_office":99,"recipient_name":109,"body_fetched_at":110,"delivery_method":111,"recipient_title":19,"reference_number":19,"action_taken_date":112,"medical_device_id":19,"response_letter_date":19},2894,[96,97,98,99,100,13,13,13],"\u003Ctime datetime=\"2022-02-01T14:20:00Z\">02\u002F01\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-01-07T05:00:00Z\">01\u002F07\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmolino-enterprises-one-inc-619323-01072022\">Molino Enterprises One, Inc.\u003C\u002Fa>","Division of Northeast Imports","Foreign Supplier Verification Program (FSVP)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL AND UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ronald Liriano-Marte\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Molino Enterprises One, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>392 E 197th Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Bronx\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>10458-3702\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Northeast Imports\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>1\u002F7\u002F2022\u003C\u002Fp>\n\n\u003Cp>Re: CMS # 619323\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Liriano-Marte:\u003C\u002Fp>\n\n\u003Cp>From August 10-September 14, 2021, the U.S. Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Molino Enterprises One, Inc., located at 392 E 197th Street, Bronx, NY 10458-3702. We also conducted an inspection on April 5, 2019. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\">https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the following foods you import: whole wheat breadsticks, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> imported from your foreign supplier \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, on September 14, 2021, our investigator provided you with a Form FDA 483a, FSVP Observations. To date, we have not received your response to the Form FDA 483a.\u003C\u002Fp>\n\n\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\n\n\u003Cp>You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for whole wheat breadsticks, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> imported from your foreign supplier \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in the \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods from the identified foreign supplier on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at \u003Ca href=\"http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\">http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\u003C\u002Fa>. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\n\n\u003Cp>Additionally, we note that you may meet the definition of a “very small importer” under 21 CFR 1.500. If you meet the definition, you are still required to follow FSVP requirements. If you are a very small importer and you choose to comply with the modified requirements in 21 CFR 1.512, you must document that you meet the definition of very small importer as required per 21 CFR 1.512(b)(1)(i). If this section applies and you choose to comply with the requirements in paragraph (b) of this section, you also are required to comply with the requirements in sections 1.502, 1.503, and 1.509, but you are not required to comply with the requirements in sections 1.504 through 1.508 or 1.510. In addition, for each food you import, you must obtain written assurance, before importing the food and at least every two years thereafter, that your foreign supplier is producing the food in compliance with processes and procedures that provide at least the same level of public health protection as those required under section 418 or 419 of the FD&amp;C Act, if either is applicable, and the implementing regulations, and is producing the food in compliance with sections 402 and 403(w) (if applicable) of the FD&amp;C Act (21 CFR 1.512(b)(3)(i)).\u003C\u002Fp>\n\n\u003Cp>Please send your reply to Food and Drug Administration, Attention: Feryal Ahmad, Compliance Officer, Division of Northeast Imports, ORAOEIONEIMPORTSWLResponses@fda.hhs.gov. Please also cc (carbon copy) Feryal.Ahmad@fda.hhs.gov. If you have any questions regarding this letter, you may contact Compliance Officer Ahmad via email at Feryal.Ahmad@fda.hhs.gov. Please reference CMS# 619323 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Theresa Smedley\u003Cbr>\nActing Program Division Director\u003Cbr>\nDivision of Northeast Imports\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL AND UNITED PARCEL SERVICE\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nRonald Liriano-Marte\n\nRecipient Title\n\nOwner\n\nMolino Enterprises One, Inc.\n\n392 E 197th Street\n\nBronx, NY 10458-3702\n\nUnited States\n\nIssuing Office:\n\nDivision of Northeast Imports\n\nUnited States\n\nWARNING LETTER\n\n1\u002F7\u002F2022\n\nRe: CMS # 619323\n\nDear Mr. Liriano-Marte:\n\nFrom August 10-September 14, 2021, the U.S. Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Molino Enterprises One, Inc., located at 392 E 197th Street, Bronx, NY 10458-3702. We also conducted an inspection on April 5, 2019. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1 subpart L.\n\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\n\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the following foods you import: whole wheat breadsticks, (b)(4), and (b)(4) imported from your foreign supplier (b)(4) located in the (b)(4). Because of these significant violations, you are not in compliance with section 805 of the FD&C Act.\n\nAt the conclusion of the inspection, on September 14, 2021, our investigator provided you with a Form FDA 483a, FSVP Observations. To date, we have not received your response to the Form FDA 483a.\n\nYour significant violations of the FSVP regulation are as follows:\n\nYou did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for whole wheat breadsticks, (b)(4), and (b)(4) imported from your foreign supplier (b)(4) located in the (b)(4).\n\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1, subpart L.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods from the identified foreign supplier on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\n\nAdditionally, we note that you may meet the definition of a “very small importer” under 21 CFR 1.500. If you meet the definition, you are still required to follow FSVP requirements. If you are a very small importer and you choose to comply with the modified requirements in 21 CFR 1.512, you must document that you meet the definition of very small importer as required per 21 CFR 1.512(b)(1)(i). If this section applies and you choose to comply with the requirements in paragraph (b) of this section, you also are required to comply with the requirements in sections 1.502, 1.503, and 1.509, but you are not required to comply with the requirements in sections 1.504 through 1.508 or 1.510. In addition, for each food you import, you must obtain written assurance, before importing the food and at least every two years thereafter, that your foreign supplier is producing the food in compliance with processes and procedures that provide at least the same level of public health protection as those required under section 418 or 419 of the FD&C Act, if either is applicable, and the implementing regulations, and is producing the food in compliance with sections 402 and 403(w) (if applicable) of the FD&C Act (21 CFR 1.512(b)(3)(i)).\n\nPlease send your reply to Food and Drug Administration, Attention: Feryal Ahmad, Compliance Officer, Division of Northeast Imports, ORAOEIONEIMPORTSWLResponses@fda.hhs.gov. Please also cc (carbon copy) Feryal.Ahmad@fda.hhs.gov. If you have any questions regarding this letter, you may contact Compliance Officer Ahmad via email at Feryal.Ahmad@fda.hhs.gov. Please reference CMS# 619323 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\n\nSincerely,\n\n\u002FS\u002F\n\nTheresa Smedley\n\nActing Program Division Director\n\nDivision of Northeast Imports","Molino Enterprises One, Inc.","molino-enterprises-one-inc-619323-01072022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmolino-enterprises-one-inc-619323-01072022","2026-10-26T08:09:27.255692+00:00","2022-02-01","619323","Ronald Liriano-Marte","2026-08-20T02:13:21.081+00:00","VIA EMAIL AND UNITED PARCEL SERVICE","2022-01-07",{"id":114,"raw":115,"subject":100,"body_html":120,"body_text":121,"firm_name":122,"letter_id":123,"created_at":124,"fei_number":19,"letter_url":125,"updated_at":126,"action_type":22,"case_status":23,"posted_date":127,"marcs_cms_no":128,"product_type":26,"closeout_date":19,"issuing_office":119,"recipient_name":129,"body_fetched_at":130,"delivery_method":131,"recipient_title":19,"reference_number":19,"action_taken_date":132,"medical_device_id":19,"response_letter_date":19},21711,[116,117,118,119,100,13,13,13],"\u003Ctime datetime=\"2026-09-29T04:00:00Z\">09\u002F29\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-08-13T04:00:00Z\">08\u002F13\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbo-wah-enterprises-inc-736539-08132026\">Bo Wah Enterprises Inc\u003C\u002Fa>","Office of Inspections and Investigations","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Danny Y.W. Au\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Bo Wah Enterprises Inc\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1037 Maunakea St\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Honolulu\u003C\u002Fspan>, \u003Cspan>HI\u003C\u002Fspan> \u003Cspan>96817-5130\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6), (b)(7)(C)\"> (b)(6), (b)(7)(C)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Inspections and Investigations\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>August 13, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Re: CMS 736539\u003C\u002Fp>\u003Cp>Dear Mr. Au:\u003C\u002Fp>\u003Cp>On June 24, June 30, and July 1, 2026, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of BO WAH ENTERPRISES INC, 1037 Maunakea St, Honolulu, HI 96817-5130. This inspection was conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\u003C\u002Fp>\u003Cp>During the inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations.\u003C\u002Fp>\u003Cp>We acknowledge receipt of your response, dated July 13, 2026, in which you stated your firm \u003Cstrong>(b)(4)\u003C\u002Fstrong> develop your FSVP, requested HACCP and \u003Cstrong>(b)(4)\u003C\u002Fstrong> certificates from your foreign suppliers, and plans to send a firm member\u002Femployee to \u003Cstrong>(b)(4)\u003C\u002Fstrong> training. We are unable to evaluate the adequacy of your response because you have not provided any supporting documentation demonstrating your corrective actions. To date, no additional FSVP documents have been received by FDA.\u003C\u002Fp>\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\u003Cp>You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import, including each of the following foods:\u003C\u002Fp>\u003Cul>\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> Huai Shan (Chinese Yam), imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> Golden Mushroom, imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> Sesame Paste, imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003C\u002Ful>\u003Cp>For thermally processed low-acid foods packaged in hermetically sealed containers (low-acid canned foods), with respect to those microbiological hazards that are controlled by following 21 CFR part 113, you must verify and document that the food was produced in accordance with 21 CFR part 113, as required by 21 CFR 1.502(b)(1). However, you did not verify and document that the canned food products you import, including but not limited to \u003Cstrong>(b)(4)\u003C\u002Fstrong> Golden Mushroom, imported from \u003Cstrong>(b)(4) \u003C\u002Fstrong>located in \u003Cstrong>(b)(4)\u003C\u002Fstrong> were produced in accordance with 21 CFR part 113 (regarding thermally processed low-acid foods packaged in hermetically sealed containers), as required by 21 CFR 1.502(b)(1).\u003C\u002Fp>\u003Cp>During our inspection close-out you provided the following documents:\u003C\u002Fp>\u003Cul>\u003Cli>HACCP plan containing a hazard analysis, a third-party audit report, and certificate from your foreign supplier \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>A Certificate of Analysis (COA) and a HACCP certificate from your foreign supplier \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>; this document identified the US Importer as \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003C\u002Ful>\u003Cp>You stated you obtained these from your import liaisons. However, it is not clear how these documents would apply to your FSVP program, and you did not explain how they would apply to your FSVP program.\u003C\u002Fp>\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html.\u003C\u002Fp>\u003Cp>In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\u003Cp>Please send your reply to Food and Drug Administration, Attention: Sandra K. Wangen Compliance Officer, Division of West Coast Imports, 934 Broadway, Suite 101, Tacoma, WA 98402; or via email to wcid@fda.hhs.gov, Attention: Sandra K. Wangen, Compliance Officer. If you have any questions regarding this letter, you may contact Sandra K. Wangen via email at sandra.wangen@fda.hhs.gov. Please reference CMS # 736539 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003Cbr>Dr. Kathleen Turner\u003Cbr>Program Division Director\u003Cbr>Division of West Coast Imports\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nDanny Y.W. Au\n\nRecipient Title\n\nPresident\n\nBo Wah Enterprises Inc\n\n1037 Maunakea St\n\nHonolulu, HI 96817-5130\n\nUnited States\n\n(b)(6), (b)(7)(C)\n\nIssuing Office:\n\nOffice of Inspections and Investigations\n\nUnited States\n\nAugust 13, 2026\nWARNING LETTER\nRe: CMS 736539\nDear Mr. Au:\nOn June 24, June 30, and July 1, 2026, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of BO WAH ENTERPRISES INC, 1037 Maunakea St, Honolulu, HI 96817-5130. This inspection was conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\nDuring the inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&C Act.\nAt the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations.\nWe acknowledge receipt of your response, dated July 13, 2026, in which you stated your firm (b)(4) develop your FSVP, requested HACCP and (b)(4) certificates from your foreign suppliers, and plans to send a firm member\u002Femployee to (b)(4) training. We are unable to evaluate the adequacy of your response because you have not provided any supporting documentation demonstrating your corrective actions. To date, no additional FSVP documents have been received by FDA.\nYour significant violations of the FSVP regulation are as follows:\nYou did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import, including each of the following foods:\n(b)(4) Huai Shan (Chinese Yam), imported from (b)(4) located in (b)(4)\n(b)(4) Golden Mushroom, imported from (b)(4) located in (b)(4)\n(b)(4) Sesame Paste, imported from (b)(4) located in (b)(4)\nFor thermally processed low-acid foods packaged in hermetically sealed containers (low-acid canned foods), with respect to those microbiological hazards that are controlled by following 21 CFR part 113, you must verify and document that the food was produced in accordance with 21 CFR part 113, as required by 21 CFR 1.502(b)(1). However, you did not verify and document that the canned food products you import, including but not limited to (b)(4) Golden Mushroom, imported from (b)(4) located in (b)(4) were produced in accordance with 21 CFR part 113 (regarding thermally processed low-acid foods packaged in hermetically sealed containers), as required by 21 CFR 1.502(b)(1).\nDuring our inspection close-out you provided the following documents:\nHACCP plan containing a hazard analysis, a third-party audit report, and certificate from your foreign supplier (b)(4) located in (b)(4)\nA Certificate of Analysis (COA) and a HACCP certificate from your foreign supplier (b)(4) located in (b)(4); this document identified the US Importer as (b)(4)\nYou stated you obtained these from your import liaisons. However, it is not clear how these documents would apply to your FSVP program, and you did not explain how they would apply to your FSVP program.\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1, subpart L.\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html.\nIn addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\nPlease send your reply to Food and Drug Administration, Attention: Sandra K. Wangen Compliance Officer, Division of West Coast Imports, 934 Broadway, Suite 101, Tacoma, WA 98402; or via email to wcid@fda.hhs.gov, Attention: Sandra K. Wangen, Compliance Officer. If you have any questions regarding this letter, you may contact Sandra K. Wangen via email at sandra.wangen@fda.hhs.gov. Please reference CMS # 736539 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\nSincerely,\n\u002FS\u002F\nDr. Kathleen Turner\nProgram Division Director\nDivision of West Coast Imports","Bo Wah Enterprises Inc","bo-wah-enterprises-inc-736539-08132026","2026-10-14T12:31:16.41489+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbo-wah-enterprises-inc-736539-08132026","2026-11-10T01:02:16.121874+00:00","2026-09-29","736539","Danny Y.W. Au","2026-10-14T12:34:32.17+00:00","Via Express Delivery","2026-08-13",{"id":134,"raw":135,"subject":140,"body_html":142,"body_text":143,"firm_name":144,"letter_id":145,"created_at":146,"fei_number":19,"letter_url":147,"updated_at":148,"action_type":22,"case_status":46,"posted_date":149,"marcs_cms_no":150,"product_type":26,"closeout_date":151,"issuing_office":139,"recipient_name":152,"body_fetched_at":153,"delivery_method":131,"recipient_title":19,"reference_number":19,"action_taken_date":154,"medical_device_id":19,"response_letter_date":19},1389,[136,137,138,139,140,13,141,13],"\u003Ctime datetime=\"2024-07-09T13:20:00Z\">07\u002F09\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-06-03T04:00:00Z\">06\u002F03\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fchoos-enterprises-ltd-683922-06032024\">Choo&#039;s Enterprises Ltd\u003C\u002Fa>","Center for Food Safety and Applied Nutrition (CFSAN)","Acidified Foods\u002FEmergency Permit Control\u002FAdulterated","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fchoos-enterprises-ltd-683922-05272025\">\u003Ctime datetime=\"2025-06-03T04:00:00Z\">06\u002F03\u002F2025\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Edwin Cho\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Choo's Enterprises Ltd\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Jordan's Complex\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Eagle Hall\u003C\u002Fspan>, \u003Cspan>Saint Michael\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Barbados\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition (CFSAN)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Reference # 683922\u003C\u002Fp>\n\n\u003Cp>June 3, 2024\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Cho,\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your low acid and acidified foods facility, Choo's Enterprises Ltd, located at Jordan's Complex, Saint Michael, Barbados on March 4 through 6, 2024. The inspection revealed serious violations of the Emergency Permit Control regulation, Title 21, Code of Federal Regulations, Part 108 (21 CFR Part 108) and the Acidified Foods regulation (21 CFR Part 114). At the conclusion of the inspection, a Form FDA 483 (FDA 483), Inspectional Observations, was issued listing the deviations found at your facility. We acknowledge receipt of your response received via email on April 4, 2024, which included a written response, a training record, and photographs. However, our evaluation of the documentation revealed that the response was not adequate, as further described in this letter.\u003C\u002Fp>\n\n\u003Cp>As a manufacturer of acidified food products intended for export to the United States, you are required to comply with the Federal Food Drug and Cosmetic Act (the Act) and the federal regulations relating to the processing of acidified foods. The Emergency Permit Control regulations were issued, in part, pursuant to section 404 of the Act, Emergency Permit Control, 21 U.S.C. § 344. A temporary emergency permit may be required for acidified foods whenever a processor has failed to fulfill the requirements of 21 CFR 108.25, including registration and filing of process information, and the mandatory requirements in 21 CFR 114. Regulations specific to the processing of acidified food products are described in 21 CFR Part 108 and 21 CFR 114. As outlined in these regulations, a commercial processor that does not adhere to all of the mandatory requirements of 21 CFR 108.25 and 21 CFR 114 could be subjected to an immediate application of the emergency permit control provisions of section 404 of the Act (21 U.S.C. 344).\u003C\u002Fp>\n\n\u003Cp>As stated in 21 CFR 108.25(j) for imported products, in lieu of issuing an order of determination that a permit is required before products from a commercial processor can be introduced into interstate commerce, FDA may take steps to refuse admission of the commercial processor's products under section 801 of the Act (21 U.S.C. 381) when offered for entry into the United States. Violation of the mandatory requirements set forth in 21 CFR 108.25 and 21 CFR 114 renders your acidified food products adulterated within the meaning of section 402(a)(4) of the Act, 21 U.S.C. 342(a)(4) in that they have been prepared, packed, or held under insanitary conditions whereby they may have been rendered injurious to health. You can find the Act and acidified foods regulations through links in FDA’s home page at www.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Your significant deviations are as follows:\u003C\u002Fp>\n\n\u003Cp>1. As a commercial processor of acidified foods, you must, not later than 60 days after registration and prior to the packing of a new product, provide the FDA information as to the scheduled processes, as required by 21 CFR 108.25(c)(2). For acidified foods, this information must include conditions for heat processing and control of pH, salt, sugar, and preservative level, and source and date of the establishment of the process, for each acidified food in each container size. Specifically, you do not have a scheduled process on file with FDA for products you have identified as acidified products, which include, but are not limited to, Windmill Baxter's Road Seasoning, Windmill Classic Mauby Syrup, Sweet &amp; Tasty Mauby Syrup, Sugar Free Mauby Syrup, Ginger Beer Syrup, and Sugar Free Ginger Beer. Further, the scheduled process must be established by a qualified person who has expert knowledge acquired through appropriate training and experience in the acidification and processing of acidified foods, as required by 21 CFR 114.83.\u003C\u002Fp>\n\n\u003Cp>Scheduled process information for acidified foods must be submitted on Form FDA 2541e a (Food Process Filing for Acidified Method). More information on registration and filing can be found in the publication \"Guidance for Industry: Submitting Form FDA 2541 (Food Canning Establishment Registration) and Forms FDA 2541d, FDA 2541e, FDA 2541f, and FDA 2541g (Food Process Filing Forms) to FDA in Electronic or Paper Format'' available at: http:\u002F\u002Fwww.fda.gov\u002Ffood\u002Fguidanceregulation\u002Fguidancedocumentsregulatoryinformation\u002Fucm309376.htm.\u003C\u002Fp>\n\n\u003Cp>Your response stated “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” You further stated that you are consulting with a process authority. However, your response did not address whether you plan to file a scheduled process for your acidified food products. You will be unable to offer acidified food products for entry into the United States without scheduled processes on file with FDA.\u003C\u002Fp>\n\n\u003Cp>This letter may not list all the deviations at your facility. You are responsible for ensuring that your processing plant operates in compliance with the Act and all applicable regulations, including the acidified foods regulations (21 CFR Parts 108 and 114) and the Current Good Manufacturing Practice regulation (21 CFR Part 117, Subpart B). You also have a responsibility to use procedures to prevent further violations of the Act and all applicable regulations.\u003C\u002Fp>\n\n\u003Cp>If you do not respond or if we find your response inadequate, we may take further action. For instance, we may take further action to refuse admission of your imported acidified food products under section 801(a) of the Act (21 U.S.C. § 381(a)), including placing them on detention without physical examination (DWPE). FDA's DWPE is an administrative procedure whereby products offered for import into the United States may be detained without physical examination upon entry. DWPE information may be conveyed in FDA's Import Alerts. For your information, an example of an Import Alert that conveys information specific to foreign firms that are not in compliance with the acidified foods regulations (21 CFR Parts 108 and 114) is Import Alert #99-37, “Detention without Physical Examination of Low-Acid Canned Foods and Acidified Foods without Filed Scheduled Processes.” This alert can be found on FDA's web site at https:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms ia\u002Fimportalert_1132.html.\u003C\u002Fp>\n\n\u003Cp>Additionally, we offer the following comment:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your firm’s operators of processing and packaging systems are not under the operating supervisions of a person who has attended and satisfactorily completed a school approved by the FDA for pH controls and critical factors in acidification. Although your response indicated that you will be having your Food Safety and Quality Assurance Officer take an online acidified foods manufacturing school, you did not provide any information on whether they have registered for the course or when they plan to take the course.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should outline the specific steps you are taking to correct these deviations. More specifically, your response should include documentation and information that will assist us in evaluating your corrections such as evidence of submission of scheduled processes and any additional information that you wish to supply that provides assurance of your intent to fully comply now and in the future with the acidified foods regulations. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to the U.S. Food and Drug Administration, Attention: Sheena Phillips, Compliance Officer, Office of Compliance, Division of Enforcement, Food Adulteration and Assessment Branch (HFS-607), 5001 Campus Drive, College Park, Maryland 20740 U.S.A. If you have any questions regarding this letter, you may contact Ms. Phillips via email at Sheena.Phillips@fda.hhs.gov. Please reference CMS # 683922 on any documents or records you provide to us and\u002For within the subject line of any email correspondence you send to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann M. Oxenham, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Food Safety and Applied Nutrition\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nEdwin Cho\n\nRecipient Title\n\nCEO\n\nChoo's Enterprises Ltd\n\nJordan's Complex\n\nEagle Hall, Saint Michael\n\nBarbados\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition (CFSAN)\n\nUnited States\n\nWARNING LETTER\n\nReference # 683922\n\nJune 3, 2024\n\nDear Mr. Cho,\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your low acid and acidified foods facility, Choo's Enterprises Ltd, located at Jordan's Complex, Saint Michael, Barbados on March 4 through 6, 2024. The inspection revealed serious violations of the Emergency Permit Control regulation, Title 21, Code of Federal Regulations, Part 108 (21 CFR Part 108) and the Acidified Foods regulation (21 CFR Part 114). At the conclusion of the inspection, a Form FDA 483 (FDA 483), Inspectional Observations, was issued listing the deviations found at your facility. We acknowledge receipt of your response received via email on April 4, 2024, which included a written response, a training record, and photographs. However, our evaluation of the documentation revealed that the response was not adequate, as further described in this letter.\n\nAs a manufacturer of acidified food products intended for export to the United States, you are required to comply with the Federal Food Drug and Cosmetic Act (the Act) and the federal regulations relating to the processing of acidified foods. The Emergency Permit Control regulations were issued, in part, pursuant to section 404 of the Act, Emergency Permit Control, 21 U.S.C. § 344. A temporary emergency permit may be required for acidified foods whenever a processor has failed to fulfill the requirements of 21 CFR 108.25, including registration and filing of process information, and the mandatory requirements in 21 CFR 114. Regulations specific to the processing of acidified food products are described in 21 CFR Part 108 and 21 CFR 114. As outlined in these regulations, a commercial processor that does not adhere to all of the mandatory requirements of 21 CFR 108.25 and 21 CFR 114 could be subjected to an immediate application of the emergency permit control provisions of section 404 of the Act (21 U.S.C. 344).\n\nAs stated in 21 CFR 108.25(j) for imported products, in lieu of issuing an order of determination that a permit is required before products from a commercial processor can be introduced into interstate commerce, FDA may take steps to refuse admission of the commercial processor's products under section 801 of the Act (21 U.S.C. 381) when offered for entry into the United States. Violation of the mandatory requirements set forth in 21 CFR 108.25 and 21 CFR 114 renders your acidified food products adulterated within the meaning of section 402(a)(4) of the Act, 21 U.S.C. 342(a)(4) in that they have been prepared, packed, or held under insanitary conditions whereby they may have been rendered injurious to health. You can find the Act and acidified foods regulations through links in FDA’s home page at www.fda.gov.\n\nYour significant deviations are as follows:\n\n1. As a commercial processor of acidified foods, you must, not later than 60 days after registration and prior to the packing of a new product, provide the FDA information as to the scheduled processes, as required by 21 CFR 108.25(c)(2). For acidified foods, this information must include conditions for heat processing and control of pH, salt, sugar, and preservative level, and source and date of the establishment of the process, for each acidified food in each container size. Specifically, you do not have a scheduled process on file with FDA for products you have identified as acidified products, which include, but are not limited to, Windmill Baxter's Road Seasoning, Windmill Classic Mauby Syrup, Sweet & Tasty Mauby Syrup, Sugar Free Mauby Syrup, Ginger Beer Syrup, and Sugar Free Ginger Beer. Further, the scheduled process must be established by a qualified person who has expert knowledge acquired through appropriate training and experience in the acidification and processing of acidified foods, as required by 21 CFR 114.83.\n\nScheduled process information for acidified foods must be submitted on Form FDA 2541e a (Food Process Filing for Acidified Method). More information on registration and filing can be found in the publication \"Guidance for Industry: Submitting Form FDA 2541 (Food Canning Establishment Registration) and Forms FDA 2541d, FDA 2541e, FDA 2541f, and FDA 2541g (Food Process Filing Forms) to FDA in Electronic or Paper Format'' available at: http:\u002F\u002Fwww.fda.gov\u002Ffood\u002Fguidanceregulation\u002Fguidancedocumentsregulatoryinformation\u002Fucm309376.htm.\n\nYour response stated “(b)(4).” You further stated that you are consulting with a process authority. However, your response did not address whether you plan to file a scheduled process for your acidified food products. You will be unable to offer acidified food products for entry into the United States without scheduled processes on file with FDA.\n\nThis letter may not list all the deviations at your facility. You are responsible for ensuring that your processing plant operates in compliance with the Act and all applicable regulations, including the acidified foods regulations (21 CFR Parts 108 and 114) and the Current Good Manufacturing Practice regulation (21 CFR Part 117, Subpart B). You also have a responsibility to use procedures to prevent further violations of the Act and all applicable regulations.\n\nIf you do not respond or if we find your response inadequate, we may take further action. For instance, we may take further action to refuse admission of your imported acidified food products under section 801(a) of the Act (21 U.S.C. § 381(a)), including placing them on detention without physical examination (DWPE). FDA's DWPE is an administrative procedure whereby products offered for import into the United States may be detained without physical examination upon entry. DWPE information may be conveyed in FDA's Import Alerts. For your information, an example of an Import Alert that conveys information specific to foreign firms that are not in compliance with the acidified foods regulations (21 CFR Parts 108 and 114) is Import Alert #99-37, “Detention without Physical Examination of Low-Acid Canned Foods and Acidified Foods without Filed Scheduled Processes.” This alert can be found on FDA's web site at https:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms ia\u002Fimportalert_1132.html.\n\nAdditionally, we offer the following comment:\n\nYour firm’s operators of processing and packaging systems are not under the operating supervisions of a person who has attended and satisfactorily completed a school approved by the FDA for pH controls and critical factors in acidification. Although your response indicated that you will be having your Food Safety and Quality Assurance Officer take an online acidified foods manufacturing school, you did not provide any information on whether they have registered for the course or when they plan to take the course.\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should outline the specific steps you are taking to correct these deviations. More specifically, your response should include documentation and information that will assist us in evaluating your corrections such as evidence of submission of scheduled processes and any additional information that you wish to supply that provides assurance of your intent to fully comply now and in the future with the acidified foods regulations. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nPlease send your reply to the U.S. Food and Drug Administration, Attention: Sheena Phillips, Compliance Officer, Office of Compliance, Division of Enforcement, Food Adulteration and Assessment Branch (HFS-607), 5001 Campus Drive, College Park, Maryland 20740 U.S.A. If you have any questions regarding this letter, you may contact Ms. Phillips via email at Sheena.Phillips@fda.hhs.gov. Please reference CMS # 683922 on any documents or records you provide to us and\u002For within the subject line of any email correspondence you send to us.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn M. Oxenham, J.D.\n\nDirector\n\nOffice of Compliance\n\nCenter for Food Safety and Applied Nutrition","Choo's Enterprises Ltd","choos-enterprises-ltd-683922-06032024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fchoos-enterprises-ltd-683922-06032024","2026-10-26T08:08:14.967321+00:00","2024-07-09","683922","2025-06-03","Edwin Cho","2026-08-19T23:59:05.755+00:00","2024-06-03",{"id":156,"raw":157,"subject":161,"body_html":163,"body_text":164,"firm_name":165,"letter_id":166,"created_at":65,"fei_number":19,"letter_url":167,"updated_at":168,"action_type":22,"case_status":46,"posted_date":169,"marcs_cms_no":170,"product_type":171,"closeout_date":172,"issuing_office":139,"recipient_name":173,"body_fetched_at":174,"delivery_method":175,"recipient_title":19,"reference_number":19,"action_taken_date":176,"medical_device_id":19,"response_letter_date":19},2584,[158,159,160,139,161,13,162,13],"\u003Ctime datetime=\"2022-07-12T12:30:00Z\">07\u002F12\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-07-01T04:00:00Z\">07\u002F01\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmks-enterprise-llc-624478-07012022\">MKS Enterprise, LLC\u003C\u002Fa>","Interstate Commerce\u002FFood\u002FAdulterated","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmks-enterprise-llc-624478-09022022\">\u003Ctime datetime=\"2026-02-13T05:00:00Z\">02\u002F13\u002F2026\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Overnight Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Satish Bhatia\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>MKS Enterprise, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>59 Paulison Ave. #13\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Passaic\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>07055\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:mks@wholesaleonline1.com\"> mks@wholesaleonline1.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:sam77usa@gmail.com\"> sam77usa@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition (CFSAN)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>July 1, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>RE: 624478\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Bhatia,\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) obtained a sample of your product Dose Vital Royal Honey VIP Honey (Vital Honey) purchased directly from your website at www.wholesaleonline1.com. FDA also reviewed your website in June 2022. Based on our review of your website and laboratory analysis of your product, FDA has identified serious violations of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Prohibited Act under Section 301(ll)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA confirmed through laboratory analysis that a sample of your Vital Honey contains the undeclared active pharmaceutical ingredient tadalafil, which is a phosphodiesterase type-5 (PDE-5) inhibitor. Tadalafil is the active ingredient in the FDA-approved prescription drug Cialis, used to treat erectile dysfunction (ED). This undeclared ingredient may interact with nitrates found in some prescription drugs such as nitroglycerin and may lower blood pressure to dangerous levels. Men with diabetes, high blood pressure, high cholesterol, or heart disease often take nitrates.\u003C\u002Fp>\n\n\u003Cp>Subject to a limited exception, it is a prohibited act under section 301(ll) of the FD&amp;C Act [21 U.S.C. 331(II)] to introduce or deliver for introduction into interstate commerce any food to which has been added a drug approved under section 505 of the FD&amp;C Act [21 U.S.C. 355] or for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public. Based on available evidence, FDA has concluded that the prohibition in section 301(ll) applies to tadalafil.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> FDA is not aware of any evidence that would call into question its conclusion that section 301(ll) of the FD&amp;C Act prohibits the introduction into interstate commerce of any food to which tadalafil has been added.\u003C\u002Fp>\n\n\u003Cp>Your Vital Honey product is a food to which tadalafil has been added. Therefore, the introduction or delivery for introduction into interstate commerce of this product is a prohibited act under section 301(II) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA reviewed your website at www.wholesaleonline1.com in June 2022 and determined you take orders there for the product Vital Honey. In addition to being a food of which the introduction or delivery for introduction into interstate commerce is prohibited under section 301(ll) of the FD&amp;C Act, this product is a drug under section 201(g)(1)(B) of the FD&amp;C Act [21 U.S.C. 321(g)(1)(B)], as established by the claims on your website, because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your product is intended for use as a drug include:\u003C\u002Fp>\n\n\u003Cp>- “Prevent arthritis and multiple sclerosis\u003Cbr>\n- Accelerating the healing and consolidation of fractured bones\u003Cbr>\n- Lower cholesterol\u003Cbr>\n- Alleviate cardiovascular ailments\u003Cbr>\n- Remedy liver disease, pancreatic, insomnia, fatigue, ulcers, and digestive and skin disorders\u003Cbr>\n- Reduce . . . anxiety states, insomnia and anorexia\u003Cbr>\n- Decreases prostate issues and illnesses in the man’s productive [sic] system.”\u003C\u002Fp>\n\n\u003Cp>Your Vital Honey is not generally recognized as safe and effective for the above-referenced uses and, therefore, the product is a “new drug” under section 201(p) of the FD&amp;C Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Drug\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your product Vital Honey is intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, Vital Honey fails to bear adequate directions for its intended use and, therefore, the product is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Additionally, we have the following comment:\u003C\u002Fp>\n\n\u003Cp>FDA has not conducted a complete review of your inventory. It is your responsibility under the FD&amp;C Act to ensure that products marketed by your firm do not contain undeclared ingredients and comply with all requirements of federal law. A full list of all tainted products discovered by FDA can be found at&nbsp;\u003Ca href=\"http:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fsda\u002FsdNavigation.cfm?sd=tainted_supplements_cder\">http:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fsda\u002FsdNavigation.cfm?sd=tainted_supplements_cder\u003C\u002Fa>. We recommend that you subscribe to our email service at&nbsp;\u003Ca href=\"https:\u002F\u002Fpublic.govdelivery.com\u002Faccounts\u002FUSFDA\u002Fsubscriber\u002Fnew\">https:\u002F\u002Fpublic.govdelivery.com\u002Faccounts\u002FUSFDA\u002Fsubscriber\u002Fnew\u003C\u002Fa> to receive regular notices about tainted products discovered by FDA.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within fifteen (15) working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written reply to the above violations should be directed to Kimberly Dutzek with the FDA via email at CFSANResponse@fda.hhs.gov. If you have any questions, you may also email at CFSANResponse@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann M. Oxenham\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Food Safety and Applied Nutrition\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>___________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> FDA approved Cialis™ (containing tadalafil as the active ingredient) as a new drug on November 21, 2003. There is an exception if the substance was marketed in food before the drug was approved or before the substantial clinical investigations involving the drug had been instituted. However, based on available evidence, FDA has concluded that this is not the case for tadalafil.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Overnight Delivery\n\nProduct:\n\nDrugs\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nSatish Bhatia\n\nMKS Enterprise, LLC\n\n59 Paulison Ave. #13\n\nPassaic, NJ 07055\n\nUnited States\n\nmks@wholesaleonline1.com\n\nsam77usa@gmail.com\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition (CFSAN)\n\nUnited States\n\nWARNING LETTER\n\nJuly 1, 2022\n\nRE: 624478\n\nDear Mr. Bhatia,\n\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) obtained a sample of your product Dose Vital Royal Honey VIP Honey (Vital Honey) purchased directly from your website at www.wholesaleonline1.com. FDA also reviewed your website in June 2022. Based on our review of your website and laboratory analysis of your product, FDA has identified serious violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act).\n\nProhibited Act under Section 301(ll)\n\nFDA confirmed through laboratory analysis that a sample of your Vital Honey contains the undeclared active pharmaceutical ingredient tadalafil, which is a phosphodiesterase type-5 (PDE-5) inhibitor. Tadalafil is the active ingredient in the FDA-approved prescription drug Cialis, used to treat erectile dysfunction (ED). This undeclared ingredient may interact with nitrates found in some prescription drugs such as nitroglycerin and may lower blood pressure to dangerous levels. Men with diabetes, high blood pressure, high cholesterol, or heart disease often take nitrates.\n\nSubject to a limited exception, it is a prohibited act under section 301(ll) of the FD&C Act [21 U.S.C. 331(II)] to introduce or deliver for introduction into interstate commerce any food to which has been added a drug approved under section 505 of the FD&C Act [21 U.S.C. 355] or for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public. Based on available evidence, FDA has concluded that the prohibition in section 301(ll) applies to tadalafil.1 FDA is not aware of any evidence that would call into question its conclusion that section 301(ll) of the FD&C Act prohibits the introduction into interstate commerce of any food to which tadalafil has been added.\n\nYour Vital Honey product is a food to which tadalafil has been added. Therefore, the introduction or delivery for introduction into interstate commerce of this product is a prohibited act under section 301(II) of the FD&C Act.\n\nUnapproved New Drug\n\nFDA reviewed your website at www.wholesaleonline1.com in June 2022 and determined you take orders there for the product Vital Honey. In addition to being a food of which the introduction or delivery for introduction into interstate commerce is prohibited under section 301(ll) of the FD&C Act, this product is a drug under section 201(g)(1)(B) of the FD&C Act [21 U.S.C. 321(g)(1)(B)], as established by the claims on your website, because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the FD&C Act.\n\nExamples of some of the website claims that provide evidence that your product is intended for use as a drug include:\n\n- “Prevent arthritis and multiple sclerosis\n\n- Accelerating the healing and consolidation of fractured bones\n\n- Lower cholesterol\n\n- Alleviate cardiovascular ailments\n\n- Remedy liver disease, pancreatic, insomnia, fatigue, ulcers, and digestive and skin disorders\n\n- Reduce . . . anxiety states, insomnia and anorexia\n\n- Decreases prostate issues and illnesses in the man’s productive [sic] system.”\n\nYour Vital Honey is not generally recognized as safe and effective for the above-referenced uses and, therefore, the product is a “new drug” under section 201(p) of the FD&C Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nMisbranded Drug\n\nYour product Vital Honey is intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, Vital Honey fails to bear adequate directions for its intended use and, therefore, the product is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nAdditionally, we have the following comment:\n\nFDA has not conducted a complete review of your inventory. It is your responsibility under the FD&C Act to ensure that products marketed by your firm do not contain undeclared ingredients and comply with all requirements of federal law. A full list of all tainted products discovered by FDA can be found at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fsda\u002FsdNavigation.cfm?sd=tainted_supplements_cder. We recommend that you subscribe to our email service at https:\u002F\u002Fpublic.govdelivery.com\u002Faccounts\u002FUSFDA\u002Fsubscriber\u002Fnew to receive regular notices about tainted products discovered by FDA.\n\nPlease notify FDA in writing, within fifteen (15) working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nYour written reply to the above violations should be directed to Kimberly Dutzek with the FDA via email at CFSANResponse@fda.hhs.gov. If you have any questions, you may also email at CFSANResponse@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn M. Oxenham\n\nDirector\n\nOffice of Compliance\n\nCenter for Food Safety and Applied Nutrition\n\nFood and Drug Administration\n\n___________________________\n\n1 FDA approved Cialis™ (containing tadalafil as the active ingredient) as a new drug on November 21, 2003. There is an exception if the substance was marketed in food before the drug was approved or before the substantial clinical investigations involving the drug had been instituted. However, based on available evidence, FDA has concluded that this is not the case for tadalafil.","MKS Enterprise, LLC","mks-enterprise-llc-624478-07012022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmks-enterprise-llc-624478-07012022","2026-10-26T08:09:26.73709+00:00","2022-07-12","624478","DrugsFood & Beverages","2026-02-13","Satish Bhatia","2026-08-20T01:46:35.713+00:00","Via Overnight Delivery","2022-07-01",{"id":178,"raw":179,"subject":186,"body_html":187,"body_text":188,"firm_name":189,"letter_id":190,"created_at":191,"fei_number":19,"letter_url":192,"updated_at":193,"action_type":22,"case_status":46,"posted_date":194,"marcs_cms_no":195,"product_type":49,"closeout_date":196,"issuing_office":183,"recipient_name":197,"body_fetched_at":198,"delivery_method":199,"recipient_title":19,"reference_number":19,"action_taken_date":200,"medical_device_id":19,"response_letter_date":19},281,[180,181,182,183,184,13,185,13],"\u003Ctime datetime=\"2026-03-10T04:00:00Z\">03\u002F10\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-03-02T05:00:00Z\">03\u002F02\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnse-products-inc-dba-nu-skin-enterprises-inc-722667-03022026\">NSE Products, Inc. DBA Nu Skin Enterprises, Inc. \u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","Electronic Drug Registration and Listing System (eDRLS)\u002FViolations\u003Cbr \u002F>\r\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnse-products-inc-dba-nu-skin-enterprises-inc-722667-07142026\">\u003Ctime datetime=\"2026-07-21T04:00:00Z\">07\u002F21\u002F2026\u003C\u002Ftime>\n\u003C\u002Fa>","Electronic Drug Registration and Listing System (eDRLS)\u002FViolations","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ryan Napierski\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>NSE Products, Inc. DBA Nu Skin Enterprises, Inc. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>75 West Center Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Provo\u003C\u002Fspan>, \u003Cspan>UT\u003C\u002Fspan> \u003Cspan>84601\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:rnaperski@nuskin.com\"> rnaperski@nuskin.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>March 2, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>RE: 3093 (CMS 722667)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Ryan Napierski:\u003C\u002Fp>\u003Cp>This letter concerns your firm’s drug listing information provided to FDA’s electronic Drug Registration and Listing System (eDRLS) for your drug products, “AP-24 Fluoride,” NDC 62839-1151; “AP-24,” NDC 62839-1152; and “AP-24 Whitening,” NDC 62839-1155.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Your firm has not fulfilled its listing obligations under section 510(j) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C 360(j). Failure to provide listing information for a drug in accordance with 510(j) of the FD&amp;C Act is prohibited under section 301(p) of the FD&amp;C Act, 21 U.S.C. 331(p). These violations are described in more detail below.\u003C\u002Fp>\u003Cp>\u003Cstrong>Drug Listing Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Section 510(j) of the FD&amp;C Act, 21 U.S.C. 360(j), and 21 CFR 207 set forth the requirements for the listing of drugs. In accordance with section 510(j)(2) of the FD&amp;C Act, 21 U.S.C 360(j)(2), and 21 CFR 207.57(b), registrants must review and update their drug listing information each June and December. Furthermore, under 21 CFR 207.57(b)(1)(iv), registrants must submit any material changes in any information previously submitted including, per 21 CFR 207.49(a)(12), manufacturing establishment information. The drug listings stated above reference a manufacturing establishment, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, that has confirmed that it has not been involved in the manufacturing of these drugs for more than five years, yet they continue to be cited in your listings with no end marketing date. Therefore, your firm has not fulfilled its listing obligations under section 510(j) of the FD&amp;C Act, 21 U.S.C. 360(j). Failure to provide listing information for a drug in accordance with 510(j) of the FD&amp;C Act is prohibited under section 301(p) of the FD&amp;C Act, 21 U.S.C. 331(p).\u003C\u002Fp>\u003Cp>Additionally, your firm has 61 drug listings that have not been updated or certified as required and therefore have been inactivated by FDA. Please update the listing information for these drugs to reflect their current status. If you no longer manufacture and distribute these drugs, then the drugs must be discontinued by adding an end marketing date.\u003C\u002Fp>\u003Cp>Complete, accurate, and up-to-date establishment registration and drug listing information is essential to promote and protect patient safety. FDA relies on establishment registration and drug listing information for several key programs, including drug establishment inspections, supply chain security, and post-market surveillance. Establishment registration and drug listing information is also widely used outside FDA for purposes such as electronic prescribing and electronic health records, insurance reimbursement, and patient education. We note that this warning letter only addresses establishment registration and drug listing issues associated with your products.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction. In absence of a corrective action, the deficient listing data will not be available for certification under 21 CFR 207.57(b)(2) requirements and will be ultimately inactivated by FDA.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Your response should be sent to U.S. Food and Drug Administration, Center for Drug Evaluation and Research\u002FOffice of Compliance\u002FOffice of Unapproved Drugs and Labeling Compliance by e-mail to eDRLS@fda.hhs.gov. Please be aware that a manual override may be required for certain types of revisions made to an existing drug listing file. If you receive a validation error or have any questions regarding the contents of this letter, please contact us at eDRLS@fda.hhs.gov for further assistance. Include the case identification numbers (3093) (CMS 722667) on all correspondence.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>___________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> On December 10, 2025, we sent your firm a drug listing deficiency letter describing the observed listing deficiencies in the information your firm submitted. In addition, we followed up on December 11, 2025, December 19, 2025, and January 16, 2026, to various points of contact. On January 24, 2026, we sent your firm a data removal notification email informing you of a data removal action. As stated in that email, the continued deficiencies resulted in your products’ data removal from FDA’s Online NDC Directory. FDA sends data deficiency letters and data removal notifications to the contact person found in the labeler code SPL submitted by your firm to FDA. If this information has changed, it is your responsibility to update this within 30 days of any change, under 21 CFR 207.33(c).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> See 84 FR 40417.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nRyan Napierski\n\nRecipient Title\n\nChief Executive Officer\n\nNSE Products, Inc. DBA Nu Skin Enterprises, Inc.\n\n75 West Center Street\n\nProvo, UT 84601\n\nUnited States\n\nrnaperski@nuskin.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nMarch 2, 2026\nRE: 3093 (CMS 722667)\nRyan Napierski:\nThis letter concerns your firm’s drug listing information provided to FDA’s electronic Drug Registration and Listing System (eDRLS) for your drug products, “AP-24 Fluoride,” NDC 62839-1151; “AP-24,” NDC 62839-1152; and “AP-24 Whitening,” NDC 62839-1155.1 Your firm has not fulfilled its listing obligations under section 510(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C 360(j). Failure to provide listing information for a drug in accordance with 510(j) of the FD&C Act is prohibited under section 301(p) of the FD&C Act, 21 U.S.C. 331(p). These violations are described in more detail below.\nDrug Listing Violations\nSection 510(j) of the FD&C Act, 21 U.S.C. 360(j), and 21 CFR 207 set forth the requirements for the listing of drugs. In accordance with section 510(j)(2) of the FD&C Act, 21 U.S.C 360(j)(2), and 21 CFR 207.57(b), registrants must review and update their drug listing information each June and December. Furthermore, under 21 CFR 207.57(b)(1)(iv), registrants must submit any material changes in any information previously submitted including, per 21 CFR 207.49(a)(12), manufacturing establishment information. The drug listings stated above reference a manufacturing establishment, (b)(4), that has confirmed that it has not been involved in the manufacturing of these drugs for more than five years, yet they continue to be cited in your listings with no end marketing date. Therefore, your firm has not fulfilled its listing obligations under section 510(j) of the FD&C Act, 21 U.S.C. 360(j). Failure to provide listing information for a drug in accordance with 510(j) of the FD&C Act is prohibited under section 301(p) of the FD&C Act, 21 U.S.C. 331(p).\nAdditionally, your firm has 61 drug listings that have not been updated or certified as required and therefore have been inactivated by FDA. Please update the listing information for these drugs to reflect their current status. If you no longer manufacture and distribute these drugs, then the drugs must be discontinued by adding an end marketing date.\nComplete, accurate, and up-to-date establishment registration and drug listing information is essential to promote and protect patient safety. FDA relies on establishment registration and drug listing information for several key programs, including drug establishment inspections, supply chain security, and post-market surveillance. Establishment registration and drug listing information is also widely used outside FDA for purposes such as electronic prescribing and electronic health records, insurance reimbursement, and patient education. We note that this warning letter only addresses establishment registration and drug listing issues associated with your products.\nConclusion\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction. In absence of a corrective action, the deficient listing data will not be available for certification under 21 CFR 207.57(b)(2) requirements and will be ultimately inactivated by FDA.2 If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\nYour response should be sent to U.S. Food and Drug Administration, Center for Drug Evaluation and Research\u002FOffice of Compliance\u002FOffice of Unapproved Drugs and Labeling Compliance by e-mail to eDRLS@fda.hhs.gov. Please be aware that a manual override may be required for certain types of revisions made to an existing drug listing file. If you receive a validation error or have any questions regarding the contents of this letter, please contact us at eDRLS@fda.hhs.gov for further assistance. Include the case identification numbers (3093) (CMS 722667) on all correspondence.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n___________________\n1 On December 10, 2025, we sent your firm a drug listing deficiency letter describing the observed listing deficiencies in the information your firm submitted. In addition, we followed up on December 11, 2025, December 19, 2025, and January 16, 2026, to various points of contact. On January 24, 2026, we sent your firm a data removal notification email informing you of a data removal action. As stated in that email, the continued deficiencies resulted in your products’ data removal from FDA’s Online NDC Directory. FDA sends data deficiency letters and data removal notifications to the contact person found in the labeler code SPL submitted by your firm to FDA. If this information has changed, it is your responsibility to update this within 30 days of any change, under 21 CFR 207.33(c).\n2 See 84 FR 40417.","NSE Products, Inc. DBA Nu Skin Enterprises, Inc.","nse-products-inc-dba-nu-skin-enterprises-inc-722667-03022026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnse-products-inc-dba-nu-skin-enterprises-inc-722667-03022026","2026-10-26T08:09:35.566122+00:00","2026-03-10","722667","2026-07-21","Ryan Napierski","2026-08-19T04:51:56.816+00:00","Via Email","2026-03-02",{"id":202,"raw":203,"subject":100,"body_html":208,"body_text":209,"firm_name":210,"letter_id":211,"created_at":212,"fei_number":19,"letter_url":213,"updated_at":214,"action_type":22,"case_status":23,"posted_date":215,"marcs_cms_no":216,"product_type":26,"closeout_date":19,"issuing_office":207,"recipient_name":217,"body_fetched_at":218,"delivery_method":131,"recipient_title":19,"reference_number":19,"action_taken_date":219,"medical_device_id":19,"response_letter_date":19},2176,[204,205,206,207,100,13,13,13],"\u003Ctime datetime=\"2023-03-07T14:20:00Z\">03\u002F07\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-01-03T05:00:00Z\">01\u002F03\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgolden-bridge-gourmet-inc-dba-golden-bridge-enterprises-640718-01032023\">Golden Bridge Gourmet, Inc. DBA Golden Bridge Enterprises\u003C\u002Fa>","Division of West Coast Imports","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Onnik (nmi) Guzelses\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Vice President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Golden Bridge Gourmet, Inc. DBA Golden Bridge Enterprises\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>8040 San Fernando Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Sun Valley\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>91352-4001\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:goldenbr321@cs.com\"> goldenbr321@cs.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of West Coast Imports\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>January 3, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nRe: CMS # 640718\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Onnik (nmi) Guzelses:\u003C\u002Fp>\n\n\u003Cp>On July 18, 2022, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Golden Bridge Gourmet, Inc. DBA Golden Bridge Enterprises located at 8040 San Fernando Rd., Sun Valley, CA 91352-4001. We also conducted an inspection on February 13, 2019. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\n\n\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\">https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, your firm is not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, our investigator provided you with a Form FDA 483a, FSVP Observations.\u003C\u002Fp>\n\n\u003Cp>We acknowledge receipt of your responses dated September 16, 2022, which consisted of several documents from your foreign suppliers \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Although we requested English translations on October 3, 2022, you did not provide translations for all documents. We were unable to fully evaluate these documents for compliance with the FSVP regulation. In your response, you also provided statements that you prepared after receipt of the Form FDA 483a, indicating that you approved the importation of specified foods from your foreign suppliers, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>, based on your review of the hazard analysis and the production flow chart they provided for each product. You stated that you consider your verification process complete, and that you will reevaluate each product in three years. We further address your response below.\u003C\u002Fp>\n\n\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\n\n\u003Cp>1. You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for the foods indicated in the attached list, including, but not limited to, the following foods you import:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Bread, cookies, biscuits and wafers manufactured by \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>Cookies, biscuits, wafers, pastry and bread sticks manufactured by \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>Spaghetti and noodles manufactured by \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>Chutney, candy, chocolates manufactured by \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>Bread sticks manufactured by \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>Cookies, biscuits, and wafers manufactured by \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>Biscuits, bread, cookies, and cakes manufactured by \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>Tomato (dried), asparagus, mixed vegetable, and relish manufactured by \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>2. You must approve your foreign suppliers on the basis of an evaluation of your foreign supplier’s performance and the risk posed by the food, in accordance with 21 CFR 1.505(a), for the products you import. We acknowledge your responses to the Form FDA 483a, indicating that you have documented evaluation and approval of two foreign suppliers based on a review of the hazard analysis and flow chart related to specific foods. However, in approving your foreign suppliers and determining the appropriate supplier verification activities, you did not consider the foreign supplier’s procedures, processes, and practices related to the safety of the food, as required by 1.505(a)(1)(iii)(A). Moreover, your evaluation did not consider applicable FDA food safety regulations and information relevant to the foreign supplier’s compliance with those regulations, as required by 21 CFR 1.505(a)(1)(iii)(B). Specifically, your Le Sfogliette Dorate Biscuit, imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> in \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and Black Olives and Unseasoned Black Olive Paste, imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> in \u003Cstrong>(b)(4)\u003C\u002Fstrong>, are foods covered under 21 CFR Part 117, Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food (Preventive Control Requirements). However, your supplier evaluation and approval documents did not demonstrate consideration of the supplier’s compliance with the Preventive Control Requirements.\u003C\u002Fp>\n\n\u003Cp>3. You did not meet the requirement to perform foreign supplier verification activities as required by 21 CFR 1.506. Specifically, you did not establish written procedures for ensuring that appropriate supplier verification activities are conducted in accordance with 21 CFR 1.506(b), and you did not document your determination of the appropriate supplier verification activity or activities, or the frequency with which the activity or activities must be conducted, as required by 21 CFR 1.506(d). Your email responses dated September 16, 2022, included documents titled, “Verification Procedures Page,” stating that you decided to import your Le Sfogliette Dorate Biscuits, Black Olives, and Unseasoned Black Olive Paste products after reviewing the hazard analyses and flow charts provided by the foreign suppliers, that the “verification process is complete”,” and that you “could reevaluate within 3 years.” Your responses also included four documents entirely in a foreign language labeled “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” as well as a copy of an audit report in a foreign language, partially translated to English, for your supplier \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The documents you provided do not demonstrate your determination that the activities performed were appropriate verification activities, as required per 1.506(d)(1)(i). Further, you did not conduct and document (or obtain documentation of) one or more of the supplier verification activities listed in 21 CFR 1.506(e)(1)(i) through (iv) for each foreign supplier before importing food and periodically thereafter, as required by 21 CFR 1.506(e). Specifically, you did not document your determination or performance of appropriate supplier verification activities for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>, or&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>With respect to the requirements of 21 CFR 1.506(e), regarding the performance of foreign supplier verification activities, while you may rely on third-party food safety audits as part of your foreign supplier verification activities, you must ensure the audit is performed by a qualified auditor and considers applicable FDA food safety regulations (or, when applicable, an onsite audit may consider relevant laws and regulations of a country whose food safety system FDA has officially recognized as comparable or determined to be equivalent to that of the United States). You must also promptly review and assess any third-party audit that constitutes a verification activity, as well as document your review and assessment, among other requirements (21 CFR 1.506(e)). For your foreign supplier \u003Cstrong>(b)(4)\u003C\u002Fstrong> in \u003Cstrong>(b)(4)\u003C\u002Fstrong>, as mentioned above, you provided a copy of an audit report primarily in a foreign language, that states in part, “FSSC 22000,” dated March 3, 2022, conducted by auditor, \u003Cstrong>(b)(6)\u003C\u002Fstrong>, and that was conducted to the scope of “design and products of table olive, olive oil, olive paste.” However, this document is only partially translated into English, and there is no information regarding whether the audit considered applicable FDA food safety regulations, as required per 1.506(e)(1)(i)(B). Further, you did not document your review of the results of this audit, using a qualified individual, as required by 1.506(e)(3).\u003C\u002Fp>\n\n\u003Cp>4. You must make all records required under this subpart available promptly to an authorized FDA representative, upon request, for inspection and copying. Upon FDA request, you must provide within a reasonable time an English translation of records maintained in a language other than English, as required by 21 CFR 1.510(b)(1). However, you did not provide an English translation of the following FSVP documents attached to your September 16, 2022, response to the FDA Form 483a, even after our October 3, 3022 request for the referenced documents in English: hazard analysis (partially translated into English) for the Le Sfogliette Dorate Biscuits, imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>; hazard analysis, flow chart, and copies of documents entirely in a foreign language that appear to relate to the importation of Black Olives and Unseasoned Black Olive Paste from \u003Cstrong>(b)(4)\u003C\u002Fstrong> in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. To date you have still not provided the requested translation of these documents.\u003C\u002Fp>\n\n\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States from the identified foreign suppliers on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at \u003Ca href=\"http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\">http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\u003C\u002Fa>. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\n\n\u003Cp>We also offer the following comment:\u003C\u002Fp>\n\n\u003Cp>During the inspection, \u003Cstrong>(b)(6)\u003C\u002Fstrong>, Import Manager was described as the firm’s contact for FSVP compliance. In your first email response to the FDA Form 483a, dated September 16, 2022, you included several records, such as a hazard analysis and flow chart, which you indicated you had reviewed prior to approving the importation of Le Sfogliette Dorate Biscuit from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your second email response, also dated September 16, 2022, included documents, such as a hazard analysis and flow chart, which you stated you had reviewed prior to approving the importation of Black Olives and Unseasoned Black Olive Paste from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, you did not provide FDA with training records or certificates of FSVP course completion for the personnel who made this determination. Note that a qualified individual must develop your FSVP and perform FSVP activities, and a qualified individual must have the education, training, or experience (or a combination thereof) necessary to perform their assigned activities, as required by 21 CFR 1.503(a).\u003C\u002Fp>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to Food and Drug Administration, Attention: Sandra K. Wangen Compliance Officer, Division of West Coast Imports, 949 Market St, Suite 602, Tacoma, WA 98402. If you have any questions regarding this letter, you may contact Sandra K. Wangen via email at sandra.wangen@fda.hhs.gov. Please reference CMS # 640718 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Dr. Kathleen Turner\u003Cbr>\nProgram Division Director\u003Cbr>\nDivision of West Coast Imports\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Onnik (nmi) Guzelses\n\nRecipient Title\n\nVice President\n\nGolden Bridge Gourmet, Inc. DBA Golden Bridge Enterprises\n\n8040 San Fernando Rd\n\nSun Valley, CA 91352-4001\n\nUnited States\n\ngoldenbr321@cs.com\n\nIssuing Office:\n\nDivision of West Coast Imports\n\nUnited States\n\nJanuary 3, 2023\n\nWARNING LETTER\n\nRe: CMS # 640718\n\nDear Mr. Onnik (nmi) Guzelses:\n\nOn July 18, 2022, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Golden Bridge Gourmet, Inc. DBA Golden Bridge Enterprises located at 8040 San Fernando Rd., Sun Valley, CA 91352-4001. We also conducted an inspection on February 13, 2019. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\n\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\n\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, your firm is not in compliance with section 805 of the FD&C Act.\n\nAt the conclusion of the inspection, our investigator provided you with a Form FDA 483a, FSVP Observations.\n\nWe acknowledge receipt of your responses dated September 16, 2022, which consisted of several documents from your foreign suppliers (b)(4), located in (b)(4), and (b)(4), located in (b)(4). Although we requested English translations on October 3, 2022, you did not provide translations for all documents. We were unable to fully evaluate these documents for compliance with the FSVP regulation. In your response, you also provided statements that you prepared after receipt of the Form FDA 483a, indicating that you approved the importation of specified foods from your foreign suppliers, (b)(4), located in (b)(4), and (b)(4), located in (b)(4), based on your review of the hazard analysis and the production flow chart they provided for each product. You stated that you consider your verification process complete, and that you will reevaluate each product in three years. We further address your response below.\n\nYour significant violations of the FSVP regulation are as follows:\n\n1. You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for the foods indicated in the attached list, including, but not limited to, the following foods you import:\n\nBread, cookies, biscuits and wafers manufactured by (b)(4), located in (b)(4)\n\nCookies, biscuits, wafers, pastry and bread sticks manufactured by (b)(4), located in (b)(4)\n\nSpaghetti and noodles manufactured by (b)(4), located in (b)(4)\n\nChutney, candy, chocolates manufactured by (b)(4), located in (b)(4)\n\nBread sticks manufactured by (b)(4), located in (b)(4)\n\nCookies, biscuits, and wafers manufactured by (b)(4), located in (b)(4)\n\nBiscuits, bread, cookies, and cakes manufactured by (b)(4), located in (b)(4)\n\nTomato (dried), asparagus, mixed vegetable, and relish manufactured by (b)(4), located in (b)(4)\n\n2. You must approve your foreign suppliers on the basis of an evaluation of your foreign supplier’s performance and the risk posed by the food, in accordance with 21 CFR 1.505(a), for the products you import. We acknowledge your responses to the Form FDA 483a, indicating that you have documented evaluation and approval of two foreign suppliers based on a review of the hazard analysis and flow chart related to specific foods. However, in approving your foreign suppliers and determining the appropriate supplier verification activities, you did not consider the foreign supplier’s procedures, processes, and practices related to the safety of the food, as required by 1.505(a)(1)(iii)(A). Moreover, your evaluation did not consider applicable FDA food safety regulations and information relevant to the foreign supplier’s compliance with those regulations, as required by 21 CFR 1.505(a)(1)(iii)(B). Specifically, your Le Sfogliette Dorate Biscuit, imported from (b)(4) in (b)(4), and Black Olives and Unseasoned Black Olive Paste, imported from (b)(4) in (b)(4), are foods covered under 21 CFR Part 117, Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food (Preventive Control Requirements). However, your supplier evaluation and approval documents did not demonstrate consideration of the supplier’s compliance with the Preventive Control Requirements.\n\n3. You did not meet the requirement to perform foreign supplier verification activities as required by 21 CFR 1.506. Specifically, you did not establish written procedures for ensuring that appropriate supplier verification activities are conducted in accordance with 21 CFR 1.506(b), and you did not document your determination of the appropriate supplier verification activity or activities, or the frequency with which the activity or activities must be conducted, as required by 21 CFR 1.506(d). Your email responses dated September 16, 2022, included documents titled, “Verification Procedures Page,” stating that you decided to import your Le Sfogliette Dorate Biscuits, Black Olives, and Unseasoned Black Olive Paste products after reviewing the hazard analyses and flow charts provided by the foreign suppliers, that the “verification process is complete”,” and that you “could reevaluate within 3 years.” Your responses also included four documents entirely in a foreign language labeled “(b)(4),” “(b)(4),” “(b)(4),” and “(b)(4),” as well as a copy of an audit report in a foreign language, partially translated to English, for your supplier (b)(4), located in (b)(4). The documents you provided do not demonstrate your determination that the activities performed were appropriate verification activities, as required per 1.506(d)(1)(i). Further, you did not conduct and document (or obtain documentation of) one or more of the supplier verification activities listed in 21 CFR 1.506(e)(1)(i) through (iv) for each foreign supplier before importing food and periodically thereafter, as required by 21 CFR 1.506(e). Specifically, you did not document your determination or performance of appropriate supplier verification activities for (b)(4), located in (b)(4), or (b)(4), located in (b)(4).\n\nWith respect to the requirements of 21 CFR 1.506(e), regarding the performance of foreign supplier verification activities, while you may rely on third-party food safety audits as part of your foreign supplier verification activities, you must ensure the audit is performed by a qualified auditor and considers applicable FDA food safety regulations (or, when applicable, an onsite audit may consider relevant laws and regulations of a country whose food safety system FDA has officially recognized as comparable or determined to be equivalent to that of the United States). You must also promptly review and assess any third-party audit that constitutes a verification activity, as well as document your review and assessment, among other requirements (21 CFR 1.506(e)). For your foreign supplier (b)(4) in (b)(4), as mentioned above, you provided a copy of an audit report primarily in a foreign language, that states in part, “FSSC 22000,” dated March 3, 2022, conducted by auditor, (b)(6), and that was conducted to the scope of “design and products of table olive, olive oil, olive paste.” However, this document is only partially translated into English, and there is no information regarding whether the audit considered applicable FDA food safety regulations, as required per 1.506(e)(1)(i)(B). Further, you did not document your review of the results of this audit, using a qualified individual, as required by 1.506(e)(3).\n\n4. You must make all records required under this subpart available promptly to an authorized FDA representative, upon request, for inspection and copying. Upon FDA request, you must provide within a reasonable time an English translation of records maintained in a language other than English, as required by 21 CFR 1.510(b)(1). However, you did not provide an English translation of the following FSVP documents attached to your September 16, 2022, response to the FDA Form 483a, even after our October 3, 3022 request for the referenced documents in English: hazard analysis (partially translated into English) for the Le Sfogliette Dorate Biscuits, imported from (b)(4); hazard analysis, flow chart, and copies of documents entirely in a foreign language that appear to relate to the importation of Black Olives and Unseasoned Black Olive Paste from (b)(4) in (b)(4). To date you have still not provided the requested translation of these documents.\n\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1, subpart L.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States from the identified foreign suppliers on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\n\nWe also offer the following comment:\n\nDuring the inspection, (b)(6), Import Manager was described as the firm’s contact for FSVP compliance. In your first email response to the FDA Form 483a, dated September 16, 2022, you included several records, such as a hazard analysis and flow chart, which you indicated you had reviewed prior to approving the importation of Le Sfogliette Dorate Biscuit from (b)(4), located in (b)(4). Your second email response, also dated September 16, 2022, included documents, such as a hazard analysis and flow chart, which you stated you had reviewed prior to approving the importation of Black Olives and Unseasoned Black Olive Paste from (b)(4), located in (b)(4). However, you did not provide FDA with training records or certificates of FSVP course completion for the personnel who made this determination. Note that a qualified individual must develop your FSVP and perform FSVP activities, and a qualified individual must have the education, training, or experience (or a combination thereof) necessary to perform their assigned activities, as required by 21 CFR 1.503(a).\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.\n\nPlease send your reply to Food and Drug Administration, Attention: Sandra K. Wangen Compliance Officer, Division of West Coast Imports, 949 Market St, Suite 602, Tacoma, WA 98402. If you have any questions regarding this letter, you may contact Sandra K. Wangen via email at sandra.wangen@fda.hhs.gov. Please reference CMS # 640718 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\n\nSincerely,\n\n\u002FS\u002F\n\nDr. Kathleen Turner\n\nProgram Division Director\n\nDivision of West Coast Imports","Golden Bridge Gourmet, Inc. DBA Golden Bridge Enterprises","golden-bridge-gourmet-inc-dba-golden-bridge-enterprises-640718-01032023","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgolden-bridge-gourmet-inc-dba-golden-bridge-enterprises-640718-01032023","2026-10-26T08:08:47.705639+00:00","2023-03-07","640718","Mr. Onnik (nmi) Guzelses","2026-08-20T01:12:58.029+00:00","2023-01-03",{"id":221,"raw":222,"subject":226,"body_html":227,"body_text":228,"firm_name":229,"letter_id":230,"created_at":18,"fei_number":19,"letter_url":231,"updated_at":232,"action_type":22,"case_status":23,"posted_date":233,"marcs_cms_no":234,"product_type":49,"closeout_date":19,"issuing_office":183,"recipient_name":19,"body_fetched_at":235,"delivery_method":236,"recipient_title":19,"reference_number":19,"action_taken_date":237,"medical_device_id":19,"response_letter_date":19},591,[223,224,225,183,226,13,13,13],"\u003Ctime datetime=\"2025-09-16T13:20:00Z\">09\u002F16\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-09-09T04:00:00Z\">09\u002F09\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgetfitmedical-llc-dba-getfitmedical-715801-09092025\">Get.Fit.Medical, LLC dba Get.Fit.Medical\u003C\u002Fa>","Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Get.Fit.Medical, LLC dba Get.Fit.Medical\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:https:\u002F\u002Fwww.getfitmedical.com\"> https:\u002F\u002Fwww.getfitmedical.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:drewcromer@getfitmedical.com\"> drewcromer@getfitmedical.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>September 9, 2025\u003C\u002Fp>\u003Cp>Get.Fit.Medical:\u003C\u002Fp>\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Fwww.getfitmedical.com in August 2025 and has observed that your website offers various compounded drug products, including sildenafil, tadalafil, semaglutide, and tirzepatide.\u003Ca id=\"footnoteref1_9e35aee\" href=\"#footnote1_9e35aee\">\u003Csup>1\u003C\u002Fsup>\u003C\u002Fa>&nbsp;As described below, your claims concerning compounded sildenafil, tadalafil, semaglutide, and tirzepatide products are false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\u003C\u002Fp>\u003Cp>Under section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\u003C\u002Fp>\u003Cp>The following claims concerning compounded sildenafil, tadalafil, semaglutide, and tirzepatide products appear on webpages that offer only compounded products:\u003Cbr>• “SILDENAFIL (GENERIC VIAGRA)”\u003Cbr>• “TADALAFIL (GENERIC CIALIS)”\u003Cbr>• “SEMAGLUTIDE (GENERIC OZEMPIC\u002FWEGOVY)”\u003Cbr>• “TIRZEPATIDE (GENERIC MOUNJARO)”\u003C\u002Fp>\u003Cp>Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The claims identified in this letter put you on notice of our concerns but do not represent an exhaustive list of misbranding violations.\u003Ca id=\"footnoteref2_gm2b1es\" href=\"#footnote2_gm2b1es\">\u003Csup>2\u003C\u002Fsup>\u003C\u002Fa>\u003C\u002Fp>\u003Cp>For the reasons discussed above, your compounded sildenafil, tadalafil, semaglutide, and tirzepatide products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\u003C\u002Fp>\u003Cp>As previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>You should take immediate action to address any violations (including, for example, ceasing and desisting from using the language cited above that misbrands the product). Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\u003Cp>If you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded drugs that cannot be legally sold to consumers in the U.S.\u003C\u002Fp>\u003Cp>All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\u003C\u002Fp>\u003Cp>\u003Cbr>Sincerely,\u003Cbr>\u002FS\u002F\u003Cbr>George Tidmarsh, M.D., Ph.D.\u003Cbr>Director\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\n\n\u003Col>\n                  \u003Cli id=\"footnote1_9e35aee\">\u003Ca href=\"#footnoteref1_9e35aee\">1\u003C\u002Fa>The sildenafil, tadalafil, semaglutide, and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fli>\n                      \u003Cli id=\"footnote2_gm2b1es\">\u003Ca href=\"#footnoteref2_gm2b1es\">2\u003C\u002Fa>Overstatements of efficacy or minimization of risk are of particular concern and may constitute misbranding.\u003C\u002Fli>\n      \u003C\u002Fol>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nRecipient:\n\nGet.Fit.Medical, LLC dba Get.Fit.Medical\n\nUnited States\n\nhttps:\u002F\u002Fwww.getfitmedical.com\n\ndrewcromer@getfitmedical.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\nSeptember 9, 2025\nGet.Fit.Medical:\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Fwww.getfitmedical.com in August 2025 and has observed that your website offers various compounded drug products, including sildenafil, tadalafil, semaglutide, and tirzepatide.1 As described below, your claims concerning compounded sildenafil, tadalafil, semaglutide, and tirzepatide products are false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\nUnder section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\nThe following claims concerning compounded sildenafil, tadalafil, semaglutide, and tirzepatide products appear on webpages that offer only compounded products:\n• “SILDENAFIL (GENERIC VIAGRA)”\n• “TADALAFIL (GENERIC CIALIS)”\n• “SEMAGLUTIDE (GENERIC OZEMPIC\u002FWEGOVY)”\n• “TIRZEPATIDE (GENERIC MOUNJARO)”\nCompounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\nThe introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The claims identified in this letter put you on notice of our concerns but do not represent an exhaustive list of misbranding violations.2\nFor the reasons discussed above, your compounded sildenafil, tadalafil, semaglutide, and tirzepatide products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\nAs previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations.\nYou should take immediate action to address any violations (including, for example, ceasing and desisting from using the language cited above that misbrands the product). Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\nWithin fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\nIf you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded drugs that cannot be legally sold to consumers in the U.S.\nAll correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\n\nSincerely,\n\u002FS\u002F\nGeorge Tidmarsh, M.D., Ph.D.\nDirector\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n\n1The sildenafil, tadalafil, semaglutide, and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\n\n2Overstatements of efficacy or minimization of risk are of particular concern and may constitute misbranding.","Get.Fit.Medical, LLC dba Get.Fit.Medical","getfitmedical-llc-dba-getfitmedical-715801-09092025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgetfitmedical-llc-dba-getfitmedical-715801-09092025","2026-10-26T08:08:45.732183+00:00","2025-09-16","715801","2026-08-19T16:21:40.471+00:00","VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED","2025-09-09",{"id":239,"raw":240,"subject":80,"body_html":244,"body_text":245,"firm_name":246,"letter_id":247,"created_at":43,"fei_number":19,"letter_url":248,"updated_at":249,"action_type":22,"case_status":23,"posted_date":250,"marcs_cms_no":251,"product_type":89,"closeout_date":19,"issuing_office":79,"recipient_name":19,"body_fetched_at":252,"delivery_method":92,"recipient_title":19,"reference_number":19,"action_taken_date":250,"medical_device_id":19,"response_letter_date":19},1617,[241,242,243,79,80,13,13,13],"\u003Ctime datetime=\"2024-02-08T20:00:00Z\">02\u002F08\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-02-08T05:00:00Z\">02\u002F08\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fr-melton-enterprises-llc-dba-north-georgia-vapor-676124-02082024\">R. Melton Enterprises LLC dba North Georgia Vapor \u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>R. Melton Enterprises LLC dba North Georgia Vapor \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>214 Atlanta Road Suite D\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Cumming\u003C\u002Fspan>, \u003Cspan>GA\u003C\u002Fspan> \u003Cspan>30040\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>February 8, 2024\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>To Whom It May Concern,\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed our inspection records, and determined that R. Melton Enterprises LLC d\u002Fb\u002Fa North Georgia Vapor manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States e-liquid products without a marketing authorization order, including: Peach.\u003C\u002Fp>\n\n\u003Cp>The e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that your firm markets new tobacco products lacking premarket authorization in the United States. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2401011, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ele Ibarra-Pratt\u003Cbr>\nActing Director\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nR. Melton Enterprises LLC dba North Georgia Vapor\n\n214 Atlanta Road Suite D\n\nCumming, GA 30040\n\nUnited States\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nFebruary 8, 2024\n\nWARNING LETTER\n\nTo Whom It May Concern,\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed our inspection records, and determined that R. Melton Enterprises LLC d\u002Fb\u002Fa North Georgia Vapor manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\n\nFDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States e-liquid products without a marketing authorization order, including: Peach.\n\nThe e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nFDA has determined that your firm markets new tobacco products lacking premarket authorization in the United States. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\n\nIt is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2401011, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nEle Ibarra-Pratt\n\nActing Director\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products","R. Melton Enterprises LLC dba North Georgia Vapor","r-melton-enterprises-llc-dba-north-georgia-vapor-676124-02082024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fr-melton-enterprises-llc-dba-north-georgia-vapor-676124-02082024","2026-10-26T08:09:46.318292+00:00","2024-02-08","676124","2026-08-20T00:19:03.509+00:00",{"id":254,"raw":255,"subject":100,"body_html":259,"body_text":260,"firm_name":261,"letter_id":262,"created_at":212,"fei_number":19,"letter_url":263,"updated_at":264,"action_type":22,"case_status":23,"posted_date":265,"marcs_cms_no":266,"product_type":26,"closeout_date":19,"issuing_office":207,"recipient_name":267,"body_fetched_at":268,"delivery_method":269,"recipient_title":19,"reference_number":19,"action_taken_date":270,"medical_device_id":19,"response_letter_date":19},2428,[256,257,258,207,100,13,13,13],"\u003Ctime datetime=\"2022-09-20T13:20:00Z\">09\u002F20\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-07-25T04:00:00Z\">07\u002F25\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbacocas-enterprises-inc-633756-07252022\">Bacocas Enterprises Inc.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ricardo (nmi) Cervantes\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Bacocas Enterprises Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2680 S. Bonnie Pl.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Vernon\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>90058-4312\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of West Coast Imports\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>July 25, 2022\u003C\u002Fp>\n\n\u003Cp>Re: CMS # 633756\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Cervantes:\u003C\u002Fp>\n\n\u003Cp>On April 8, 2022, the Food and Drug Administration conducted a Foreign Supplier Verification Program (FSVP) inspection of Bacocas Enterprises, Inc. located at 2680 S. Bonnie Pl., Vernon, CA 90058-4312. We also conducted an inspection on June 16, 2020. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\n\n\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\">https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, our investigator provided you with a Form FDA 483a, FSVP Observations. We have not received your response to the Form FDA 483a issued on April 8, 2022.\u003C\u002Fp>\n\n\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\n\n\u003Cp>You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the food that you import, including each of the following food products imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Watermelon\u003C\u002Fli>\n\t\u003Cli>Spaghetti squash\u003C\u002Fli>\n\t\u003Cli>Kabocha squash\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert #99-41 at&nbsp;\u003Ca href=\"http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\">http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\u003C\u002Fa>. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\n\n\u003Cp>Additionally, we offer the following comment:\u003C\u002Fp>\n\n\u003Cp>You import watermelons, which are “covered produce” as defined in 21 CFR 112.3. Your FSVP must demonstrate that your supplier is producing the food in compliance with processes and procedures that provide at least the same level of public health protection as those required under section 419 of the FD&amp;C Act (21 U.S.C. § 350h) (regarding standards for produce safety) and the implementing regulations in the Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption (21 CFR part 112).\u003C\u002Fp>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP, and any additional information that you wish to supply relevant to your compliance with the FSVP regulation). If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to Food and Drug Administration, Attention: Debbie Giang, Compliance Officer, Division of West Coast Imports, One World Trade Center, Suite 300, Long Beach, CA 90831. If you have any questions regarding this letter, you may contact Debbie Giang via email at debbie.giang@fda.hhs.gov. Please reference CMS #633756 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Dr. Kathleen Turner\u003Cbr>\nProgram Division Director\u003Cbr>\nDivision of West Coast Imports\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nRicardo (nmi) Cervantes\n\nRecipient Title\n\nOwner\n\nBacocas Enterprises Inc.\n\n2680 S. Bonnie Pl.\n\nVernon, CA 90058-4312\n\nUnited States\n\nIssuing Office:\n\nDivision of West Coast Imports\n\nUnited States\n\nWARNING LETTER\n\nJuly 25, 2022\n\nRe: CMS # 633756\n\nDear Mr. Cervantes:\n\nOn April 8, 2022, the Food and Drug Administration conducted a Foreign Supplier Verification Program (FSVP) inspection of Bacocas Enterprises, Inc. located at 2680 S. Bonnie Pl., Vernon, CA 90058-4312. We also conducted an inspection on June 16, 2020. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\n\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\n\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&C Act.\n\nAt the conclusion of the inspection, our investigator provided you with a Form FDA 483a, FSVP Observations. We have not received your response to the Form FDA 483a issued on April 8, 2022.\n\nYour significant violations of the FSVP regulation are as follows:\n\nYou did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the food that you import, including each of the following food products imported from (b)(4) located in (b)(4):\n\nWatermelon\n\nSpaghetti squash\n\nKabocha squash\n\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1, subpart L.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert #99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\n\nAdditionally, we offer the following comment:\n\nYou import watermelons, which are “covered produce” as defined in 21 CFR 112.3. Your FSVP must demonstrate that your supplier is producing the food in compliance with processes and procedures that provide at least the same level of public health protection as those required under section 419 of the FD&C Act (21 U.S.C. § 350h) (regarding standards for produce safety) and the implementing regulations in the Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption (21 CFR part 112).\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP, and any additional information that you wish to supply relevant to your compliance with the FSVP regulation). If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.\n\nPlease send your reply to Food and Drug Administration, Attention: Debbie Giang, Compliance Officer, Division of West Coast Imports, One World Trade Center, Suite 300, Long Beach, CA 90831. If you have any questions regarding this letter, you may contact Debbie Giang via email at debbie.giang@fda.hhs.gov. Please reference CMS #633756 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\n\nSincerely,\n\n\u002FS\u002F\n\nDr. Kathleen Turner\n\nProgram Division Director\n\nDivision of West Coast Imports","Bacocas Enterprises Inc.","bacocas-enterprises-inc-633756-07252022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbacocas-enterprises-inc-633756-07252022","2026-10-26T08:08:00.298603+00:00","2022-09-20","633756","Ricardo (nmi) Cervantes","2026-08-20T01:33:03.881+00:00","VIA UNITED PARCEL SERVICE","2022-07-25",{"id":272,"raw":273,"subject":80,"body_html":277,"body_text":278,"firm_name":279,"letter_id":280,"created_at":212,"fei_number":19,"letter_url":281,"updated_at":282,"action_type":22,"case_status":23,"posted_date":283,"marcs_cms_no":284,"product_type":89,"closeout_date":19,"issuing_office":79,"recipient_name":285,"body_fetched_at":286,"delivery_method":92,"recipient_title":19,"reference_number":19,"action_taken_date":283,"medical_device_id":19,"response_letter_date":19},2408,[274,275,276,79,80,13,13,13],"\u003Ctime datetime=\"2022-10-06T19:00:00Z\">10\u002F06\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-10-06T04:00:00Z\">10\u002F06\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwillyanjel-enterprises-llc-dba-emote-vapes-643268-10062022\">WillyAnjel Enterprises LLC dba Emote Vapes\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Angela Carol Funderburk\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>WillyAnjel Enterprises LLC dba Emote Vapes\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>107 Crye Leike Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Fort Oglethorpe\u003C\u002Fspan>, \u003Cspan>GA\u003C\u002Fspan> \u003Cspan>30742\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:anjel@emotevapes.com\"> anjel@emotevapes.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 6, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mrs. Funderburk:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that WillyAnjel Enterprises LLC d\u002Fb\u002Fa Emote Vapes manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14\">https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States BLUE MOON e-liquid products without a marketing authorization order.\u003C\u002Fp>\n\n\u003Cp>The e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has not received an application from your firm requesting marketing authorization for the products listed in this Warning Letter. These products and any other new tobacco product on the market without the statutorily required premarket authorization are adulterated and misbranded and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ERER2200699, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nAngela Carol Funderburk\n\nRecipient Title\n\nOwner\n\nWillyAnjel Enterprises LLC dba Emote Vapes\n\n107 Crye Leike Drive\n\nFort Oglethorpe, GA 30742\n\nUnited States\n\nanjel@emotevapes.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nOctober 6, 2022\n\nWARNING LETTER\n\nDear Mrs. Funderburk:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that WillyAnjel Enterprises LLC d\u002Fb\u002Fa Emote Vapes manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\n\nFDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States BLUE MOON e-liquid products without a marketing authorization order.\n\nThe e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nFDA has not received an application from your firm requesting marketing authorization for the products listed in this Warning Letter. These products and any other new tobacco product on the market without the statutorily required premarket authorization are adulterated and misbranded and are subject to enforcement action at FDA’s discretion.\n\nIt is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ERER2200699, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products","WillyAnjel Enterprises LLC dba Emote Vapes","willyanjel-enterprises-llc-dba-emote-vapes-643268-10062022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwillyanjel-enterprises-llc-dba-emote-vapes-643268-10062022","2026-10-26T08:10:32.099247+00:00","2022-10-06","643268","Angela Carol Funderburk","2026-08-20T01:31:29.276+00:00",{"id":288,"raw":289,"subject":12,"body_html":293,"body_text":294,"firm_name":295,"letter_id":296,"created_at":18,"fei_number":19,"letter_url":297,"updated_at":298,"action_type":22,"case_status":23,"posted_date":299,"marcs_cms_no":300,"product_type":301,"closeout_date":19,"issuing_office":11,"recipient_name":302,"body_fetched_at":303,"delivery_method":199,"recipient_title":19,"reference_number":19,"action_taken_date":304,"medical_device_id":19,"response_letter_date":19},566,[290,291,292,11,12,13,13,13],"\u003Ctime datetime=\"2025-09-30T04:00:00Z\">09\u002F30\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-07-17T04:00:00Z\">07\u002F17\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvalentine-enterprises-inc-705119-07172025\">Valentine Enterprises, Inc.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Dietary Supplements                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Alan W. Smith\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u002FCEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Valentine Enterprises, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1291 Progress Center Ave\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Lawrenceville\u003C\u002Fspan>, \u003Cspan>GA\u003C\u002Fspan> \u003Cspan>30043-4801\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:awsmith@veiusa.com\"> awsmith@veiusa.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Human Foods Program\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>July 17, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>CMS # 705119\u003C\u002Fp>\u003Cp>Dear Mr. Smith:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) conducted an inspection of your facility located at 1291 Progress Center Ave., Lawrenceville, GA 30043-4801 from October 8 – 24, 2024. Based on inspectional findings and review of the product documents collected during the inspection, we have identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on FDA's home page at www.fda.gov.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection on October 24, 2024, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We acknowledge receipt of your written responses dated November 7, and December 5, 2024, and January 31, February 28, March 31, 2025, May 30, and June 30, 2025, and we address your responses below.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Adulterated Dietary Supplements\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The inspection of your facility from October 8 through October 24, 2024, identified serious violations of the FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). These violations cause the dietary supplement product, Vibrant Health Green Vibrance (“VH Green Vibrance”), manufactured at your facility to be adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. 342(g)(1)] because it has been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements.\u003C\u002Fp>\u003Cp>Your significant violations of the CGMP requirements are as follows:\u003C\u002Fp>\u003Cp>1. Your firm failed to, for each dietary supplement that you manufacture, establish product specifications for the identity, purity, strength, composition and limits on contamination of the finished batch of the dietary supplement as required in 21 CFR 111.70(e).\u003C\u002Fp>\u003Cp>Specifically, your document, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” for your product VH Green Vibrance, does not establish an identity specification that includes a test method that will adequately identify the finished product. Your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” sheet purports to use organoleptic attributes (taste, texture, aroma and color), with a specification that states “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” for identity testing. However, this does not provide sufficient detail for your firm to be able to confirm the identity of a multi-ingredient finished product in powder form, and it does not ensure that you can distinguish one product from any other mix of powdered substances. Additionally:\u003C\u002Fp>\u003Cp>- Only eighteen of the dietary ingredients in VH Green Vibrance are listed to be tested on a rotating basis, which is not adequate to establish identity for each batch of the dietary supplement, and there is no acceptance criteria written on the specification form.\u003C\u002Fp>\u003Cp>Your responses dated 12\u002F06\u002F24, 1\u002F31\u002F25, 2\u002F28\u002F25, 3\u002F31\u002F25, 5\u002F30\u002F25, and 6\u002F30\u002F25 include updated finished product specifications for VH Green Vibrance. They include methods for some of the ingredients, however, the frequency of first lot\u002Fannually or rotating is not supported by a scientific rationale as to how this confirms the identity specifications of every lot. Additionally, some of the test methods are from private labs or internal, so we are unable to evaluate if they are adequate for the intended target.\u003C\u002Fp>\u003Cp>Additionally, for VH Green Vibrance, the label lists probiotic bacteria ingredients and respective quantities, but you state \u003Cstrong>(b)(4)\u003C\u002Fstrong>. We understand you are in discussions with the client about taking corrective action on this issue. We will evaluate the adequacy of your corrective action at the next inspection.\u003C\u002Fp>\u003Cp>We note that in addition to establishing the required specifications, your firm must determine whether such specifications are met, in accordance with 21 CFR 111.73 and 111.75.\u003C\u002Fp>\u003Cp>2. You failed to verify that the laboratory examination and testing methodologies are appropriate for their intended use, as required by 21 CFR 111.320(a).\u003C\u002Fp>\u003Cp>Specifically, you rely on a third-party laboratory to conduct your pathogen testing for finished products. Your third-party laboratory said they did not determine the suitability of the following methods for testing VH Green Vibrance:\u003C\u002Fp>\u003Cul>\u003Cli>BAM chapter 12 for testing for presence of \u003Cem>S. aureus\u003C\u002Fem>;\u003C\u002Fli>\u003Cli>AOAC 991.14 for testing for presence of \u003Cem>E. coli\u003C\u002Fem>;\u003C\u002Fli>\u003Cli>AOAC-RI 121501 for testing for the presence of \u003Cem>Salmonella\u003C\u002Fem>.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your responses dated 12\u002F06\u002F24, 1\u002F31\u002F25, 2\u002F28\u002F25, 3\u002F31\u002F25, 5\u002F30\u002F25, and 6\u002F30\u002F25, include updated finished product microbial testing specifications and you state you \u003Cstrong>(b)(4)\u003C\u002Fstrong> for pathogen testing for finished products. However, we are unable to evaluate the adequacy of your response because you did not provide supporting documentation demonstrating that you have verified that such tests are appropriate for their intended use in your products.\u003C\u002Fp>\u003Cp>3. Your firm failed to include complete information in your batch production records relating to the production and control of each batch, as required by 21 CFR 111.255(b) and in accordance with 21 CFR 111.260.\u003C\u002Fp>\u003Cp>Specifically, for VH Green Vibrance, your BPRs did not include:\u003C\u002Fp>\u003Cp>a. The date and time of maintenance, cleaning, and sanitizing of the equipment and processing lines used in producing the batch, or a cross-reference to records where this information is retained, as required by 21 CFR 111.260(c).\u003Cbr>b. The results of any testing or examination performed during the batch production, or a cross-reference to such results, as required by 21 CFR 111.260(h).\u003C\u002Fp>\u003Cp>Your responses dated 12\u002F06\u002F24, 1\u002F31\u002F25, 2\u002F28\u002F25, 3\u002F31\u002F25, 5\u002F30\u002F25, and 6\u002F30\u002F25 include updated procedures and you reference updated MMRs which you state \u003Cstrong>(b)(4)\u003C\u002Fstrong>. We will evaluate the adequacy of your corrective actions at the next inspection.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Misbranded Dietary Supplements\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In addition, we reviewed your product labels collected during the inspection and have determined the MuscleTech EuphoriQ Pre-Workout Watermelon Candy, VH Green Vibrance, Vibrant Health Joint Vibrance, and Premium Green Superfood Cytogreens products you manufacture are misbranded under section 403 of the Act [21 U.S.C. 343] because they do not comply with the labeling requirements for dietary supplements.\u003C\u002Fp>\u003Cp>1. The products are misbranded within the meaning of section 403(i)(2) of the Act [21 U.S.C. § 343(i)(2)] in that the product labels fail to declare all the common or usual names of each ingredient used as required by 21 CFR 101.36 and 21 CFR 101.4. Specifically,\u003C\u002Fp>\u003Cp>- For MuscleTech EuphoriQ Pre-Workout Watermelon Candy you declare the dietary ingredient “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” 10 mcg. Your MMRs’ “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” identifies the ingredient as “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” Your raw material specification 88-517 provided in your 2\u002F28\u002F25 response describes the ingredient as “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” It appears that you add an extract of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, but the label does not mention the extract.\u003C\u002Fp>\u003Cp>- For VH Green Vibrance – you declare as “\u003Cstrong>(b)(4)\u003C\u002Fstrong> natural flavor, which is not a common or usual name.\u003C\u002Fp>\u003Cp>- For Vibrant Health Joint Vibrance and Premium Green Superfood Cytogreens – the “\u003Cstrong>(b)(4)\u003C\u002Fstrong> is not a common or usual name.\u003C\u002Fp>\u003Cp>2. The products are misbranded within the meaning of section 403(q)(1)(A) of the Act [21 U.S.C. § 343(q)(1)(A)] because the serving size declared on the label is incorrect. Serving size for a dietary supplement is the maximum amount consumed per eating occasion as recommended on the product label as defined in 21 CFR 101.9(b) and 21 CFR 101.12(b) Table 2. Specifically:\u003C\u002Fp>\u003Cp>- For Vibrant Health Joint Vibrance - the product’s label declares serving size as 1 scoop. The directions state to take one to two (1 to 2) scoops.\u003C\u002Fp>\u003Cp>- For products 8 Greens Super Greens Powder and Premium Green Superfood Cytogreens - the serving size needs to be expressed using the term that is appropriate for the form of the supplement, such as “tablets,” “capsules,” “packets,” or “teaspoonfuls,” as required by 21 CFR 101.36(b)(1)(i). The appropriate term would be “1 Scoop (x g)” as stated in the directions for use.\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>We also have the following comment:\u003C\u002Fp>\u003Cp>On the label of 8 Greens Super Greens Powder, you compare the amounts of vitamins and zinc to what is contained in fruits and vegetables. Please note all information on the product label must be truthful and not misleading.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Your written reply should be directed to Sara J. Dent Acosta, United States Food and Drug Administration, Human Foods Program, Office of Enforcement, 5001 Campus Drive, College Park, Maryland 20740-3835 or via email at HFP-OCE-DietarySupplements@fda.hhs.gov. Please reference CMS #705119 on any submissions and within the subject line of any emails to us. If you have any questions, you may email at HFP-OCE-DietarySupplements@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Maria S. Knirk, JD, MBA\u003Cbr>Acting Director, Office of Enforcement\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Human Foods Program\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDietary Supplements\n\nRecipient:\n\nRecipient Name\n\nAlan W. Smith\n\nRecipient Title\n\nPresident\u002FCEO\n\nValentine Enterprises, Inc.\n\n1291 Progress Center Ave\n\nLawrenceville, GA 30043-4801\n\nUnited States\n\nawsmith@veiusa.com\n\nIssuing Office:\n\nHuman Foods Program\n\nUnited States\n\nJuly 17, 2025\nWARNING LETTER\nCMS # 705119\nDear Mr. Smith:\nThe U.S. Food and Drug Administration (FDA) conducted an inspection of your facility located at 1291 Progress Center Ave., Lawrenceville, GA 30043-4801 from October 8 – 24, 2024. Based on inspectional findings and review of the product documents collected during the inspection, we have identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on FDA's home page at www.fda.gov.\nAt the conclusion of the inspection on October 24, 2024, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We acknowledge receipt of your written responses dated November 7, and December 5, 2024, and January 31, February 28, March 31, 2025, May 30, and June 30, 2025, and we address your responses below.\nAdulterated Dietary Supplements\nThe inspection of your facility from October 8 through October 24, 2024, identified serious violations of the FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). These violations cause the dietary supplement product, Vibrant Health Green Vibrance (“VH Green Vibrance”), manufactured at your facility to be adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. 342(g)(1)] because it has been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements.\nYour significant violations of the CGMP requirements are as follows:\n1. Your firm failed to, for each dietary supplement that you manufacture, establish product specifications for the identity, purity, strength, composition and limits on contamination of the finished batch of the dietary supplement as required in 21 CFR 111.70(e).\nSpecifically, your document, “(b)(4)” for your product VH Green Vibrance, does not establish an identity specification that includes a test method that will adequately identify the finished product. Your “(b)(4)” sheet purports to use organoleptic attributes (taste, texture, aroma and color), with a specification that states “(b)(4)” for identity testing. However, this does not provide sufficient detail for your firm to be able to confirm the identity of a multi-ingredient finished product in powder form, and it does not ensure that you can distinguish one product from any other mix of powdered substances. Additionally:\n- Only eighteen of the dietary ingredients in VH Green Vibrance are listed to be tested on a rotating basis, which is not adequate to establish identity for each batch of the dietary supplement, and there is no acceptance criteria written on the specification form.\nYour responses dated 12\u002F06\u002F24, 1\u002F31\u002F25, 2\u002F28\u002F25, 3\u002F31\u002F25, 5\u002F30\u002F25, and 6\u002F30\u002F25 include updated finished product specifications for VH Green Vibrance. They include methods for some of the ingredients, however, the frequency of first lot\u002Fannually or rotating is not supported by a scientific rationale as to how this confirms the identity specifications of every lot. Additionally, some of the test methods are from private labs or internal, so we are unable to evaluate if they are adequate for the intended target.\nAdditionally, for VH Green Vibrance, the label lists probiotic bacteria ingredients and respective quantities, but you state (b)(4). We understand you are in discussions with the client about taking corrective action on this issue. We will evaluate the adequacy of your corrective action at the next inspection.\nWe note that in addition to establishing the required specifications, your firm must determine whether such specifications are met, in accordance with 21 CFR 111.73 and 111.75.\n2. You failed to verify that the laboratory examination and testing methodologies are appropriate for their intended use, as required by 21 CFR 111.320(a).\nSpecifically, you rely on a third-party laboratory to conduct your pathogen testing for finished products. Your third-party laboratory said they did not determine the suitability of the following methods for testing VH Green Vibrance:\nBAM chapter 12 for testing for presence of S. aureus;\nAOAC 991.14 for testing for presence of E. coli;\nAOAC-RI 121501 for testing for the presence of Salmonella.\nYour responses dated 12\u002F06\u002F24, 1\u002F31\u002F25, 2\u002F28\u002F25, 3\u002F31\u002F25, 5\u002F30\u002F25, and 6\u002F30\u002F25, include updated finished product microbial testing specifications and you state you (b)(4) for pathogen testing for finished products. However, we are unable to evaluate the adequacy of your response because you did not provide supporting documentation demonstrating that you have verified that such tests are appropriate for their intended use in your products.\n3. Your firm failed to include complete information in your batch production records relating to the production and control of each batch, as required by 21 CFR 111.255(b) and in accordance with 21 CFR 111.260.\nSpecifically, for VH Green Vibrance, your BPRs did not include:\na. The date and time of maintenance, cleaning, and sanitizing of the equipment and processing lines used in producing the batch, or a cross-reference to records where this information is retained, as required by 21 CFR 111.260(c).\nb. The results of any testing or examination performed during the batch production, or a cross-reference to such results, as required by 21 CFR 111.260(h).\nYour responses dated 12\u002F06\u002F24, 1\u002F31\u002F25, 2\u002F28\u002F25, 3\u002F31\u002F25, 5\u002F30\u002F25, and 6\u002F30\u002F25 include updated procedures and you reference updated MMRs which you state (b)(4). We will evaluate the adequacy of your corrective actions at the next inspection.\nMisbranded Dietary Supplements\nIn addition, we reviewed your product labels collected during the inspection and have determined the MuscleTech EuphoriQ Pre-Workout Watermelon Candy, VH Green Vibrance, Vibrant Health Joint Vibrance, and Premium Green Superfood Cytogreens products you manufacture are misbranded under section 403 of the Act [21 U.S.C. 343] because they do not comply with the labeling requirements for dietary supplements.\n1. The products are misbranded within the meaning of section 403(i)(2) of the Act [21 U.S.C. § 343(i)(2)] in that the product labels fail to declare all the common or usual names of each ingredient used as required by 21 CFR 101.36 and 21 CFR 101.4. Specifically,\n- For MuscleTech EuphoriQ Pre-Workout Watermelon Candy you declare the dietary ingredient “(b)(4)” 10 mcg. Your MMRs’ “(b)(4)” identifies the ingredient as “(b)(4).” Your raw material specification 88-517 provided in your 2\u002F28\u002F25 response describes the ingredient as “(b)(4).” It appears that you add an extract of (b)(4), but the label does not mention the extract.\n- For VH Green Vibrance – you declare as “(b)(4) natural flavor, which is not a common or usual name.\n- For Vibrant Health Joint Vibrance and Premium Green Superfood Cytogreens – the “(b)(4) is not a common or usual name.\n2. The products are misbranded within the meaning of section 403(q)(1)(A) of the Act [21 U.S.C. § 343(q)(1)(A)] because the serving size declared on the label is incorrect. Serving size for a dietary supplement is the maximum amount consumed per eating occasion as recommended on the product label as defined in 21 CFR 101.9(b) and 21 CFR 101.12(b) Table 2. Specifically:\n- For Vibrant Health Joint Vibrance - the product’s label declares serving size as 1 scoop. The directions state to take one to two (1 to 2) scoops.\n- For products 8 Greens Super Greens Powder and Premium Green Superfood Cytogreens - the serving size needs to be expressed using the term that is appropriate for the form of the supplement, such as “tablets,” “capsules,” “packets,” or “teaspoonfuls,” as required by 21 CFR 101.36(b)(1)(i). The appropriate term would be “1 Scoop (x g)” as stated in the directions for use.\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\nWe also have the following comment:\nOn the label of 8 Greens Super Greens Powder, you compare the amounts of vitamins and zinc to what is contained in fruits and vegetables. Please note all information on the product label must be truthful and not misleading.\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\nYour written reply should be directed to Sara J. Dent Acosta, United States Food and Drug Administration, Human Foods Program, Office of Enforcement, 5001 Campus Drive, College Park, Maryland 20740-3835 or via email at HFP-OCE-DietarySupplements@fda.hhs.gov. Please reference CMS #705119 on any submissions and within the subject line of any emails to us. If you have any questions, you may email at HFP-OCE-DietarySupplements@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nMaria S. Knirk, JD, MBA\nActing Director, Office of Enforcement\nOffice of Compliance and Enforcement\nHuman Foods Program","Valentine Enterprises, Inc.","valentine-enterprises-inc-705119-07172025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvalentine-enterprises-inc-705119-07172025","2026-10-26T08:10:19.11619+00:00","2025-09-30","705119","Dietary Supplements","Alan W. Smith","2026-08-19T16:16:58.748+00:00","2025-07-17",{"id":306,"raw":307,"subject":311,"body_html":312,"body_text":313,"firm_name":314,"letter_id":315,"created_at":146,"fei_number":19,"letter_url":316,"updated_at":317,"action_type":22,"case_status":23,"posted_date":318,"marcs_cms_no":319,"product_type":49,"closeout_date":19,"issuing_office":183,"recipient_name":320,"body_fetched_at":321,"delivery_method":322,"recipient_title":19,"reference_number":323,"action_taken_date":324,"medical_device_id":19,"response_letter_date":19},1066,[308,309,310,183,311,13,13,13],"\u003Ctime datetime=\"2025-02-11T05:00:00Z\">02\u002F11\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-01-30T05:00:00Z\">01\u002F30\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fstrukmyer-llc-dba-strukmyer-medical-692686-01302025\">Strukmyer LLC dba Strukmyer Medical \u003C\u002Fa>","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Electronic Mail Return Confirmation Requested\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-37\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Sudheer Kancherla\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Strukmyer LLC dba Strukmyer Medical \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1801 Big Town Blvd. Ste. 100\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Mesquite\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>75149-1011\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-37\u003C\u002Fp>\u003Cp>January 30, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Kancherla:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Strukmyer LLC dba Strukmyer Medical, FEI 3000205837, at 1801 Big Town Blvd. Ste. 100, Mesquite, TX, from July 8 to August 1, 2024.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your August 22, 2024 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>On over 60 occasions, your firm isolated objectionable microorganisms (e.g., \u003Cem>Burkholderia, Pseudomonas, Staphylococcus, Bacillus\u003C\u002Fem>, and \u003Cem>Aspergillus\u003C\u002Fem> species) from your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system used as a component to manufacture over-the-counter (OTC) drug products intended for use in wounds and on burns between November 1, 2022 and July 10, 2024. For example, Pseudomonas and Burkholderia were recovered from samples of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system on August 15 and August 21, 2023, respectively, and water from this system was used to manufacture \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> on August 21, 2023. You failed to adequately investigate and implement corrective actions to determine root causes and prevent recurrence of these contamination incidents. We note that this drug product was previously the subject of a recall in 2020 for microbial contamination with \u003Cem>Burkholderia cepacia\u003C\u002Fem>.\u003C\u002Fp>\u003Cp>In your response, you state that you updated your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water monitoring procedures to include specifications for the absence of objectionable organisms. You also state that you conducted an investigation into the implicated \u003Cstrong>(b)(4)\u003C\u002Fstrong> lots and incidents of \u003Cem>Burkholderia\u003C\u002Fem> and \u003Cem>Pseudomonas\u003C\u002Fem> isolates in your water system and concluded there is no product impact because subsequent water samples collected at the time the water was used to manufacture the drug product were tested and results were observed to be within limits. Further, you state that your finished drug products met your microbial specifications.\u003C\u002Fp>\u003Cp>Your response is inadequate. Your investigation did not adequately identify the root cause of the contamination of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system with objectionable microorganisms and failed to consider the impact to your distributed drug products that were manufactured with \u003Cstrong>(b)(4)\u003C\u002Fstrong> water contaminated with objectionable microorganisms. Microbial contamination is not typically uniformly distributed, especially in a deficient system, and thus samples may not be representative of the type or level of contamination that may exist in other individual units of a batch.\u003C\u002Fp>\u003Cp>Inadequate investigations can lead to unidentified root causes, ineffective corrective actions and preventive actions (CAPA), and recurring problems that compromise the ability to manufacture safe and effective drug products. Frequent microbiological excursions suggest that your purified water system may not be in an adequate state of control.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment of the design and control of your firm’s manufacturing operations, with a detailed and thorough review of all microbiological hazards.\u003C\u002Fli>\u003Cli>A detailed risk assessment addressing the hazards posed by distributing drug products with potentially objectionable contamination. Specify actions you will take in response to the risk assessment, such as customer notifications and product recalls.\u003C\u002Fli>\u003Cli>Complete investigations into all batches with potential objectionable microbial contamination or an out-of-specification (OOS) microbiological result (whether or not later invalidated). The investigations should detail your findings regarding the root causes of the contamination.\u003C\u002Fli>\u003Cli>Appropriate microbiological batch release specifications (i.e., total counts, identification of bioburden to detect objectionable microbes) for each of your drug products.\u003C\u002Fli>\u003Cli>All chemical and microbial test methods used to analyze each of your drug products.\u003C\u002Fli>\u003Cli>A summary of results from testing retain samples of all drug product batches within expiry. You should test all appropriate quality attributes including, but not limited to, identity and strength of active ingredients and microbiological quality (total counts and identification of bioburden to detect any objectionable microbes) of each batch. If testing yields an OOS result, indicate the corrective actions you will take, including notifying customers and initiating recalls.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\u003Cli>An independent assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigations trends, improves the CAPA program when needed, implements final quality unit decisions, and is fully supported by executive management.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to perform adequate incoming testing of each component lot used in the manufacture of your OTC drug products, such as Therabreath Mild Mint Toothpaste intended for use in children. You also relied on your suppliers’ certificate of analysis (COA) without establishing the reliability of your component suppliers’ test analyses at appropriate intervals.\u003C\u002Fp>\u003Cp>\u003Cem>Glycerin\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You failed to adequately test each shipment of each lot of glycerin for identity, a component at high-risk of diethylene glycol (DEG) or ethylene glycol (EG) contamination. Identity testing for glycerin and certain other high-risk drug components\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> includes a limit test in the United States Pharmacopeia (USP) to ensure the component meets the relevant safety limits for levels of DEG or EG. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in the manufacture of your drug products.\u003C\u002Fp>\u003Cp>The use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\u003C\u002Fp>\u003Cp>In your response, you state that you would update the specifications for your glycerin component to include identity testing, including DEG and EG testing, at a \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing frequency. Additionally, you state that you tested retain sample of one glycerin lot from each \u003Cstrong>(b)(4)\u003C\u002Fstrong> since May 2023 to verify the quality of previously manufactured batches. You also committed to performing DEG and EG testing on the first lot of glycerin received each \u003Cstrong>(b)(4)\u003C\u002Fstrong> to confirm the reliability of the testing results on the supplier’s COA.\u003C\u002Fp>\u003Cp>Your response is inadequate. CGMP requires that each shipment of each lot of a component undergo appropriate identity testing (which for glycerin, as noted above, includes a limit test for DEG and EG) before use in drug product manufacturing. Your response also did not include an evaluation of the quality of your drug products currently on the U.S market with inadequate component testing.\u003C\u002Fp>\u003Cp>Component testing is fundamental to quality. Without adequate testing, you do not have scientific evidence that your incoming components conform to appropriate specifications before us in the manufacture of drug products.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\u003C\u002Fli>\u003Cli>The chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\u003C\u002Fli>\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\u003Cli>A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\u003C\u002Fli>\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements (21 CFR 211.67(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to demonstrate your cleaning and disinfection practices are adequate to remove all contaminants from the equipment used to manufacture your topical OTC drug products. For example, your cleaning validation only tested for the absence of Gram-negative bacteria, but you have previously isolated fungi and gram-positive microorganisms from your water system.\u003C\u002Fp>\u003Cp>Inadequate removal of microbial organisms from manufacturing equipment during cleaning can result in contamination of your drug products, which can potentially cause patient harm depending on the organism.\u003C\u002Fp>\u003Cp>In your response, you committed to performing a new cleaning validation based on “worst-case” scenarios, including a toxicological and microbiological risk assessment of all raw materials using in manufacturing.\u003C\u002Fp>\u003Cp>Your response is inadequate in that the test methods appear to be incomplete.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>Your total microbial count limits to monitor whether this system is producing water suitable for the intended uses for each of your drug products.\u003C\u002Fli>\u003Cli>A summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>4. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your quality unit (QU) failed to ensure the chemical and microbial testing methods performed by your contract laboratory for finished drug product release testing and water system monitoring were not adequately validated or verified as appropriate.\u003C\u002Fp>\u003Cp>In your response, you state that you sent drug product and \u003Cstrong>(b)(4)\u003C\u002Fstrong> water samples to your contract laboratory to complete method verification for your chemical and microbial tests. You also updated your procedure to require that method validations and verifications be performed on required test methods.\u003C\u002Fp>\u003Cp>Your response is inadequate. It did not provide assurance that the analytical test methods used to test your components and finished drug products are suitable for the intended purpose. Further, you did not provide an evaluation of potential impact to drug products currently on the U.S. market.\u003C\u002Fp>\u003Cp>An adequate QU overseeing all elements of CGMP is necessary to consistently ensure drug product quality. Your firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload for help in implementing quality systems and risk management approaches.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm to ensure you have an adequate contract testing facility are robust and appropriate.\u003Cbr>o Provisions for QU oversight throughout your laboratory operations to evaluate adherence to appropriate practices.\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPA before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Cosmetics Manufactured for Distribution in the United States\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In addition, we note that some of the products you manufacture may be regulated as cosmetics, as defined in section 201(i) of the FD&amp;C Act. Any cosmetics you manufacture must comply with applicable statutory and regulatory requirements, including the FD&amp;C Act. A cosmetic is deemed adulterated under section 601(c) of the FD&amp;C Act [21 U.S.C. 361(c)] if it has been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with filth or whereby it may have been rendered injurious to health.\u003C\u002Fp>\u003Cp>Some conditions that cause the drug products you manufacture to be adulterated may also cause any cosmetics you manufacture to be adulterated. We note that under section 301(a) of the FD&amp;C Act [21 U.S.C. 331(a)], it is a prohibited act to introduce or deliver for introduction into interstate commerce a cosmetic that is adulterated. Further, your facility may be subject to requirements under the Modernization of Cosmetics Regulations Act of 2022 (MoCRA). Information on MoCRA requirements may be found at https:\u002F\u002Fwww.fda.gov\u002Fcosmetics\u002Fcosmetics-laws-regulations\u002Fmodernization-cosmetics-regulation-act-2022-mocra.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3000205837 and ATTN: Philip Kreiter.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>___________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Components with higher risk of DEG or EG contamination compared to other drug components.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Electronic Mail Return Confirmation Requested\n\nReference #:\n\n320-25-37\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Sudheer Kancherla\n\nRecipient Title\n\nChief Executive Officer\n\nStrukmyer LLC dba Strukmyer Medical\n\n1801 Big Town Blvd. Ste. 100\n\nMesquite, TX 75149-1011\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-37\nJanuary 30, 2025\nDear Mr. Kancherla:\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Strukmyer LLC dba Strukmyer Medical, FEI 3000205837, at 1801 Big Town Blvd. Ste. 100, Mesquite, TX, from July 8 to August 1, 2024.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your August 22, 2024 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\nOn over 60 occasions, your firm isolated objectionable microorganisms (e.g., Burkholderia, Pseudomonas, Staphylococcus, Bacillus, and Aspergillus species) from your (b)(4) water system used as a component to manufacture over-the-counter (OTC) drug products intended for use in wounds and on burns between November 1, 2022 and July 10, 2024. For example, Pseudomonas and Burkholderia were recovered from samples of your (b)(4) water system on August 15 and August 21, 2023, respectively, and water from this system was used to manufacture (b)(4) batches (b)(4) and (b)(4) on August 21, 2023. You failed to adequately investigate and implement corrective actions to determine root causes and prevent recurrence of these contamination incidents. We note that this drug product was previously the subject of a recall in 2020 for microbial contamination with Burkholderia cepacia.\nIn your response, you state that you updated your (b)(4) water monitoring procedures to include specifications for the absence of objectionable organisms. You also state that you conducted an investigation into the implicated (b)(4) lots and incidents of Burkholderia and Pseudomonas isolates in your water system and concluded there is no product impact because subsequent water samples collected at the time the water was used to manufacture the drug product were tested and results were observed to be within limits. Further, you state that your finished drug products met your microbial specifications.\nYour response is inadequate. Your investigation did not adequately identify the root cause of the contamination of your (b)(4) water system with objectionable microorganisms and failed to consider the impact to your distributed drug products that were manufactured with (b)(4) water contaminated with objectionable microorganisms. Microbial contamination is not typically uniformly distributed, especially in a deficient system, and thus samples may not be representative of the type or level of contamination that may exist in other individual units of a batch.\nInadequate investigations can lead to unidentified root causes, ineffective corrective actions and preventive actions (CAPA), and recurring problems that compromise the ability to manufacture safe and effective drug products. Frequent microbiological excursions suggest that your purified water system may not be in an adequate state of control.\nIn response to this letter, provide:\nA comprehensive, independent assessment of the design and control of your firm’s manufacturing operations, with a detailed and thorough review of all microbiological hazards.\nA detailed risk assessment addressing the hazards posed by distributing drug products with potentially objectionable contamination. Specify actions you will take in response to the risk assessment, such as customer notifications and product recalls.\nComplete investigations into all batches with potential objectionable microbial contamination or an out-of-specification (OOS) microbiological result (whether or not later invalidated). The investigations should detail your findings regarding the root causes of the contamination.\nAppropriate microbiological batch release specifications (i.e., total counts, identification of bioburden to detect objectionable microbes) for each of your drug products.\nAll chemical and microbial test methods used to analyze each of your drug products.\nA summary of results from testing retain samples of all drug product batches within expiry. You should test all appropriate quality attributes including, but not limited to, identity and strength of active ingredients and microbiological quality (total counts and identification of bioburden to detect any objectionable microbes) of each batch. If testing yields an OOS result, indicate the corrective actions you will take, including notifying customers and initiating recalls.\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\nAn independent assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigations trends, improves the CAPA program when needed, implements final quality unit decisions, and is fully supported by executive management.\n2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\nYou failed to perform adequate incoming testing of each component lot used in the manufacture of your OTC drug products, such as Therabreath Mild Mint Toothpaste intended for use in children. You also relied on your suppliers’ certificate of analysis (COA) without establishing the reliability of your component suppliers’ test analyses at appropriate intervals.\nGlycerin\nYou failed to adequately test each shipment of each lot of glycerin for identity, a component at high-risk of diethylene glycol (DEG) or ethylene glycol (EG) contamination. Identity testing for glycerin and certain other high-risk drug components1 includes a limit test in the United States Pharmacopeia (USP) to ensure the component meets the relevant safety limits for levels of DEG or EG. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in the manufacture of your drug products.\nThe use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\nIn your response, you state that you would update the specifications for your glycerin component to include identity testing, including DEG and EG testing, at a (b)(4) testing frequency. Additionally, you state that you tested retain sample of one glycerin lot from each (b)(4) since May 2023 to verify the quality of previously manufactured batches. You also committed to performing DEG and EG testing on the first lot of glycerin received each (b)(4) to confirm the reliability of the testing results on the supplier’s COA.\nYour response is inadequate. CGMP requires that each shipment of each lot of a component undergo appropriate identity testing (which for glycerin, as noted above, includes a limit test for DEG and EG) before use in drug product manufacturing. Your response also did not include an evaluation of the quality of your drug products currently on the U.S market with inadequate component testing.\nComponent testing is fundamental to quality. Without adequate testing, you do not have scientific evidence that your incoming components conform to appropriate specifications before us in the manufacture of drug products.\nIn response to this letter, provide:\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\nThe chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\nA comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\nA summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\n3. Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements (21 CFR 211.67(a)).\nYou failed to demonstrate your cleaning and disinfection practices are adequate to remove all contaminants from the equipment used to manufacture your topical OTC drug products. For example, your cleaning validation only tested for the absence of Gram-negative bacteria, but you have previously isolated fungi and gram-positive microorganisms from your water system.\nInadequate removal of microbial organisms from manufacturing equipment during cleaning can result in contamination of your drug products, which can potentially cause patient harm depending on the organism.\nIn your response, you committed to performing a new cleaning validation based on “worst-case” scenarios, including a toxicological and microbiological risk assessment of all raw materials using in manufacturing.\nYour response is inadequate in that the test methods appear to be incomplete.\nIn response to this letter, provide:\nYour total microbial count limits to monitor whether this system is producing water suitable for the intended uses for each of your drug products.\nA summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\n4. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\nYour quality unit (QU) failed to ensure the chemical and microbial testing methods performed by your contract laboratory for finished drug product release testing and water system monitoring were not adequately validated or verified as appropriate.\nIn your response, you state that you sent drug product and (b)(4) water samples to your contract laboratory to complete method verification for your chemical and microbial tests. You also updated your procedure to require that method validations and verifications be performed on required test methods.\nYour response is inadequate. It did not provide assurance that the analytical test methods used to test your components and finished drug products are suitable for the intended purpose. Further, you did not provide an evaluation of potential impact to drug products currently on the U.S. market.\nAn adequate QU overseeing all elements of CGMP is necessary to consistently ensure drug product quality. Your firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload for help in implementing quality systems and risk management approaches.\nIn response to this letter, provide:\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm to ensure you have an adequate contract testing facility are robust and appropriate.\no Provisions for QU oversight throughout your laboratory operations to evaluate adherence to appropriate practices.\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPA before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nCosmetics Manufactured for Distribution in the United States\nIn addition, we note that some of the products you manufacture may be regulated as cosmetics, as defined in section 201(i) of the FD&C Act. Any cosmetics you manufacture must comply with applicable statutory and regulatory requirements, including the FD&C Act. A cosmetic is deemed adulterated under section 601(c) of the FD&C Act [21 U.S.C. 361(c)] if it has been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with filth or whereby it may have been rendered injurious to health.\nSome conditions that cause the drug products you manufacture to be adulterated may also cause any cosmetics you manufacture to be adulterated. We note that under section 301(a) of the FD&C Act [21 U.S.C. 331(a)], it is a prohibited act to introduce or deliver for introduction into interstate commerce a cosmetic that is adulterated. Further, your facility may be subject to requirements under the Modernization of Cosmetics Regulations Act of 2022 (MoCRA). Information on MoCRA requirements may be found at https:\u002F\u002Fwww.fda.gov\u002Fcosmetics\u002Fcosmetics-laws-regulations\u002Fmodernization-cosmetics-regulation-act-2022-mocra.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3000205837 and ATTN: Philip Kreiter.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n___________________\n1 Components with higher risk of DEG or EG contamination compared to other drug components.","Strukmyer LLC dba Strukmyer Medical","strukmyer-llc-dba-strukmyer-medical-692686-01302025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fstrukmyer-llc-dba-strukmyer-medical-692686-01302025","2026-10-26T08:10:06.710761+00:00","2025-02-11","692686","Mr. Sudheer Kancherla","2026-08-19T17:02:33.632+00:00","Via Electronic Mail Return Confirmation Requested","320-25-37","2025-01-30",{"id":326,"raw":327,"subject":334,"body_html":335,"body_text":336,"firm_name":337,"letter_id":338,"created_at":339,"fei_number":19,"letter_url":340,"updated_at":341,"action_type":22,"case_status":46,"posted_date":342,"marcs_cms_no":343,"product_type":171,"closeout_date":344,"issuing_office":331,"recipient_name":345,"body_fetched_at":346,"delivery_method":92,"recipient_title":19,"reference_number":19,"action_taken_date":347,"medical_device_id":19,"response_letter_date":19},3140,[328,329,330,331,332,13,333,13],"\u003Ctime datetime=\"2021-09-14T13:20:00Z\">09\u002F14\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-07-20T04:00:00Z\">07\u002F20\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbrilliant-enterprises-llc-609523-07202021\">Brilliant Enterprises LLC\u003C\u002Fa>","Office of Human and Animal Food Operations Division- East 6","Unapproved New Drugs\u002FMisbranded ","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbrilliant-enterprises-llc-609523-12062021\">\u003Ctime datetime=\"2021-12-14T05:00:00Z\">12\u002F14\u002F2021\u003C\u002Ftime>\n\u003C\u002Fa>","Unapproved New Drugs\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail \n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Adam and Angela Schultz\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Brilliant Enterprises LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>621 Main Street, Unit 182\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Gaylord\u003C\u002Fspan>, \u003Cspan>MI\u003C\u002Fspan> \u003Cspan>49735\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:support@levelupmushrooms.com\"> support@levelupmushrooms.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Human and Animal Food Operations Division- East 6\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nFY 21- HAFE6 WL- 03\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>July 20, 2021\u003C\u002Fp>\n\n\u003Cp>Dear Adam and Angela Schultz:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at https:\u002F\u002Flevelupmushrooms.comin June and July 2021 and has determined that you take orders there for the products Lion’s Mane, BoomChaga, CordaCex, and LVL:MAX. We have also reviewed your social media websites atwww.instagram.com\u002Flevelupmushrooms and https:\u002F\u002Ftwitter.com\u002FLvlUpMushrooms, which direct consumers to your website https:\u002F\u002Flevelupmushrooms.com to purchase your products. The claims on your websites establish that these products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Examples of some of the claims observed on your websites that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Lion’s Mane\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the product webpage for Lion’s Mane of your website https:\u002F\u002Flevelupmushrooms.com:\u003Cbr>\n• “Protects Against Ulcers in the Stomach: Goodbye Pain”\u003Cbr>\n• “Relieves Depression and Anxiety: We All Need Relief”\u003Cbr>\n• “[R]elieves depression and anxiety…”\u003C\u002Fp>\n\n\u003Cp>On the scientific studies webpage of your website https:\u002F\u002Flevelupmushrooms.com, under the heading “Lion’s Mane Scientific Studies”:\u003Cbr>\n• “Lion’s Mane May Be Effective in Combating Dementia\u002FAlzheimer’s Disease”\u003Cbr>\n• “Lion’s Mane Has Shown In Studies That It Could Reduce Anxiety And Depression”\u003Cbr>\n• “Animal Testing Shows Lion’s Mane Helps Control Diabetes Symptoms By Keeping Blood Sugar Low”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>BoomChaga\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the product webpage for BoomChaga of your website https:\u002F\u002Flevelupmushrooms.com:\u003Cbr>\n• “Lowers Cholesterol: Live Longer”\u003Cbr>\n• “BoomChaga is 100% Chaga Mushroom. …More importantly, this mushroom is absolutely LOADED in antioxidants which are known cancer fighters.”\u003Cbr>\n• “Chaga contains more antioxidants . . . Antioxidants are those things that you always hear about but don’t know what they do. What they do is … because they repair DNA and ward off cancer. . . . it also improves health by showing its ability to fight inflammation and help with irritable bowel syndrom in other studies.”\u003Cbr>\n• “Data has shown that Chaga could help ward off the following health problems: Diabetes, lrratable Bowel Syndrome, and viral infections such as Herpes.”\u003C\u002Fp>\n\n\u003Cp>On the scientific studies webpage of your website https:\u002F\u002Flevelupmushrooms.com, under the heading “Chaga (BOOMCHAGA!) Scientific Studies”:\u003Cbr>\n• “Potential For Fighting Cancer Due To The Extremely High Level of Anti-oxidants In Chaga”\u003Cbr>\n• “Anti-diabetic Effects”\u003Cbr>\n• “Help For Inflammatory Bowel Disease (irritable bowel)”\u003Cbr>\n• “Anti-viral Effects (herpes simplex)”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CordaCex\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the product webpage for CordaCex of your website https:\u002F\u002Flevelupmushrooms.com:\u003Cbr>\n• “CORDACEX BENEFITS…reduces inflammation, shows cancer fighting properties...”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>LVL:MAX\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the product webpage for LVL:MAX of your website https:\u002F\u002Flevelupmushrooms.com:\u003Cbr>\n• “Our product has helped 100's of people with anxiety and other mental problems...”\u003C\u002Fp>\n\n\u003Cp>On your social media website www.instagram.com\u002Flevelupmushrooms:\u003Cbr>\n• “…Feeling a little down and depressed?… Did you know we can help with all that and more with just some awesome mushrooms?... #LevelUpMushrooms . . . #DepressionAndAnxiety #BeatDepression #BeatAnxiety. . .” [From a June 25, 2020 post that includes an image of your LVL:MAX product]\u003C\u002Fp>\n\n\u003Cp>On your social media website https:\u002F\u002Ftwitter.com\u002FLvlUpMushrooms:\u003Cbr>\n• “LVL:MAX . . . Protects Against Ulcers in the Stomach: Goodbye Pain… Relieves Depression and Anxiety… Lowers Cholesterol: Live Longer…Lower Inflammation…” [From a Nov 12, 2019 post]\u003C\u002Fp>\n\n\u003Cp>Your Lion’s Mane, BoomChaga, CordaCex, and LVL:MAX products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)].With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from the FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d) and 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your Lion’s Mane, BoomChaga, CordaCex, and LVL:MAX products are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, Lion’s Mane, BoomChaga, CordaCex, and LVL:MAX fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to U.S. Food and Drug Administration, Lauren Sexton, Compliance Officer, 300 River Place, Suite 5900, Detroit, MI 48207 or by email to Lauren.Sexton@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>William R. Weissinger, MS\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food Operations\u003Cbr>\nDivision- East 6\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nDrugs\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nAdam and Angela Schultz\n\nBrilliant Enterprises LLC\n\n621 Main Street, Unit 182\n\nGaylord, MI 49735\n\nUnited States\n\nsupport@levelupmushrooms.com\n\nIssuing Office:\n\nOffice of Human and Animal Food Operations Division- East 6\n\nUnited States\n\nWARNING LETTER\n\nFY 21- HAFE6 WL- 03\n\nJuly 20, 2021\n\nDear Adam and Angela Schultz:\n\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at https:\u002F\u002Flevelupmushrooms.comin June and July 2021 and has determined that you take orders there for the products Lion’s Mane, BoomChaga, CordaCex, and LVL:MAX. We have also reviewed your social media websites atwww.instagram.com\u002Flevelupmushrooms and https:\u002F\u002Ftwitter.com\u002FLvlUpMushrooms, which direct consumers to your website https:\u002F\u002Flevelupmushrooms.com to purchase your products. The claims on your websites establish that these products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nExamples of some of the claims observed on your websites that provide evidence that your products are intended for use as drugs include:\n\nLion’s Mane\n\nOn the product webpage for Lion’s Mane of your website https:\u002F\u002Flevelupmushrooms.com:\n\n• “Protects Against Ulcers in the Stomach: Goodbye Pain”\n\n• “Relieves Depression and Anxiety: We All Need Relief”\n\n• “[R]elieves depression and anxiety…”\n\nOn the scientific studies webpage of your website https:\u002F\u002Flevelupmushrooms.com, under the heading “Lion’s Mane Scientific Studies”:\n\n• “Lion’s Mane May Be Effective in Combating Dementia\u002FAlzheimer’s Disease”\n\n• “Lion’s Mane Has Shown In Studies That It Could Reduce Anxiety And Depression”\n\n• “Animal Testing Shows Lion’s Mane Helps Control Diabetes Symptoms By Keeping Blood Sugar Low”\n\nBoomChaga\n\nOn the product webpage for BoomChaga of your website https:\u002F\u002Flevelupmushrooms.com:\n\n• “Lowers Cholesterol: Live Longer”\n\n• “BoomChaga is 100% Chaga Mushroom. …More importantly, this mushroom is absolutely LOADED in antioxidants which are known cancer fighters.”\n\n• “Chaga contains more antioxidants . . . Antioxidants are those things that you always hear about but don’t know what they do. What they do is … because they repair DNA and ward off cancer. . . . it also improves health by showing its ability to fight inflammation and help with irritable bowel syndrom in other studies.”\n\n• “Data has shown that Chaga could help ward off the following health problems: Diabetes, lrratable Bowel Syndrome, and viral infections such as Herpes.”\n\nOn the scientific studies webpage of your website https:\u002F\u002Flevelupmushrooms.com, under the heading “Chaga (BOOMCHAGA!) Scientific Studies”:\n\n• “Potential For Fighting Cancer Due To The Extremely High Level of Anti-oxidants In Chaga”\n\n• “Anti-diabetic Effects”\n\n• “Help For Inflammatory Bowel Disease (irritable bowel)”\n\n• “Anti-viral Effects (herpes simplex)”\n\nCordaCex\n\nOn the product webpage for CordaCex of your website https:\u002F\u002Flevelupmushrooms.com:\n\n• “CORDACEX BENEFITS…reduces inflammation, shows cancer fighting properties...”\n\nLVL:MAX\n\nOn the product webpage for LVL:MAX of your website https:\u002F\u002Flevelupmushrooms.com:\n\n• “Our product has helped 100's of people with anxiety and other mental problems...”\n\nOn your social media website www.instagram.com\u002Flevelupmushrooms:\n\n• “…Feeling a little down and depressed?… Did you know we can help with all that and more with just some awesome mushrooms?... #LevelUpMushrooms . . . #DepressionAndAnxiety #BeatDepression #BeatAnxiety. . .” [From a June 25, 2020 post that includes an image of your LVL:MAX product]\n\nOn your social media website https:\u002F\u002Ftwitter.com\u002FLvlUpMushrooms:\n\n• “LVL:MAX . . . Protects Against Ulcers in the Stomach: Goodbye Pain… Relieves Depression and Anxiety… Lowers Cholesterol: Live Longer…Lower Inflammation…” [From a Nov 12, 2019 post]\n\nYour Lion’s Mane, BoomChaga, CordaCex, and LVL:MAX products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)].With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from the FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d) and 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour Lion’s Mane, BoomChaga, CordaCex, and LVL:MAX products are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, Lion’s Mane, BoomChaga, CordaCex, and LVL:MAX fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour response should be sent to U.S. Food and Drug Administration, Lauren Sexton, Compliance Officer, 300 River Place, Suite 5900, Detroit, MI 48207 or by email to Lauren.Sexton@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nWilliam R. Weissinger, MS\n\nProgram Division Director\n\nOffice of Human and Animal Food Operations\n\nDivision- East 6","Brilliant Enterprises LLC","brilliant-enterprises-llc-609523-07202021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbrilliant-enterprises-llc-609523-07202021","2026-10-26T08:08:09.100562+00:00","2021-09-14","609523","2021-12-14","Adam and Angela Schultz","2026-08-20T02:36:00.42+00:00","2021-07-20",{"id":349,"raw":350,"subject":334,"body_html":355,"body_text":356,"firm_name":357,"letter_id":358,"created_at":212,"fei_number":19,"letter_url":359,"updated_at":360,"action_type":22,"case_status":23,"posted_date":361,"marcs_cms_no":362,"product_type":171,"closeout_date":19,"issuing_office":363,"recipient_name":364,"body_fetched_at":365,"delivery_method":199,"recipient_title":19,"reference_number":19,"action_taken_date":366,"medical_device_id":19,"response_letter_date":19},2118,[351,352,353,354,334,13,13,13],"\u003Ctime datetime=\"2023-04-25T13:20:00Z\">04\u002F25\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-03-08T05:00:00Z\">03\u002F08\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fspartan-enterprises-inc-dba-watershed-wellness-center-642030-03082023\">Spartan Enterprises Inc. dba Watershed Wellness Center\u003C\u002Fa>"," Division of Human and Animal Food Operations East VI","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Robert F. McCauley\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u002FOwner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Spartan Enterprises Inc. dba Watershed Wellness Center\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>16280 National Parkway\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Lansing\u003C\u002Fspan>, \u003Cspan>MI\u003C\u002Fspan> \u003Cspan>48906\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Human and Animal Food Operations East VI\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nFY23-HAFE6-01 CMS 642030\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>March 8, 2023\u003Cbr>\n\u003Cbr>\nDear Mr. McCauley:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your dietary supplement manufacturing facility, located at 16280 National Parkway, Lansing MI, from June 29 through July 25, 2022. We also reviewed your websites at www.watershed.net and www.shop.watershed.net in December 2022, and your YouTube channel. Based on inspectional findings and a review of your websites, we have identified serious violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on the FDA’s home page at&nbsp;http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New\u002FMisbranded Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the FDA reviewed your product labels following the inspection of your facility. In addition, FDA reviewed your website www.shop.watershed.net in December 2022, and determined you take orders there for the products Dr. Bob’s Naturals Spirulina, Dr. Bob’s Naturals Magtein, Dr. Bob’s Naturals Tulsi-Holy Basil Extract Capsules, Dr. Bob’s Naturals Milk Thistle Liver Support, Dr. Bob’s Naturals Stone Breaker Powder, Dr. Bob’s Parasite Killer, Dr. Bob’s Naturals Parasite Killer Bundle, Dr. Bob’s Naturals Parasite Killer Bundle MINI, Dr. Bob’s Naturals Yew VeggieCaps, Dr. Bob’s Naturals Gingko Magic, and Dr. Bob’s Naturals Chlorella, and Raw Food World Ashwagandha Extract. We also reviewed your website www.watershed.net, which directs consumers to your website www.shop.watershed.net to purchase your products, and your YouTube Channel at www.youtube.com\u002Fc\u002FDrBobMcCauley, in December 2022. The claims on your product labels, websites, and your YouTube Channel establish that these products are drugs under section 201(g)(1)(B) of the Act [21 U.SC. § 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing, or delivering for introduction into interstate commerce for such uses violates the Act.\u003C\u002Fp>\n\n\u003Cp>Examples of some of the claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\n\n\u003Cp>From your website at www.watershed.net:\u003C\u002Fp>\n\n\u003Cp>&nbsp; o \u003Cstrong>Spirulina [an ingredient in Dr. Bob’s Naturals Spirulina tablets]:\u003C\u002Fstrong> the following statements are included in the description: “Lowers LDL and Triglyceride Levels”, “Anti-Inflammatory Properties”, “Fights Anemia”\u003C\u002Fp>\n\n\u003Cp>&nbsp; o \u003Cstrong>Ashwagandha [an ingredient in the Raw Food World Ashwagandha Extract]:\u003C\u002Fstrong> the following statements are included in the description: “It is commonly used to relieve…pain, skin, joint, digestive issues asn [sic] well as neurological issues.”\u003C\u002Fp>\n\n\u003Cp>From your website at www.shop.watershed.net:\u003C\u002Fp>\n\n\u003Cp>&nbsp; o \u003Cstrong>Dr. Bob’s Naturals Magtei:\u003C\u002Fstrong> “Magnesium repairs the damaged synapses of the brain, which is the cause of the various types of neurological and brain-related diseases.”\u003C\u002Fp>\n\n\u003Cp>&nbsp; o \u003Cstrong>Dr. Bob’s Naturals Tulsi-Holy Basil Extract Capsules:\u003C\u002Fstrong>\u003Cbr>\n&nbsp; &nbsp; o “Regulates Insulin Levels to Help Balance Blood Sugar”\u003Cbr>\n&nbsp; &nbsp; o “Contains Antibacterial, Antifungal Properties”\u003Cbr>\n&nbsp; &nbsp; o “Holy Basil…regulates insulin levels…. It has Antibacterial, anti-fungal, and anti-inflammatory properties.”\u003C\u002Fp>\n\n\u003Cp>&nbsp; o \u003Cstrong>Dr. Bob’s Naturals Milk Thistle Liver Support:\u003C\u002Fstrong>\u003Cbr>\n&nbsp; &nbsp; o “Milk Thistle ….is…anti-inflammatory”\u003Cbr>\n&nbsp; &nbsp; o “Benefits:\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp; 􀂃 Reduces Cholesterol\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp; 􀂃 Anti-allergic\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp; 􀂃 Asthma Support\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp; 􀂃 Reduces Insulin Resistance\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp; 􀂃 Anti-inflammatory”\u003C\u002Fp>\n\n\u003Cp>&nbsp; o \u003Cstrong>Dr. Bob’s Naturals Stone Breaker Powder:\u003C\u002Fstrong> “Stone Breaker (Chanca Piedra) has been used by the indigenous peoples of the Amazon Forests for centuries to treat and remove of [sic] kidney and gall stones. It helps dissolve the stones so they can be eliminated from the body. Chanca Piedra interferes with stone formation by relaxing urinary passages so small stones are more easily passed. It can be used in conjunction with lithotripsy, a shock wave procedure that fragments stones”\u003C\u002Fp>\n\n\u003Cp>&nbsp; o \u003Cstrong>Dr. Bob’s Naturals Parasite Killer Bundle:\u003C\u002Fstrong> “Six Products that kill viruses, bacteria, yeast, mold, and fungus in the bloodstream and digestive tract. Silver: Kills viruses, bacteria, yeast, mold, and fungus in the bloodstream. (16 oz) Bismuth: Kills bacteria in the digestive tract. (16 oz) Papaya Seed Powder: Parasite removal. Parasite Killer BlendTM: Kills viruses, bacteria, yeast, mold, and fungus in the digestive tract. Dissolve Bioactive Silicate: Removes biofilm and nano-bacteria from the arteries and body. Proferment [sic].”\u003C\u002Fp>\n\n\u003Cp>&nbsp; o \u003Cstrong>Dr. Bob’s Naturals Parasite Killer Bundle MINI: \u003C\u002Fstrong>“Dr. Bob’s Parasite Killer Bundle MINI is identical to Dr. Bob’s Parasite Killer Bundle except the bottles are 2 oz (NOT 16 oz). Six Products that kill viruses, bacteria, yeast, mold, and fungus in the bloodstream and digestive tract. Silver: Kills viruses, bacteria, yeast, mold, and fungus in the bloodstream. (2 oz) Bismuth: Kills bacteria in the digestive tract. (2 oz) Papaya Seed Powder: Parasite removal. Parasite Killer Blend\u003Csup>TM\u003C\u002Fsup>: Kills viruses, bacteria, yeast, mold, and fungus in the digestive tract. Dissolve Bioactive Silicate: Removes biofilm and nano-bacteria from the arteries and body. Preferment – Probiotic.”\u003C\u002Fp>\n\n\u003Cp>&nbsp; o \u003Cstrong>Dr. Bob’s Naturals Parasite Killer:\u003C\u002Fstrong> “Dr. Bob’s Parasite Killer is formulated with parasiticidal, anti-fungal, anti-viral, and antibacterial ingredients with the intention of killing everything in the digestive tract. Once that is accomplished then the next step is to reintroduce probiotics, the friendly bacteria that…. keep our digestive tract free of parasites and unhealthy bacteria.”\u003C\u002Fp>\n\n\u003Cp>From your YouTube Channel:\u003C\u002Fp>\n\n\u003Cp>&nbsp; o \u003Cstrong>A video titled “Amazing herb – Little Known: YEW Tree with Taxane” [an ingredient in Dr. Bob’s Naturals Yew VeggieCaps]\u003C\u002Fstrong> at https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=kudldIcMIXU, in which the URL for your website www.watershed.net appears onscreen during the video and you state: “Very powerful anti-cancer properties…used in conjunction with chemotherapy and other cancer treatments, but not only does it have anti-cancer properties it also has a lot of other properties as well…the way that Taxane works in the body to fight cancer is it causes cell apoptosis in cancer cells. So it doesn’t allow the cancer cell to replicate…. Is also very powerful anti-inflammatory…on top of being anti-cancer…. you take two or three capsules a day as a maintenance dosage, or if you have a serious health challenge maybe you got cancer or something, you’re going to triple that dosage and do three of those three times a day ….”\u003C\u002Fp>\n\n\u003Cp>&nbsp; o Your description of the video says, “Buy Yew Capsules Here” and hyperlinks to the Dr. Bob’s Naturals Yew VeggieCaps product page of your website, https:\u002F\u002Fshop.watershed.net\u002Findex.php\u002Fherbal-extracts\u002Fimmune-system-builder\u002Fyew\u002Fyewcaps.html, and also contains the following written statements:\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp; 􀂃 “Anti-inflammatory”\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp; 􀂃 “Taxane a chemical substance derived from a yew tree of the Pacific Coast: used yew tree experimentally as a drug in the treatment of cancer. It is derived from Yew trees – Taxus Brevafolia – and bushes and used to kill dividing cells, especially tumor cells.”\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp; 􀂃 “The taxanes are mitotic inhibitors, meaning that they inhibit tumors primarily by preventing cells from entering mitosis, a process of cell division. The taxanes accomplish this by inhibiting microtubule polymerization. In addition, taxanes appear to stimulate apoptosis, or programmed cell death, which is often inhibited in cancer cells.”\u003C\u002Fp>\n\n\u003Cp>&nbsp; o \u003Cstrong>A video titled “Gingko Biloba Benefits” [an ingredient in Dr. Bob’s Naturals Gingko Magic] \u003C\u002Fstrong>at https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=6SstxpuWwZg, in which the URL for your website www.watershed.net appears onscreen during the video and you state: “It’s used for Alzheimer’s, memory loss ….Good for…ADHD ….It also helps with…arthritis….It also helps with…asthma…it is opening up those bronchial tubes and increasing circulation to the lungs….gingko biloba world’s most famous herb use for all your…fibromyalgia…increasing that circulation to relieve that pain…be good for MS [multiple sclerosis] as well for that reason….”\u003Cbr>\n&nbsp; o During the video, the following written statements appear as on-screen text:\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp; 􀂃 “Reduces Risk for Dementia\u002FAlzheimer’s”\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp; 􀂃 “Helps fight Fibromyalgia”\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp; 􀂃 “Helps fight Headaches\u002FMigraines”\u003C\u002Fp>\n\n\u003Cp>&nbsp; o Your description of the video says, “Buy Our Ginkgo Veggie Capsules Here” and hyperlinks to your website https:\u002F\u002Fshop.watershed.net\u002Findex.php\u002Fherbal-extracts\u002Fbrainhealth\u002Fgingko-biloba\u002Fginkgo-veggiecaps.html, and also contains the following written statements:\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp; 􀂃 “Helps fight Headaches\u002FMigraines”\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp; 􀂃 “Reduces Memory Loss”\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp; 􀂃 “Helps fight Muscle and Nerve Pain”\u003C\u002Fp>\n\n\u003Cp>&nbsp; o \u003Cstrong>A video titled “Increase your Synaptic Activity with Magnesium for the Brain” [an\u003Cbr>\ningredient in Dr. Bob’s Naturals Magtein]\u003C\u002Fstrong> at https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=AoZv9ESLFpY, in which the URL for your website www.watershed.net appears onscreen during the video and you state: “[m]agnesium…a lot of people have heart attacks just because they are short on magnesium….there’s another type of magnesium that gets to your brain….they started autopsying Alzheimer’s patients after they passed away and stupid monkeys and smart monkeys and they found the people with the Alzheimer’s and stupid monkeys had absolutely no magnesium in the brain and smart monkeys were full of magnesium in the brain. Well what does that tell you? Magnesium is really needed in the brain it increases synaptic activity and actually increases synapses themselves in the brain.”\u003Cbr>\n&nbsp; o During the video, the following written statement appears as on-screen text:\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp; 􀂃 “6 grams (2 tsp or 12 capsules) per day if you have memory issues or DEMENTIA”.\u003C\u002Fp>\n\n\u003Cp>&nbsp; o Your description of the video hyperlinks to the Dr. Bob Naturals Magtein product page of your website, https:\u002F\u002Fshop.watershed.net\u002Findex.php\u002Fsupplements\u002Fmagtein\u002Fmagtein-miracle-magnesium-for-the-brain-veggie-capsules.html, and contains the following written statements:\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp; 􀂃 “Magnesium repairs the damaged synapses of the brain.”\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp; 􀂃 “Decreases the Onset Of Memory Loss”\u003Cbr>\n&nbsp; &nbsp; &nbsp; &nbsp; 􀂃 “Repairs Damaged Synapses”\u003C\u002Fp>\n\n\u003Cp>From your product labels:\u003C\u002Fp>\n\n\u003Cp>&nbsp; o \u003Cstrong>Dr. Bob’s Naturals Ginkgo Magic:\u003C\u002Fstrong> “Ginkgo is an anti-inflammatory”\u003C\u002Fp>\n\n\u003Cp>&nbsp; o \u003Cstrong>Dr. Bob’s Naturals Yew VeggieCaps:\u003C\u002Fstrong> “The Yew tree (taxus brevifolia) contains a substance called taxane. Taxanes . . . prevent harmful cells from entering mitosis. Taxane has been used in chemotherapy for many years.”\u003Cbr>\n&nbsp; &nbsp; o “Anti-Inflammatory”\u003C\u002Fp>\n\n\u003Cp>&nbsp; o \u003Cstrong>Dr. Bob’s Naturals Parasite Killer: \u003C\u002Fstrong>“Dr. Bob’s Parasite Killer is formulated with parasiticidal, anti-fungal, anti-viral and anti-bacterial ingredients with the intention of killing everything in the digestive tract.”\u003C\u002Fp>\n\n\u003Cp>&nbsp; o \u003Cstrong>Dr. Bob’s Naturals Spirulina:\u003C\u002Fstrong> “Helps Balance Blood Sugar”\u003C\u002Fp>\n\n\u003Cp>&nbsp; o \u003Cstrong>Dr. Bob’s Naturals Chlorella:\u003C\u002Fstrong> “Helps Balance Blood Sugar”\u003C\u002Fp>\n\n\u003Cp>&nbsp; o \u003Cstrong>Dr. Bob’s Holy Basil Extract:\u003C\u002Fstrong> “Tulsi, or Holy Basil…. regulates insulin helping balance blood sugar levels in the body. It also contains antibacterial, antifungal, and anti-inflammatory properties.”&nbsp;\u003C\u002Fp>\n\n\u003Cp>&nbsp; o \u003Cstrong>Dr. Bob’s Naturals Milk Thistle Liver Support:\u003C\u002Fstrong> “Milk Thistle …. is also…anti-inflammatory ….”\u003Cbr>\n&nbsp; &nbsp; o “Reduces Cholesterol\u003Cbr>\n&nbsp; &nbsp; o Reduces Insulin Resistance\u003Cbr>\n&nbsp; &nbsp; o Anti-Inflammatory\u003Cbr>\n&nbsp; &nbsp; o Asthma Support”\u003C\u002Fp>\n\n\u003Cp>&nbsp; o \u003Cstrong>Dr. Bob’s Naturals Stone Breaker Capsules:\u003C\u002Fstrong> “Gall and Kidney Stone Removal”\u003Cbr>\n&nbsp; &nbsp; o “Stone Breaker (Chanca Piedra) has been used…to treat and remove kidney and gall stones. It helps dissolve the stones …. Chanca Piedra interferes with stone formation by relaxing urinary passages so small stones are more easily passed.”\u003C\u002Fp>\n\n\u003Cp>Your products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. §§ 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your Dr. Bob’s Naturals Yew VeggieCaps, Gingko Magic, Milk Thistle Liver Support, Stone Breaker Capsules and Powder, and Magtein products are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, your Dr. Bob’s Naturals Yew VeggieCaps, Gingko Magic, Milk Thistle Liver Support, Stone Breaker Capsules and Powder, and Magtein products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulterated Dietary Supplements\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The inspection revealed serious violations of the FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR 111). Based on these violations, your Dr. Bob’s Naturals NootriTonic ULTRA, Dr. Bob’s Naturals Parasite Killer, and Raw Food World Sleep Deep Powder products are adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. § 342(g)(1)] in that they were prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements.\u003C\u002Fp>\n\n\u003Cp>The violations include the following:\u003C\u002Fp>\n\n\u003Cp>1. You failed to establish specifications required under 21 CFR 111.70. Specifically:\u003Cbr>\na. You failed to establish component specifications that are necessary to ensure that specifications for the purity, strength, and composition of dietary supplements manufactured using the components are met, as required by 21 CFR 111.70(b)(2). For example, Chanca Piedra is an ingredient in your Dr. Bob’s Naturals Parasite Killer, but you did not establish such component specifications for Chanca Piedra. Likewise, Yuan Zhi is an ingredient in your Raw Food World Sleep Deep powder, but you did not establish such component specifications for Yuan Zhi.\u003Cbr>\nb. You failed to establish specifications for each dietary supplement that you manufacture for the identity, purity, strength, and composition of the finished batch of the dietary supplement, and for limits on those types of contamination that may adulterate, or lead to the adulteration of, the finished batch of the dietary supplement to ensure the quality of the dietary supplement, as required by 21 CFR 111.70(e). For example, you did not establish any finished product specifications for Dr. Bob’s Naturals NootriTonic ULTRA, Raw Food World Sleep Deep Powder, and Dr. Bob’s Naturals Parasite Killer.\u003C\u002Fp>\n\n\u003Cp>Once you have established specifications required under 21 CFR 111.70, you must determine whether the specifications are met, as required by 21 CFR 111.75. You must also ensure that the tests and examinations that you use to determine whether the specifications are met are appropriate, scientifically valid methods, as required by 21 CFR 111.75(h)(1), and you must make and keep records of the specifications established, as required by 21 CFR 111.95(b)(1).\u003C\u002Fp>\n\n\u003Cp>We have reviewed your responses, dated August 12 and August 23, 2022, in which you state you will establish specifications for the purity, strength, and composition of each of the ingredients used in your supplements, and that you will develop procedures to demonstrate that the products you manufacture meet your specifications. We also reviewed your January 22, 2023, response in which you state you have overhauled and improved your document protocols. However, you did not provide any supporting documentation, such as copies of your specifications. We are unable to evaluate the adequacy of your corrective action, because you did not provide documentation to support that you have established component and finished product specifications.\u003C\u002Fp>\n\n\u003Cp>2. You must prepare and follow a master manufacturing record (MMR) for each unique formulation of dietary supplement that you manufacture, and for each batch size, to ensure uniformity in the finished batch from batch to batch, as required by 21 CFR 111.205(a), and the MMR must include the information required under 21 CFR 111.210. The MMRs used in the manufacture of your Dr. Bob’s Naturals NootriTonic ULTRA, Raw Food World Sleep Deep Powder, and Dr. Bob’s Naturals Parasite Killer, failed to include the following information, as required by 21 CFR 111.210:\u003Cbr>\na. The identity and weight or measure of each dietary ingredient that will be declared on the Supplement Facts label [21 CFR 111.210(d)].\u003Cbr>\nb. A statement of theoretical yield of a manufactured dietary supplement at each point, step, or stage of the manufacturing process where control is needed to ensure the quality of the dietary supplement, and the expected yield when you finish manufacturing the dietary supplement, including the maximum and minimum percentages of theoretical yield beyond which a deviation investigation of a batch is necessary and material review is conducted and disposition decision is made [21 CFR 111.210(f)].\u003Cbr>\nc. A description of packaging and a representative label, or a cross-reference to the physical location of the actual or representative label [21 CFR 111.210(g)].\u003Cbr>\nd. Written instructions, including specifications for each step, point or stage in the manufacturing process where control is necessary to ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the MMR [21 CFR 111.210(h)(1)].\u003Cbr>\ne. Procedures for sampling and a cross-reference to procedures for tests or examinations [21 CFR 111.210(h)(2)].\u003Cbr>\nf. Written instructions, including specific actions necessary to perform and verify points, steps, or stages in the manufacturing process where control is necessary to ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the MMR [21 CFR 111.210(h)(3)].\u003Cbr>\ng. Corrective action plans for use when a specification is not met [21 CFR 111.210(h)(5)].\u003C\u002Fp>\n\n\u003Cp>In addition, the MMRs for Dr. Bob’s Naturals Parasite Killer and Raw Food World Sleep Deep Powder also do not include the strength, concentration, weight, or measure of each dietary ingredient for each batch size [21 CFR 111.210(a)] and an accurate statement of the weight or measure of each component to be used [21 CFR 111.210(c)], nor does the MMR for Dr. Bob’s Naturals Parasite Killer include a complete list of components to be used [21 CFR 111.210(b)].\u003C\u002Fp>\n\n\u003Cp>We have reviewed your responses dated August 12, 2022, and August 23, 2022, in which you state you will develop written instructions and include them with your MMRs to reflect your procedures in greater detail, including quality control points, manufacturing stages, reserve collection and storage. You also state that you will implement in writing detailed manufacturing procedures, including which utensils are used, and how they should be cleaned and properly stored. We also reviewed your January 22, 2023, response in which you state you have overhauled and improved your document protocols. However, you did not provide any supporting documentation, such as copies of revised MMRs for your products. We are unable to evaluate the adequacy of your corrective action, because you did not provide documentation to support that you revised your MMRs and that they are compliant with 21 CFR 111.210.\u003C\u002Fp>\n\n\u003Cp>3. You must prepare a batch production record (BPR) every time you manufactured a batch of dietary supplement, as required by 21 CFR 111.255(a), and the BPR must include the information required under 21 CFR 111.260. The BPRs you provided for your Raw Food World Sleep Deep (Lots 8070, 8079), Dr. Bob’s Naturals Parasite Killer (Lots 7036, 7087), and Dr. Bob’s Naturals NootriTonic ULTRA (Lots 8067, 8044) dietary supplements lacked the following information that must be included in a BPR, as required by 21 CFR 111.260:\u003C\u002Fp>\n\n\u003Cp>a. The identity of equipment and processing lines used in producing the batch [21 CFR 111.260(b)].\u003Cbr>\nb. The date and time of maintenance, cleaning and sanitizing of the equipment and processing lines used in producing the batch, or a cross-reference to records where this information is retained [21 CFR 111.260(c)].\u003Cbr>\nc. The unique identifier that you assigned to each component, packaging, and label used [21 CFR 111.260(d)].\u003Cbr>\nd. The identity and weight or measure of each component used [21 CFR 111.260(e)].\u003Cbr>\ne. A statement of the actual yield or statement of the percentage of theoretical yield at appropriate phases of processing [21 CFR 111.260(f)].\u003Cbr>\nf. The actual results obtained during any monitoring operations [21 CFR 111.260(g)].\u003Cbr>\ng. The results of any testing or examination performed during the batch production, or a cross-reference to such results [21 CFR 111.260(h)].\u003Cbr>\nh. Documentation that the finished dietary supplement meets specifications established in accordance with 21 CFR 111.70(e) and (g) [21 CFR 111.260(i)].\u003Cbr>\ni. Documentation, at the time of performance, of the manufacture of the batch, including the information required under 21 CFR 111.260(j) [21 CFR 111.260(j)].\u003Cbr>\nj. Documentation, at the time of performance, of packaging and labeling operations, including the information required under 21 CFR 111.260(k) [21 CFR 111.260(k)].\u003Cbr>\nk. Documentation at the time of performance, that quality control personnel reviewed the batch production record, and approved and released, or rejected, the batch for distribution [21 CFR 111.260(l)(3)].\u003Cbr>\nl. Documentation at the time of performance of any required material review and disposition decision [21 CFR 111.260(m)].\u003C\u002Fp>\n\n\u003Cp>We have reviewed your responses, dated August 12 and August 23, 2022, in which you state you will keep detailed cleaning and sanitation records for each production run of any supplement you are manufacturing, that cleaning procedures in sanitation records will become part of all your SOPs, and that each batch record will reflect what cleaning and sanitation was done before and after the batch was manufactured. We also reviewed your January 22, 2023, response in which you state you have overhauled and improved your document protocols. However, you did not provide any supporting documentation, such as copies of BPRs for your products. We are unable to evaluate the adequacy of your corrective action, because you did not provide documentation to support that you have revised your BPRs and that they are compliant with 21 CFR 111.260.\u003C\u002Fp>\n\n\u003Cp>4. You failed to maintain your physical plant in a clean and sanitary condition, as required by 21 CFR 111.15(b)(1). Specifically:\u003C\u002Fp>\n\n\u003Cp>a. In your repacking room, there was green residue built up on a ceiling vent for the A\u002FC unit, on the protective grating on a ceiling vent, and on various ceiling tiles. Further, your “Weekly Cleaning Procedure” includes wiping down walls and vents but does not include instructions for cleaning the ceiling tiles.\u003Cbr>\nb. In your new packing room, there were several multicolored stains on the walls of the room that were in direct contact with the table used for manufacturing powdered and capsuled dietary supplements. There was dark brown residue built up on a ceiling vent for the A\u002FC unit. You stated during the inspection that this room is used to repack and manufacture dietary supplements such as Dr. Bob’s Naturals Parasite Killer and to repack food products such as your Empress Blend mix, which contains raw pistachios. You provided two cleaning procedures for this room during the inspection, neither of which contains instructions for preventing allergen cross-contact, nor were you able to provide evidence of implementation of either of these procedures.\u003Cbr>\nc. In the warehouse our investigator observed a lawn mower, a snow blower, three orange gas containers, four bags of weed killer (one of which was opened), two canisters of pest control spray, two containers of engine\u002Fmotor oil, and assorted lawn and gardening equipment that were directly touching or immediately surrounding a number of your products.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your responses and acknowledge that in your August 23, 2022, response you indicated that the green and brown residues are caused when you do not change filters often enough, and that you will change the filters in the rooftop\u002Fheating and cooling unit.\u003C\u002Fp>\n\n\u003Cp>In addition, you stated that you cleaned the wall that had the stain on it. You also stated that all gasoline, oil, and other petroleum products have been removed from the building entirely and that you have hired a contractor to maintain the outside of the facility. However, you did not provide evidence of corrective actions, such as photographs of replaced filters, cleaned ceiling tiles and vents, and the warehouse. Further, your response did not indicate that you would update your cleaning and\u002For maintenance procedures to include cleaning ceiling tiles and a filter replacement schedule, nor did you provide a copy of updated cleaning and\u002For maintenance procedures. Therefore, we are unable to evaluate the adequacy of your corrective action.\u003C\u002Fp>\n\n\u003Cp>5. Your quality control personnel did not approve or reject written procedures that may affect the identity, purity, strength, or composition of a dietary supplement, as required by 21 CFR 111.105(a). Specifically, during the inspection, we reviewed your “Production Quality Control SOP,” “Incoming Quality Control (IQC) SOP,” “Finished Batches Meeting Product Specifications SOP,” and none of these procedures included a signature from your quality control personnel. Likewise, your quality control personnel did not approve all MMRs, as required by 21 CFR 111.123(a)(1). Specifically during the inspection, we reviewed the MMRs for Dr. Bob’s Naturals NootriTonic ULTRA (50g), Raw Food World Sleep Deep Powder (2 oz.), and Dr. Bob’s Naturals Parasite Killer (60 capsules), and none of these MMRs included a signature from your quality control personnel.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your responses dated August 12, 2022, and August 23, 2022, in which you state you will implement a more detailed quality control protocol and that you are working with a consultant to make the necessary corrections in your current system. We also reviewed your January 22, 2023, response in which you state you have overhauled and improved your document protocols. We are unable to evaluate the adequacy of your corrective action, because you did not provide documentation to support that your quality control unit is reviewing and approving your written procedures and master manufacturing records.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Dietary Supplements\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Even if your Dr. Bob’s Naturals Ginkgo Magic, Yew VeggieCaps, and Parasite Killer products were not unapproved new drugs, the products would be misbranded under section 403 of the Act [21 U.S.C. 343] because they do not comply with the labeling requirements for dietary supplements. Additionally, your Dr. Bob’s Naturals NootriTonic ULTRA and The Raw Food World Sleep Deep Powder products also do not comply with the labeling requirements for dietary supplements. Specifically, we identified the following:\u003C\u002Fp>\n\n\u003Cp>1. Your Dr. Bob’s Naturals Ginkgo Magic, Dr. Bob’s Naturals Yew VeggieCaps, Dr. Bob’s Naturals NootriTonic ULTRA, Dr. Bob’s Naturals Parasite Killer, and The Raw Food World Sleep Deep Powder products are each misbranded within the meaning of section 403(e)(1) of the Act [21 U.S.C. § 343(e)(1)] in that the labels fail to list the name and place of business of the manufacturer, packer, or distributor, in accordance with 21 CFR 101.5.\u003C\u002Fp>\n\n\u003Cp>2. Your Dr. Bob’s Naturals Ginkgo Magic, Dr. Bob’s Naturals Yew VeggieCaps, Dr. Bob’s Naturals NootriTonic ULTRA, Dr. Bob’s Naturals Parasite Killer, and The Raw Food World Sleep Deep Powder products are misbranded within the meaning of section 403(s)(2)(B) of the Act [21 U.S.C. § 343(s)(2)(B)] because they do not include a statement of identity as a “dietary supplement,” as required by 21 CFR 101.3(g).\u003C\u002Fp>\n\n\u003Cp>3. Your Dr. Bob’s Naturals Yew VeggieCaps, Dr. Bob’s Naturals Parasite Killer, Dr. Bob’s Naturals NootriTonic ULTRA, and The Raw Food World Sleep Deep Powder products are misbranded within the meaning of section 403(i)(2) of the Act [21 U.S.C. § 343(i)(2)] in that the product labels fail to declare all common or usual names of each ingredient used, as required by 21 CFR 101.36 and 21 CFR 101.4. Specifically:\u003C\u002Fp>\n\n\u003Cp>a. The Dr. Bob’s Naturals Yew VeggieCaps and Dr. Bob’s Naturals Parasite Killer products are manufactured into capsules, but the label fails to declare the ingredients that form the capsule itself.\u003Cbr>\nb. The Dr. Bob’s Naturals Yew VeggieCaps product label fails to declare the standardized common name of Pacific Yew for the declared dietary ingredient \u003Cem>Taxus brevifolia\u003C\u002Fem> (“Yew powder”), as listed in the reference Herbs of Commerce.\u003Cbr>\nc. The Raw Food World Sleep Deep Powder product label fails to declare the standardized common name of polygala for the declared dietary ingredient \u003Cem>Yuan zhi\u003C\u002Fem>. Additionally, the product label fails to declare the standardized common name of oriental arborvitae for the declared dietary ingredient bai zi ren (\u003Cem>Platycladus orientalis\u003C\u002Fem>).\u003Cbr>\nd. The Dr. Bob’s Naturals NootriTonic ULTRA product label fails to declare the common or usual name for alpha-GPC, fruit punch flavor, and P5P.\u003Cbr>\ne. The Dr. Bob’s Parasite Killer fails to declare the standardized common name for the ingredients “Mimosa Pudica” and “Chandra Piedra” as listed in Herbs of Commerce. Mimosa Pudica is not a standardized common name, but an other common name. In addition, we note that your website indicates that “Chandra Piedra’ is an unidentified species of \u003Cem>Phyllanthus\u003C\u002Fem>.\u003C\u002Fp>\n\n\u003Cp>4. The Raw Food World Sleep Deep Powder product is misbranded within the meaning of section 403(y) of the Act [21 U.S.C. § 343(y)] in that the product label fails to bear a domestic address or domestic phone number through which the responsible person (as described in section 761) may receive a report of a serious adverse event with such dietary supplement.\u003C\u002Fp>\n\n\u003Cp>5. Your Dr. Bob’s Naturals Ginkgo Magic, Dr. Bob’s Naturals Yew VeggieCaps, Dr. Bob’s Naturals NootriTonic ULTRA, Dr. Bob’s Naturals Parasite Killer, and The Raw Food World Sleep Deep Powder products are misbranded within the meaning of section 403(s)(2)(C) of the Act [21 U.S.C. § 343(s)(2)(C)] because the labels fail to identify the part of the plant (e.g., root, leaves) from which each botanical dietary ingredient in the products are derived, as required by 21 CFR 101.4(h)(1). Specifically:\u003C\u002Fp>\n\n\u003Cp>a. The Dr. Bob’s Naturals Ginkgo Magic product label fails to include the part of the plant from which the Ginkgo biloba extract is derived.\u003Cbr>\nb. The Dr. Bob’s Naturals Yew VeggieCaps product label fails to include the part of the plant from which the Yew powder is derived.\u003Cbr>\nc. The Dr. Bob’s Naturals Parasite Killer product label fails to include the part of the plant from which its botanical ingredients are derived, including clove powder, wormwood, guarana, bearberry, epazote, and “mimosa pudica.”\u003Cbr>\nd. The Raw Food World Sleep Deep Powder product label fails to declare in English the part of the plant from which the bai zi ren and yuan zhi are derived.\u003C\u002Fp>\n\n\u003Cp>6. Your Dr. Bob’s Naturals Ginkgo Magic, Dr. Bob’s Naturals Yew VeggieCaps, and Dr. Bob’s Naturals Parasite Killer products are misbranded within the meaning of section 403(q)(1)(A) [21 U.S.C. § 343(q)(1)(A)] because the serving size declared on the label is incorrect. Serving size for a dietary supplement is the maximum amount consumed per eating occasion as recommended on the product label as defined in 21 CFR 101.9(b) and 21 CFR 101.12(b) Table 2. Specifically:\u003C\u002Fp>\n\n\u003Cp>a. The dosage amount listed on Dr. Bob’s Naturals Ginkgo Magic product label suggest the consumer take a “maintenance dosage” of 2-4 capsules daily or a “health challenge” dosage of 5-8 capsules daily, but the serving size listed is 2 capsules.\u003Cbr>\nb. The dosage amount listed on Dr. Bob’s Naturals Yew VeggieCaps product label suggests the consumer take a “maintenance dosage” of 2 capsules daily or a “health challenge” dosage of 5-8 capsules daily, but the serving size listed is 2 capsules.\u003Cbr>\nc. The dosage amount listed on Dr. Bob’s Naturals Parasite Killer product label indicates two to four capsules on an empty stomach. Furthermore, the serving size of 750 mg in the Supplement Facts label does not correlate with the dosage declaration.\u003C\u002Fp>\n\n\u003Cp>7. Your Dr. Bob’s Naturals Ginkgo Magic, Dr. Bob’s Naturals Yew VeggieCaps, Dr. Bob’s Naturals NootriTonic ULTRA, Dr. Bob’s Naturals Parasite Killer, and The Raw Food World Sleep Deep Powder products are misbranded within the meaning of sections 403(q)(5)(F) and 403(q)(1)(A) of the Act [21 U.S.C. §§ 343(q)(1)(A) and (q)(5)(F)] in that the presentation of the nutrition information on the labeling of your products does not comply with 21 CFR 101.36.\u003Cbr>\nSpecifically:\u003C\u002Fp>\n\n\u003Cp>a. Dr. Bob’s Naturals Ginkgo Magic:\u003Cbr>\n&nbsp; i. The product label lists its dietary ingredient, ginkgo biloba extract, outside the nutrition label of the supplement facts label. This dietary ingredient should be listed inside the supplement facts label along with its quantitative amount by weight per serving in metric units in accordance with 21 CFR 101.36(b)(3).\u003Cbr>\n&nbsp; ii. The product label declares nutrients with quantitative amounts of zero. Any (b)(2)-dietary ingredients not present, or in amount that can be declared as zero in 21 CFR 101.9(c), shall not be declared, in accordance with 21 CFR 101.36(b)(2).\u003C\u002Fp>\n\n\u003Cp>b. Dr. Bob’s Naturals Yew VeggieCaps\u003Cbr>\n&nbsp; i. The product label lists its dietary ingredient, “yew powder”, outside the nutrition label of the supplement facts label. This dietary ingredient should be listed inside the supplement facts label along with its quantitative amount by weight per serving in metric units in accordance with 21 CFR 101.36(b)(3).\u003Cbr>\n&nbsp; ii. The product label contains nutrients which may be declared as zero. Any (b)(2)-dietary ingredients not present, or in amount that can be declared as zero in 21 CFR 101.9(c), shall not be declared, in accordance with 21 CFR 101.36(b)(2).\u003C\u002Fp>\n\n\u003Cp>c. Dr. Bob’s Naturals NootriTonic ULTRA\u003Cbr>\n&nbsp; i. The product label lists dietary ingredients, including alpha-GPC, tyrosine, phosphatidylserine, theanine, carnitine, and P5P, outside the nutrition label of the supplement facts label. These dietary ingredients should be listed inside the supplement facts label along with each dietary ingredient’s quantitative amount by weight per serving in metric units in accordance with 21 CFR 101.36(b)(3).\u003Cbr>\n&nbsp; ii. The product label declares dietary ingredients with quantitative amounts of zero. Any (b)(2)-dietary ingredients not present, or in amounts that can be declared as zero in 21 CFR 101.9(c), shall not be declared, in accordance with 21 CFR 101.36(b)(2).\u003Cbr>\n&nbsp; iii. The serving size for the product must be expressed in common household measures as set forth in 21 CFR 101.9(b) and must be followed by the equivalent metric quantity in parenthesis (fluids in milliliters and all other foods in grams).\u003Cbr>\n&nbsp; iv. The title, “Supplement Facts,” is not in bolded font nor set at full width of the nutrition label in accordance with 21 CFR 101.36(e)(1).\u003C\u002Fp>\n\n\u003Cp>d. Dr. Bob’s Naturals Parasite Killer product label lists dietary ingredients, including papaya seed, golden seal leaf, clove powder, wormwood, guarana, bearberry, epazote, pumpkin seed, grapefruit seed, “mimosa pudica,” cayenne pepper, and black walnut hull, outside the nutrition label of the supplement facts label. These dietary ingredients should be listed inside the supplement facts label along with each dietary ingredient’s quantitative amount by weight per serving in metric units in accordance with 21 CFR 101.36(b)(3).\u003C\u002Fp>\n\n\u003Cp>e. The Raw Food World Sleep Deep Powder product label lists dietary ingredients, including “bai zi ren” and “yuan zhi,” outside the nutrition label of the supplement facts label. These dietary ingredients should be listed as the standardized common name of each dietary ingredient inside the supplement facts label along with its quantitative amount by weight per serving in metric units in accordance with 21 CFR 101.36(b)(3).\u003C\u002Fp>\n\n\u003Cp>f. Dr. Bob’s Naturals Ginkgo Magic, Dr. Bob’s Naturals Yew VeggieCaps, and Dr. Bob’s Naturals NootriTonic ULTRA products Supplement Facts labels each declare a statement referencing a 2,000 calorie diet. This statement is only permitted when the percent of Daily Value is declared for total fat, saturated fat, total carbohydrate, dietary fiber, or protein as required by 21 CFR 101.9(c) and 21 CFR 101.36(b)(2)(iii)(D). Furthermore, for the Dr. Bob’s Naturals Yew VeggieCaps there is no provision for the statement “Not a significant source of vitamin D, calcium, iron, and …” in the Supplement Facts label.\u003C\u002Fp>\n\n\u003Cp>8. Your Dr. Bob’s Naturals NootriTonic ULTRA product is misbranded within the meaning of section 403(e)(2) of the Act [21 U.S.C. § 343(e)(2)] because the label fails to declare the net quantity of contents on the principal display panel as required by 21 CFR 101.7. In accordance with 21 CFR 101.7(b)(1), statements of weight shall be in terms of avoirdupois pound and ounce. The net quantity of contents statement, expressed in terms of weight, must specify both metric (i.e., grams or kilograms) and U.S. Customary System (i.e., ounces or pounds), to comply with 21 CFR 101.7 and 15 U.S.C. 1453(a)(2) of the Fair Packaging and Labeling Act.\u003C\u002Fp>\n\n\u003Cp>9. The Dr. Bob’s Naturals Parasite Killer product is misbranded within the meaning of section 403(w) of the Act [21 U.S.C. § 343(w)] in that the finished product label lists black walnut in the ingredients statement while the “Contains” statement declares that no tree nut is present in the product, which is not in accordance with section 403(w) of the Act.\u003C\u002Fp>\n\n\u003Cp>Section 201(qq) of the Act, 21 U.S.C. 321(qq), defines a major food allergen as milk, egg, fish, Crustacean shellfish, tree nuts, wheat, peanuts, and soybeans, as well as any food ingredient that contains protein derived from one of these foods, with certain exceptions, e.g., highly refined oils derived from a major food allergen. A food is misbranded if it is not a raw agricultural commodity and it is, or it contains, an ingredient that bears or contains, a major food allergen, unless either:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>The word “Contains,” followed by the name of the food source from which the major food allergen is derived, is printed immediately after or is adjacent to the list of ingredients [section 403(w)(1)(A) of the Act, 21 U.S.C. § 343(w)(1)(A)]; or\u003C\u002Fli>\n\t\u003Cli>The common or usual name of the major food allergen in the list of ingredients is followed in parentheses by the name of the food source from which the major food allergen is derived, except that the name of the food source is not required when either the common or usual name of the ingredient uses the name of the food source or the name of the food source appears elsewhere in the ingredient list (unless the name of the food source that appears elsewhere in the ingredient list appears as part of the name of an ingredient that is not a major food allergen) [section 403(w)(1)(B) of the Act, 21 U.S.C. § 343(w)(1)(B)].\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>10. Your Dr. Bob’s Naturals Ginkgo Magic, Dr. Bob’s Naturals NootriTonic ULTRA, and The Raw Food World Sleep Deep Powder are each misbranded withing the meaning of section 403(r)(6) [21 U.S.C. § 343(r)(6)] in that the products make structure function claims but fail to bear the required dietary supplement disclaimer in accordance with 21 CFR 101.93(b).\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>We also have the following comments:\u003C\u002Fp>\n\n\u003Cp>1. You may confirm the identity of other components (that are not dietary ingredients) by relying on a certificate of analysis from the supplier of the component that you receive provided that you:\u003Cbr>\n&nbsp; &nbsp; • First establish component specifications, as required by 21 CFR 111.70(b).\u003Cbr>\n&nbsp; &nbsp; • Meet the requirements of 21 CFR 111.75(a)(2)(ii).\u003C\u002Fp>\n\n\u003Cp>Your Dr. Bob’s Naturals NootriTonic ULTRA product label declares “stevia’ in the Ingredient list. If you are using highly purified steviol glycosides obtained from stevia leaves in your product, please note that “stevia” refers to the botanical and is not the common or usual name of these highly purified ingredients. Rather, the common or usual name for highly purified steviol glycosides depends on the ingredient composition. If the sweetener is purified to contain 95 percent or more of a single steviol glycoside, the specific name of that single steviol glycoside is the common or usual name. For example, the name “rebaudioside A” should be used for ingredients with 95% or more rebaudioside A; the name “stevioside” should be used for ingredients with 95% or more stevioside. If the sweetener is purified to contain 95 percent or more of a mixture of two or more steviol glycosides, the name “steviol glycosides” would be the common or usual name.\u003C\u002Fp>\n\n\u003Cp>2. Your Raw Food World Sleep Deep Powder product displays text in pinyin; pinyin is considered a foreign language. A product is misbranded if the product label contains information in two languages but does not repeat all the required label information (including the nutrition information) in both languages. [section 403(f) of the Act [21 U.S.C. § 343(f)] and 21 CFR 101.15(c)].\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to do so may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your reply should be addressed to the U.S. Food and Drug Administration; Attn: Lauren Crivellone, Compliance Officer, via email at ORAHAFEAST6FirmResponses@fda.hhs.gov or at 550 W. Jackson Blvd, Chicago, IL 60661. You may reach Ms. Crivellone at 312-206-5264 or via email at Lauren.Crivellone@fda.hhs.gov if you have any questions about this matter.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Lawrence Stringer\u003Cbr>\nActing Program Division Director\u003Cbr>\nOffice of Human and Animal Food\u003Cbr>\nOperations Division East 6\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nRobert F. McCauley\n\nRecipient Title\n\nPresident\u002FOwner\n\nSpartan Enterprises Inc. dba Watershed Wellness Center\n\n16280 National Parkway\n\nLansing, MI 48906\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations East VI\n\nUnited States\n\nWARNING LETTER\n\nFY23-HAFE6-01 CMS 642030\n\nMarch 8, 2023\n\nDear Mr. McCauley:\n\nThe U.S. Food and Drug Administration (FDA) inspected your dietary supplement manufacturing facility, located at 16280 National Parkway, Lansing MI, from June 29 through July 25, 2022. We also reviewed your websites at www.watershed.net and www.shop.watershed.net in December 2022, and your YouTube channel. Based on inspectional findings and a review of your websites, we have identified serious violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on the FDA’s home page at http:\u002F\u002Fwww.fda.gov.\n\nUnapproved New\u002FMisbranded Drugs\n\nThis is to advise you that the FDA reviewed your product labels following the inspection of your facility. In addition, FDA reviewed your website www.shop.watershed.net in December 2022, and determined you take orders there for the products Dr. Bob’s Naturals Spirulina, Dr. Bob’s Naturals Magtein, Dr. Bob’s Naturals Tulsi-Holy Basil Extract Capsules, Dr. Bob’s Naturals Milk Thistle Liver Support, Dr. Bob’s Naturals Stone Breaker Powder, Dr. Bob’s Parasite Killer, Dr. Bob’s Naturals Parasite Killer Bundle, Dr. Bob’s Naturals Parasite Killer Bundle MINI, Dr. Bob’s Naturals Yew VeggieCaps, Dr. Bob’s Naturals Gingko Magic, and Dr. Bob’s Naturals Chlorella, and Raw Food World Ashwagandha Extract. We also reviewed your website www.watershed.net, which directs consumers to your website www.shop.watershed.net to purchase your products, and your YouTube Channel at www.youtube.com\u002Fc\u002FDrBobMcCauley, in December 2022. The claims on your product labels, websites, and your YouTube Channel establish that these products are drugs under section 201(g)(1)(B) of the Act [21 U.SC. § 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing, or delivering for introduction into interstate commerce for such uses violates the Act.\n\nExamples of some of the claims that provide evidence that your products are intended for use as drugs include:\n\nFrom your website at www.watershed.net:\n\no Spirulina [an ingredient in Dr. Bob’s Naturals Spirulina tablets]: the following statements are included in the description: “Lowers LDL and Triglyceride Levels”, “Anti-Inflammatory Properties”, “Fights Anemia”\n\no Ashwagandha [an ingredient in the Raw Food World Ashwagandha Extract]: the following statements are included in the description: “It is commonly used to relieve…pain, skin, joint, digestive issues asn [sic] well as neurological issues.”\n\nFrom your website at www.shop.watershed.net:\n\no Dr. Bob’s Naturals Magtei: “Magnesium repairs the damaged synapses of the brain, which is the cause of the various types of neurological and brain-related diseases.”\n\no Dr. Bob’s Naturals Tulsi-Holy Basil Extract Capsules:\n\no “Regulates Insulin Levels to Help Balance Blood Sugar”\n\no “Contains Antibacterial, Antifungal Properties”\n\no “Holy Basil…regulates insulin levels…. It has Antibacterial, anti-fungal, and anti-inflammatory properties.”\n\no Dr. Bob’s Naturals Milk Thistle Liver Support:\n\no “Milk Thistle ….is…anti-inflammatory”\n\no “Benefits:\n\n􀂃 Reduces Cholesterol\n\n􀂃 Anti-allergic\n\n􀂃 Asthma Support\n\n􀂃 Reduces Insulin Resistance\n\n􀂃 Anti-inflammatory”\n\no Dr. Bob’s Naturals Stone Breaker Powder: “Stone Breaker (Chanca Piedra) has been used by the indigenous peoples of the Amazon Forests for centuries to treat and remove of [sic] kidney and gall stones. It helps dissolve the stones so they can be eliminated from the body. Chanca Piedra interferes with stone formation by relaxing urinary passages so small stones are more easily passed. It can be used in conjunction with lithotripsy, a shock wave procedure that fragments stones”\n\no Dr. Bob’s Naturals Parasite Killer Bundle: “Six Products that kill viruses, bacteria, yeast, mold, and fungus in the bloodstream and digestive tract. Silver: Kills viruses, bacteria, yeast, mold, and fungus in the bloodstream. (16 oz) Bismuth: Kills bacteria in the digestive tract. (16 oz) Papaya Seed Powder: Parasite removal. Parasite Killer BlendTM: Kills viruses, bacteria, yeast, mold, and fungus in the digestive tract. Dissolve Bioactive Silicate: Removes biofilm and nano-bacteria from the arteries and body. Proferment [sic].”\n\no Dr. Bob’s Naturals Parasite Killer Bundle MINI: “Dr. Bob’s Parasite Killer Bundle MINI is identical to Dr. Bob’s Parasite Killer Bundle except the bottles are 2 oz (NOT 16 oz). Six Products that kill viruses, bacteria, yeast, mold, and fungus in the bloodstream and digestive tract. Silver: Kills viruses, bacteria, yeast, mold, and fungus in the bloodstream. (2 oz) Bismuth: Kills bacteria in the digestive tract. (2 oz) Papaya Seed Powder: Parasite removal. Parasite Killer BlendTM: Kills viruses, bacteria, yeast, mold, and fungus in the digestive tract. Dissolve Bioactive Silicate: Removes biofilm and nano-bacteria from the arteries and body. Preferment – Probiotic.”\n\no Dr. Bob’s Naturals Parasite Killer: “Dr. Bob’s Parasite Killer is formulated with parasiticidal, anti-fungal, anti-viral, and antibacterial ingredients with the intention of killing everything in the digestive tract. Once that is accomplished then the next step is to reintroduce probiotics, the friendly bacteria that…. keep our digestive tract free of parasites and unhealthy bacteria.”\n\nFrom your YouTube Channel:\n\no A video titled “Amazing herb – Little Known: YEW Tree with Taxane” [an ingredient in Dr. Bob’s Naturals Yew VeggieCaps] at https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=kudldIcMIXU, in which the URL for your website www.watershed.net appears onscreen during the video and you state: “Very powerful anti-cancer properties…used in conjunction with chemotherapy and other cancer treatments, but not only does it have anti-cancer properties it also has a lot of other properties as well…the way that Taxane works in the body to fight cancer is it causes cell apoptosis in cancer cells. So it doesn’t allow the cancer cell to replicate…. Is also very powerful anti-inflammatory…on top of being anti-cancer…. you take two or three capsules a day as a maintenance dosage, or if you have a serious health challenge maybe you got cancer or something, you’re going to triple that dosage and do three of those three times a day ….”\n\no Your description of the video says, “Buy Yew Capsules Here” and hyperlinks to the Dr. Bob’s Naturals Yew VeggieCaps product page of your website, https:\u002F\u002Fshop.watershed.net\u002Findex.php\u002Fherbal-extracts\u002Fimmune-system-builder\u002Fyew\u002Fyewcaps.html, and also contains the following written statements:\n\n􀂃 “Anti-inflammatory”\n\n􀂃 “Taxane a chemical substance derived from a yew tree of the Pacific Coast: used yew tree experimentally as a drug in the treatment of cancer. It is derived from Yew trees – Taxus Brevafolia – and bushes and used to kill dividing cells, especially tumor cells.”\n\n􀂃 “The taxanes are mitotic inhibitors, meaning that they inhibit tumors primarily by preventing cells from entering mitosis, a process of cell division. The taxanes accomplish this by inhibiting microtubule polymerization. In addition, taxanes appear to stimulate apoptosis, or programmed cell death, which is often inhibited in cancer cells.”\n\no A video titled “Gingko Biloba Benefits” [an ingredient in Dr. Bob’s Naturals Gingko Magic] at https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=6SstxpuWwZg, in which the URL for your website www.watershed.net appears onscreen during the video and you state: “It’s used for Alzheimer’s, memory loss ….Good for…ADHD ….It also helps with…arthritis….It also helps with…asthma…it is opening up those bronchial tubes and increasing circulation to the lungs….gingko biloba world’s most famous herb use for all your…fibromyalgia…increasing that circulation to relieve that pain…be good for MS [multiple sclerosis] as well for that reason….”\n\no During the video, the following written statements appear as on-screen text:\n\n􀂃 “Reduces Risk for Dementia\u002FAlzheimer’s”\n\n􀂃 “Helps fight Fibromyalgia”\n\n􀂃 “Helps fight Headaches\u002FMigraines”\n\no Your description of the video says, “Buy Our Ginkgo Veggie Capsules Here” and hyperlinks to your website https:\u002F\u002Fshop.watershed.net\u002Findex.php\u002Fherbal-extracts\u002Fbrainhealth\u002Fgingko-biloba\u002Fginkgo-veggiecaps.html, and also contains the following written statements:\n\n􀂃 “Helps fight Headaches\u002FMigraines”\n\n􀂃 “Reduces Memory Loss”\n\n􀂃 “Helps fight Muscle and Nerve Pain”\n\no A video titled “Increase your Synaptic Activity with Magnesium for the Brain” [an\n\ningredient in Dr. Bob’s Naturals Magtein] at https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=AoZv9ESLFpY, in which the URL for your website www.watershed.net appears onscreen during the video and you state: “[m]agnesium…a lot of people have heart attacks just because they are short on magnesium….there’s another type of magnesium that gets to your brain….they started autopsying Alzheimer’s patients after they passed away and stupid monkeys and smart monkeys and they found the people with the Alzheimer’s and stupid monkeys had absolutely no magnesium in the brain and smart monkeys were full of magnesium in the brain. Well what does that tell you? Magnesium is really needed in the brain it increases synaptic activity and actually increases synapses themselves in the brain.”\n\no During the video, the following written statement appears as on-screen text:\n\n􀂃 “6 grams (2 tsp or 12 capsules) per day if you have memory issues or DEMENTIA”.\n\no Your description of the video hyperlinks to the Dr. Bob Naturals Magtein product page of your website, https:\u002F\u002Fshop.watershed.net\u002Findex.php\u002Fsupplements\u002Fmagtein\u002Fmagtein-miracle-magnesium-for-the-brain-veggie-capsules.html, and contains the following written statements:\n\n􀂃 “Magnesium repairs the damaged synapses of the brain.”\n\n􀂃 “Decreases the Onset Of Memory Loss”\n\n􀂃 “Repairs Damaged Synapses”\n\nFrom your product labels:\n\no Dr. Bob’s Naturals Ginkgo Magic: “Ginkgo is an anti-inflammatory”\n\no Dr. Bob’s Naturals Yew VeggieCaps: “The Yew tree (taxus brevifolia) contains a substance called taxane. Taxanes . . . prevent harmful cells from entering mitosis. Taxane has been used in chemotherapy for many years.”\n\no “Anti-Inflammatory”\n\no Dr. Bob’s Naturals Parasite Killer: “Dr. Bob’s Parasite Killer is formulated with parasiticidal, anti-fungal, anti-viral and anti-bacterial ingredients with the intention of killing everything in the digestive tract.”\n\no Dr. Bob’s Naturals Spirulina: “Helps Balance Blood Sugar”\n\no Dr. Bob’s Naturals Chlorella: “Helps Balance Blood Sugar”\n\no Dr. Bob’s Holy Basil Extract: “Tulsi, or Holy Basil…. regulates insulin helping balance blood sugar levels in the body. It also contains antibacterial, antifungal, and anti-inflammatory properties.”\n\no Dr. Bob’s Naturals Milk Thistle Liver Support: “Milk Thistle …. is also…anti-inflammatory ….”\n\no “Reduces Cholesterol\n\no Reduces Insulin Resistance\n\no Anti-Inflammatory\n\no Asthma Support”\n\no Dr. Bob’s Naturals Stone Breaker Capsules: “Gall and Kidney Stone Removal”\n\no “Stone Breaker (Chanca Piedra) has been used…to treat and remove kidney and gall stones. It helps dissolve the stones …. Chanca Piedra interferes with stone formation by relaxing urinary passages so small stones are more easily passed.”\n\nYour products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. §§ 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour Dr. Bob’s Naturals Yew VeggieCaps, Gingko Magic, Milk Thistle Liver Support, Stone Breaker Capsules and Powder, and Magtein products are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, your Dr. Bob’s Naturals Yew VeggieCaps, Gingko Magic, Milk Thistle Liver Support, Stone Breaker Capsules and Powder, and Magtein products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. § 331(a)].\n\nAdulterated Dietary Supplements\n\nThe inspection revealed serious violations of the FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR 111). Based on these violations, your Dr. Bob’s Naturals NootriTonic ULTRA, Dr. Bob’s Naturals Parasite Killer, and Raw Food World Sleep Deep Powder products are adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. § 342(g)(1)] in that they were prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements.\n\nThe violations include the following:\n\n1. You failed to establish specifications required under 21 CFR 111.70. Specifically:\n\na. You failed to establish component specifications that are necessary to ensure that specifications for the purity, strength, and composition of dietary supplements manufactured using the components are met, as required by 21 CFR 111.70(b)(2). For example, Chanca Piedra is an ingredient in your Dr. Bob’s Naturals Parasite Killer, but you did not establish such component specifications for Chanca Piedra. Likewise, Yuan Zhi is an ingredient in your Raw Food World Sleep Deep powder, but you did not establish such component specifications for Yuan Zhi.\n\nb. You failed to establish specifications for each dietary supplement that you manufacture for the identity, purity, strength, and composition of the finished batch of the dietary supplement, and for limits on those types of contamination that may adulterate, or lead to the adulteration of, the finished batch of the dietary supplement to ensure the quality of the dietary supplement, as required by 21 CFR 111.70(e). For example, you did not establish any finished product specifications for Dr. Bob’s Naturals NootriTonic ULTRA, Raw Food World Sleep Deep Powder, and Dr. Bob’s Naturals Parasite Killer.\n\nOnce you have established specifications required under 21 CFR 111.70, you must determine whether the specifications are met, as required by 21 CFR 111.75. You must also ensure that the tests and examinations that you use to determine whether the specifications are met are appropriate, scientifically valid methods, as required by 21 CFR 111.75(h)(1), and you must make and keep records of the specifications established, as required by 21 CFR 111.95(b)(1).\n\nWe have reviewed your responses, dated August 12 and August 23, 2022, in which you state you will establish specifications for the purity, strength, and composition of each of the ingredients used in your supplements, and that you will develop procedures to demonstrate that the products you manufacture meet your specifications. We also reviewed your January 22, 2023, response in which you state you have overhauled and improved your document protocols. However, you did not provide any supporting documentation, such as copies of your specifications. We are unable to evaluate the adequacy of your corrective action, because you did not provide documentation to support that you have established component and finished product specifications.\n\n2. You must prepare and follow a master manufacturing record (MMR) for each unique formulation of dietary supplement that you manufacture, and for each batch size, to ensure uniformity in the finished batch from batch to batch, as required by 21 CFR 111.205(a), and the MMR must include the information required under 21 CFR 111.210. The MMRs used in the manufacture of your Dr. Bob’s Naturals NootriTonic ULTRA, Raw Food World Sleep Deep Powder, and Dr. Bob’s Naturals Parasite Killer, failed to include the following information, as required by 21 CFR 111.210:\n\na. The identity and weight or measure of each dietary ingredient that will be declared on the Supplement Facts label [21 CFR 111.210(d)].\n\nb. A statement of theoretical yield of a manufactured dietary supplement at each point, step, or stage of the manufacturing process where control is needed to ensure the quality of the dietary supplement, and the expected yield when you finish manufacturing the dietary supplement, including the maximum and minimum percentages of theoretical yield beyond which a deviation investigation of a batch is necessary and material review is conducted and disposition decision is made [21 CFR 111.210(f)].\n\nc. A description of packaging and a representative label, or a cross-reference to the physical location of the actual or representative label [21 CFR 111.210(g)].\n\nd. Written instructions, including specifications for each step, point or stage in the manufacturing process where control is necessary to ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the MMR [21 CFR 111.210(h)(1)].\n\ne. Procedures for sampling and a cross-reference to procedures for tests or examinations [21 CFR 111.210(h)(2)].\n\nf. Written instructions, including specific actions necessary to perform and verify points, steps, or stages in the manufacturing process where control is necessary to ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the MMR [21 CFR 111.210(h)(3)].\n\ng. Corrective action plans for use when a specification is not met [21 CFR 111.210(h)(5)].\n\nIn addition, the MMRs for Dr. Bob’s Naturals Parasite Killer and Raw Food World Sleep Deep Powder also do not include the strength, concentration, weight, or measure of each dietary ingredient for each batch size [21 CFR 111.210(a)] and an accurate statement of the weight or measure of each component to be used [21 CFR 111.210(c)], nor does the MMR for Dr. Bob’s Naturals Parasite Killer include a complete list of components to be used [21 CFR 111.210(b)].\n\nWe have reviewed your responses dated August 12, 2022, and August 23, 2022, in which you state you will develop written instructions and include them with your MMRs to reflect your procedures in greater detail, including quality control points, manufacturing stages, reserve collection and storage. You also state that you will implement in writing detailed manufacturing procedures, including which utensils are used, and how they should be cleaned and properly stored. We also reviewed your January 22, 2023, response in which you state you have overhauled and improved your document protocols. However, you did not provide any supporting documentation, such as copies of revised MMRs for your products. We are unable to evaluate the adequacy of your corrective action, because you did not provide documentation to support that you revised your MMRs and that they are compliant with 21 CFR 111.210.\n\n3. You must prepare a batch production record (BPR) every time you manufactured a batch of dietary supplement, as required by 21 CFR 111.255(a), and the BPR must include the information required under 21 CFR 111.260. The BPRs you provided for your Raw Food World Sleep Deep (Lots 8070, 8079), Dr. Bob’s Naturals Parasite Killer (Lots 7036, 7087), and Dr. Bob’s Naturals NootriTonic ULTRA (Lots 8067, 8044) dietary supplements lacked the following information that must be included in a BPR, as required by 21 CFR 111.260:\n\na. The identity of equipment and processing lines used in producing the batch [21 CFR 111.260(b)].\n\nb. The date and time of maintenance, cleaning and sanitizing of the equipment and processing lines used in producing the batch, or a cross-reference to records where this information is retained [21 CFR 111.260(c)].\n\nc. The unique identifier that you assigned to each component, packaging, and label used [21 CFR 111.260(d)].\n\nd. The identity and weight or measure of each component used [21 CFR 111.260(e)].\n\ne. A statement of the actual yield or statement of the percentage of theoretical yield at appropriate phases of processing [21 CFR 111.260(f)].\n\nf. The actual results obtained during any monitoring operations [21 CFR 111.260(g)].\n\ng. The results of any testing or examination performed during the batch production, or a cross-reference to such results [21 CFR 111.260(h)].\n\nh. Documentation that the finished dietary supplement meets specifications established in accordance with 21 CFR 111.70(e) and (g) [21 CFR 111.260(i)].\n\ni. Documentation, at the time of performance, of the manufacture of the batch, including the information required under 21 CFR 111.260(j) [21 CFR 111.260(j)].\n\nj. Documentation, at the time of performance, of packaging and labeling operations, including the information required under 21 CFR 111.260(k) [21 CFR 111.260(k)].\n\nk. Documentation at the time of performance, that quality control personnel reviewed the batch production record, and approved and released, or rejected, the batch for distribution [21 CFR 111.260(l)(3)].\n\nl. Documentation at the time of performance of any required material review and disposition decision [21 CFR 111.260(m)].\n\nWe have reviewed your responses, dated August 12 and August 23, 2022, in which you state you will keep detailed cleaning and sanitation records for each production run of any supplement you are manufacturing, that cleaning procedures in sanitation records will become part of all your SOPs, and that each batch record will reflect what cleaning and sanitation was done before and after the batch was manufactured. We also reviewed your January 22, 2023, response in which you state you have overhauled and improved your document protocols. However, you did not provide any supporting documentation, such as copies of BPRs for your products. We are unable to evaluate the adequacy of your corrective action, because you did not provide documentation to support that you have revised your BPRs and that they are compliant with 21 CFR 111.260.\n\n4. You failed to maintain your physical plant in a clean and sanitary condition, as required by 21 CFR 111.15(b)(1). Specifically:\n\na. In your repacking room, there was green residue built up on a ceiling vent for the A\u002FC unit, on the protective grating on a ceiling vent, and on various ceiling tiles. Further, your “Weekly Cleaning Procedure” includes wiping down walls and vents but does not include instructions for cleaning the ceiling tiles.\n\nb. In your new packing room, there were several multicolored stains on the walls of the room that were in direct contact with the table used for manufacturing powdered and capsuled dietary supplements. There was dark brown residue built up on a ceiling vent for the A\u002FC unit. You stated during the inspection that this room is used to repack and manufacture dietary supplements such as Dr. Bob’s Naturals Parasite Killer and to repack food products such as your Empress Blend mix, which contains raw pistachios. You provided two cleaning procedures for this room during the inspection, neither of which contains instructions for preventing allergen cross-contact, nor were you able to provide evidence of implementation of either of these procedures.\n\nc. In the warehouse our investigator observed a lawn mower, a snow blower, three orange gas containers, four bags of weed killer (one of which was opened), two canisters of pest control spray, two containers of engine\u002Fmotor oil, and assorted lawn and gardening equipment that were directly touching or immediately surrounding a number of your products.\n\nWe have reviewed your responses and acknowledge that in your August 23, 2022, response you indicated that the green and brown residues are caused when you do not change filters often enough, and that you will change the filters in the rooftop\u002Fheating and cooling unit.\n\nIn addition, you stated that you cleaned the wall that had the stain on it. You also stated that all gasoline, oil, and other petroleum products have been removed from the building entirely and that you have hired a contractor to maintain the outside of the facility. However, you did not provide evidence of corrective actions, such as photographs of replaced filters, cleaned ceiling tiles and vents, and the warehouse. Further, your response did not indicate that you would update your cleaning and\u002For maintenance procedures to include cleaning ceiling tiles and a filter replacement schedule, nor did you provide a copy of updated cleaning and\u002For maintenance procedures. Therefore, we are unable to evaluate the adequacy of your corrective action.\n\n5. Your quality control personnel did not approve or reject written procedures that may affect the identity, purity, strength, or composition of a dietary supplement, as required by 21 CFR 111.105(a). Specifically, during the inspection, we reviewed your “Production Quality Control SOP,” “Incoming Quality Control (IQC) SOP,” “Finished Batches Meeting Product Specifications SOP,” and none of these procedures included a signature from your quality control personnel. Likewise, your quality control personnel did not approve all MMRs, as required by 21 CFR 111.123(a)(1). Specifically during the inspection, we reviewed the MMRs for Dr. Bob’s Naturals NootriTonic ULTRA (50g), Raw Food World Sleep Deep Powder (2 oz.), and Dr. Bob’s Naturals Parasite Killer (60 capsules), and none of these MMRs included a signature from your quality control personnel.\n\nWe have reviewed your responses dated August 12, 2022, and August 23, 2022, in which you state you will implement a more detailed quality control protocol and that you are working with a consultant to make the necessary corrections in your current system. We also reviewed your January 22, 2023, response in which you state you have overhauled and improved your document protocols. We are unable to evaluate the adequacy of your corrective action, because you did not provide documentation to support that your quality control unit is reviewing and approving your written procedures and master manufacturing records.\n\nMisbranded Dietary Supplements\n\nEven if your Dr. Bob’s Naturals Ginkgo Magic, Yew VeggieCaps, and Parasite Killer products were not unapproved new drugs, the products would be misbranded under section 403 of the Act [21 U.S.C. 343] because they do not comply with the labeling requirements for dietary supplements. Additionally, your Dr. Bob’s Naturals NootriTonic ULTRA and The Raw Food World Sleep Deep Powder products also do not comply with the labeling requirements for dietary supplements. Specifically, we identified the following:\n\n1. Your Dr. Bob’s Naturals Ginkgo Magic, Dr. Bob’s Naturals Yew VeggieCaps, Dr. Bob’s Naturals NootriTonic ULTRA, Dr. Bob’s Naturals Parasite Killer, and The Raw Food World Sleep Deep Powder products are each misbranded within the meaning of section 403(e)(1) of the Act [21 U.S.C. § 343(e)(1)] in that the labels fail to list the name and place of business of the manufacturer, packer, or distributor, in accordance with 21 CFR 101.5.\n\n2. Your Dr. Bob’s Naturals Ginkgo Magic, Dr. Bob’s Naturals Yew VeggieCaps, Dr. Bob’s Naturals NootriTonic ULTRA, Dr. Bob’s Naturals Parasite Killer, and The Raw Food World Sleep Deep Powder products are misbranded within the meaning of section 403(s)(2)(B) of the Act [21 U.S.C. § 343(s)(2)(B)] because they do not include a statement of identity as a “dietary supplement,” as required by 21 CFR 101.3(g).\n\n3. Your Dr. Bob’s Naturals Yew VeggieCaps, Dr. Bob’s Naturals Parasite Killer, Dr. Bob’s Naturals NootriTonic ULTRA, and The Raw Food World Sleep Deep Powder products are misbranded within the meaning of section 403(i)(2) of the Act [21 U.S.C. § 343(i)(2)] in that the product labels fail to declare all common or usual names of each ingredient used, as required by 21 CFR 101.36 and 21 CFR 101.4. Specifically:\n\na. The Dr. Bob’s Naturals Yew VeggieCaps and Dr. Bob’s Naturals Parasite Killer products are manufactured into capsules, but the label fails to declare the ingredients that form the capsule itself.\n\nb. The Dr. Bob’s Naturals Yew VeggieCaps product label fails to declare the standardized common name of Pacific Yew for the declared dietary ingredient Taxus brevifolia (“Yew powder”), as listed in the reference Herbs of Commerce.\n\nc. The Raw Food World Sleep Deep Powder product label fails to declare the standardized common name of polygala for the declared dietary ingredient Yuan zhi. Additionally, the product label fails to declare the standardized common name of oriental arborvitae for the declared dietary ingredient bai zi ren (Platycladus orientalis).\n\nd. The Dr. Bob’s Naturals NootriTonic ULTRA product label fails to declare the common or usual name for alpha-GPC, fruit punch flavor, and P5P.\n\ne. The Dr. Bob’s Parasite Killer fails to declare the standardized common name for the ingredients “Mimosa Pudica” and “Chandra Piedra” as listed in Herbs of Commerce. Mimosa Pudica is not a standardized common name, but an other common name. In addition, we note that your website indicates that “Chandra Piedra’ is an unidentified species of Phyllanthus.\n\n4. The Raw Food World Sleep Deep Powder product is misbranded within the meaning of section 403(y) of the Act [21 U.S.C. § 343(y)] in that the product label fails to bear a domestic address or domestic phone number through which the responsible person (as described in section 761) may receive a report of a serious adverse event with such dietary supplement.\n\n5. Your Dr. Bob’s Naturals Ginkgo Magic, Dr. Bob’s Naturals Yew VeggieCaps, Dr. Bob’s Naturals NootriTonic ULTRA, Dr. Bob’s Naturals Parasite Killer, and The Raw Food World Sleep Deep Powder products are misbranded within the meaning of section 403(s)(2)(C) of the Act [21 U.S.C. § 343(s)(2)(C)] because the labels fail to identify the part of the plant (e.g., root, leaves) from which each botanical dietary ingredient in the products are derived, as required by 21 CFR 101.4(h)(1). Specifically:\n\na. The Dr. Bob’s Naturals Ginkgo Magic product label fails to include the part of the plant from which the Ginkgo biloba extract is derived.\n\nb. The Dr. Bob’s Naturals Yew VeggieCaps product label fails to include the part of the plant from which the Yew powder is derived.\n\nc. The Dr. Bob’s Naturals Parasite Killer product label fails to include the part of the plant from which its botanical ingredients are derived, including clove powder, wormwood, guarana, bearberry, epazote, and “mimosa pudica.”\n\nd. The Raw Food World Sleep Deep Powder product label fails to declare in English the part of the plant from which the bai zi ren and yuan zhi are derived.\n\n6. Your Dr. Bob’s Naturals Ginkgo Magic, Dr. Bob’s Naturals Yew VeggieCaps, and Dr. Bob’s Naturals Parasite Killer products are misbranded within the meaning of section 403(q)(1)(A) [21 U.S.C. § 343(q)(1)(A)] because the serving size declared on the label is incorrect. Serving size for a dietary supplement is the maximum amount consumed per eating occasion as recommended on the product label as defined in 21 CFR 101.9(b) and 21 CFR 101.12(b) Table 2. Specifically:\n\na. The dosage amount listed on Dr. Bob’s Naturals Ginkgo Magic product label suggest the consumer take a “maintenance dosage” of 2-4 capsules daily or a “health challenge” dosage of 5-8 capsules daily, but the serving size listed is 2 capsules.\n\nb. The dosage amount listed on Dr. Bob’s Naturals Yew VeggieCaps product label suggests the consumer take a “maintenance dosage” of 2 capsules daily or a “health challenge” dosage of 5-8 capsules daily, but the serving size listed is 2 capsules.\n\nc. The dosage amount listed on Dr. Bob’s Naturals Parasite Killer product label indicates two to four capsules on an empty stomach. Furthermore, the serving size of 750 mg in the Supplement Facts label does not correlate with the dosage declaration.\n\n7. Your Dr. Bob’s Naturals Ginkgo Magic, Dr. Bob’s Naturals Yew VeggieCaps, Dr. Bob’s Naturals NootriTonic ULTRA, Dr. Bob’s Naturals Parasite Killer, and The Raw Food World Sleep Deep Powder products are misbranded within the meaning of sections 403(q)(5)(F) and 403(q)(1)(A) of the Act [21 U.S.C. §§ 343(q)(1)(A) and (q)(5)(F)] in that the presentation of the nutrition information on the labeling of your products does not comply with 21 CFR 101.36.\n\nSpecifically:\n\na. Dr. Bob’s Naturals Ginkgo Magic:\n\ni. The product label lists its dietary ingredient, ginkgo biloba extract, outside the nutrition label of the supplement facts label. This dietary ingredient should be listed inside the supplement facts label along with its quantitative amount by weight per serving in metric units in accordance with 21 CFR 101.36(b)(3).\n\nii. The product label declares nutrients with quantitative amounts of zero. Any (b)(2)-dietary ingredients not present, or in amount that can be declared as zero in 21 CFR 101.9(c), shall not be declared, in accordance with 21 CFR 101.36(b)(2).\n\nb. Dr. Bob’s Naturals Yew VeggieCaps\n\ni. The product label lists its dietary ingredient, “yew powder”, outside the nutrition label of the supplement facts label. This dietary ingredient should be listed inside the supplement facts label along with its quantitative amount by weight per serving in metric units in accordance with 21 CFR 101.36(b)(3).\n\nii. The product label contains nutrients which may be declared as zero. Any (b)(2)-dietary ingredients not present, or in amount that can be declared as zero in 21 CFR 101.9(c), shall not be declared, in accordance with 21 CFR 101.36(b)(2).\n\nc. Dr. Bob’s Naturals NootriTonic ULTRA\n\ni. The product label lists dietary ingredients, including alpha-GPC, tyrosine, phosphatidylserine, theanine, carnitine, and P5P, outside the nutrition label of the supplement facts label. These dietary ingredients should be listed inside the supplement facts label along with each dietary ingredient’s quantitative amount by weight per serving in metric units in accordance with 21 CFR 101.36(b)(3).\n\nii. The product label declares dietary ingredients with quantitative amounts of zero. Any (b)(2)-dietary ingredients not present, or in amounts that can be declared as zero in 21 CFR 101.9(c), shall not be declared, in accordance with 21 CFR 101.36(b)(2).\n\niii. The serving size for the product must be expressed in common household measures as set forth in 21 CFR 101.9(b) and must be followed by the equivalent metric quantity in parenthesis (fluids in milliliters and all other foods in grams).\n\niv. The title, “Supplement Facts,” is not in bolded font nor set at full width of the nutrition label in accordance with 21 CFR 101.36(e)(1).\n\nd. Dr. Bob’s Naturals Parasite Killer product label lists dietary ingredients, including papaya seed, golden seal leaf, clove powder, wormwood, guarana, bearberry, epazote, pumpkin seed, grapefruit seed, “mimosa pudica,” cayenne pepper, and black walnut hull, outside the nutrition label of the supplement facts label. These dietary ingredients should be listed inside the supplement facts label along with each dietary ingredient’s quantitative amount by weight per serving in metric units in accordance with 21 CFR 101.36(b)(3).\n\ne. The Raw Food World Sleep Deep Powder product label lists dietary ingredients, including “bai zi ren” and “yuan zhi,” outside the nutrition label of the supplement facts label. These dietary ingredients should be listed as the standardized common name of each dietary ingredient inside the supplement facts label along with its quantitative amount by weight per serving in metric units in accordance with 21 CFR 101.36(b)(3).\n\nf. Dr. Bob’s Naturals Ginkgo Magic, Dr. Bob’s Naturals Yew VeggieCaps, and Dr. Bob’s Naturals NootriTonic ULTRA products Supplement Facts labels each declare a statement referencing a 2,000 calorie diet. This statement is only permitted when the percent of Daily Value is declared for total fat, saturated fat, total carbohydrate, dietary fiber, or protein as required by 21 CFR 101.9(c) and 21 CFR 101.36(b)(2)(iii)(D). Furthermore, for the Dr. Bob’s Naturals Yew VeggieCaps there is no provision for the statement “Not a significant source of vitamin D, calcium, iron, and …” in the Supplement Facts label.\n\n8. Your Dr. Bob’s Naturals NootriTonic ULTRA product is misbranded within the meaning of section 403(e)(2) of the Act [21 U.S.C. § 343(e)(2)] because the label fails to declare the net quantity of contents on the principal display panel as required by 21 CFR 101.7. In accordance with 21 CFR 101.7(b)(1), statements of weight shall be in terms of avoirdupois pound and ounce. The net quantity of contents statement, expressed in terms of weight, must specify both metric (i.e., grams or kilograms) and U.S. Customary System (i.e., ounces or pounds), to comply with 21 CFR 101.7 and 15 U.S.C. 1453(a)(2) of the Fair Packaging and Labeling Act.\n\n9. The Dr. Bob’s Naturals Parasite Killer product is misbranded within the meaning of section 403(w) of the Act [21 U.S.C. § 343(w)] in that the finished product label lists black walnut in the ingredients statement while the “Contains” statement declares that no tree nut is present in the product, which is not in accordance with section 403(w) of the Act.\n\nSection 201(qq) of the Act, 21 U.S.C. 321(qq), defines a major food allergen as milk, egg, fish, Crustacean shellfish, tree nuts, wheat, peanuts, and soybeans, as well as any food ingredient that contains protein derived from one of these foods, with certain exceptions, e.g., highly refined oils derived from a major food allergen. A food is misbranded if it is not a raw agricultural commodity and it is, or it contains, an ingredient that bears or contains, a major food allergen, unless either:\n\nThe word “Contains,” followed by the name of the food source from which the major food allergen is derived, is printed immediately after or is adjacent to the list of ingredients [section 403(w)(1)(A) of the Act, 21 U.S.C. § 343(w)(1)(A)]; or\n\nThe common or usual name of the major food allergen in the list of ingredients is followed in parentheses by the name of the food source from which the major food allergen is derived, except that the name of the food source is not required when either the common or usual name of the ingredient uses the name of the food source or the name of the food source appears elsewhere in the ingredient list (unless the name of the food source that appears elsewhere in the ingredient list appears as part of the name of an ingredient that is not a major food allergen) [section 403(w)(1)(B) of the Act, 21 U.S.C. § 343(w)(1)(B)].\n\n10. Your Dr. Bob’s Naturals Ginkgo Magic, Dr. Bob’s Naturals NootriTonic ULTRA, and The Raw Food World Sleep Deep Powder are each misbranded withing the meaning of section 403(r)(6) [21 U.S.C. § 343(r)(6)] in that the products make structure function claims but fail to bear the required dietary supplement disclaimer in accordance with 21 CFR 101.93(b).\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nWe also have the following comments:\n\n1. You may confirm the identity of other components (that are not dietary ingredients) by relying on a certificate of analysis from the supplier of the component that you receive provided that you:\n\n• First establish component specifications, as required by 21 CFR 111.70(b).\n\n• Meet the requirements of 21 CFR 111.75(a)(2)(ii).\n\nYour Dr. Bob’s Naturals NootriTonic ULTRA product label declares “stevia’ in the Ingredient list. If you are using highly purified steviol glycosides obtained from stevia leaves in your product, please note that “stevia” refers to the botanical and is not the common or usual name of these highly purified ingredients. Rather, the common or usual name for highly purified steviol glycosides depends on the ingredient composition. If the sweetener is purified to contain 95 percent or more of a single steviol glycoside, the specific name of that single steviol glycoside is the common or usual name. For example, the name “rebaudioside A” should be used for ingredients with 95% or more rebaudioside A; the name “stevioside” should be used for ingredients with 95% or more stevioside. If the sweetener is purified to contain 95 percent or more of a mixture of two or more steviol glycosides, the name “steviol glycosides” would be the common or usual name.\n\n2. Your Raw Food World Sleep Deep Powder product displays text in pinyin; pinyin is considered a foreign language. A product is misbranded if the product label contains information in two languages but does not repeat all the required label information (including the nutrition information) in both languages. [section 403(f) of the Act [21 U.S.C. § 343(f)] and 21 CFR 101.15(c)].\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to do so may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour reply should be addressed to the U.S. Food and Drug Administration; Attn: Lauren Crivellone, Compliance Officer, via email at ORAHAFEAST6FirmResponses@fda.hhs.gov or at 550 W. Jackson Blvd, Chicago, IL 60661. You may reach Ms. Crivellone at 312-206-5264 or via email at Lauren.Crivellone@fda.hhs.gov if you have any questions about this matter.\n\nSincerely,\n\n\u002FS\u002F\n\nLawrence Stringer\n\nActing Program Division Director\n\nOffice of Human and Animal Food\n\nOperations Division East 6","Spartan Enterprises Inc. dba Watershed Wellness Center","spartan-enterprises-inc-dba-watershed-wellness-center-642030-03082023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fspartan-enterprises-inc-dba-watershed-wellness-center-642030-03082023","2026-10-26T08:10:02.613344+00:00","2023-04-25","642030","Division of Human and Animal Food Operations East VI","Robert F. McCauley","2026-08-20T01:08:53.457+00:00","2023-03-08",{"id":368,"raw":369,"subject":373,"body_html":374,"body_text":375,"firm_name":376,"letter_id":377,"created_at":43,"fei_number":19,"letter_url":378,"updated_at":379,"action_type":22,"case_status":23,"posted_date":380,"marcs_cms_no":381,"product_type":26,"closeout_date":19,"issuing_office":139,"recipient_name":382,"body_fetched_at":383,"delivery_method":175,"recipient_title":19,"reference_number":19,"action_taken_date":384,"medical_device_id":19,"response_letter_date":19},1716,[370,371,372,139,373,13,13,13],"\u003Ctime datetime=\"2023-12-05T14:20:00Z\">12\u002F05\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-09-28T04:00:00Z\">09\u002F28\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgchnc-llc-dba-hemp-xrgate-city-hemp-dba-hemp-xrallaziya-enterprises-llc-dba-hemp-xr-656057-09282023\">GCHNC LLC dba Hemp XR\u002FGate City Hemp dba Hemp XR\u002FAllaziya Enterprises, LLC dba Hemp XR\u003C\u002Fa>","Premarket Approval\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Overnight Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Alaa Odeh Mahmoud Hamed and Abdulraouf B. Allamandani\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Registered Agents\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>GCHNC LLC dba Hemp XR\u002FGate City Hemp dba Hemp XR\u002FAllaziya Enterprises, LLC dba Hemp XR\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2138-B Lawndale Dr.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Greensboro\u003C\u002Fspan>, \u003Cspan>NC\u003C\u002Fspan> \u003Cspan>27408\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:hempxr@gmail.com\"> hempxr@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition (CFSAN)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>September 28, 2023\u003C\u002Fp>\n\n\u003Cp>3741 Battleground Ave Ste C\u003Cbr>\nGreensboro, NC 27410\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>RE: # 656057\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Alaa Odeh Mahmoud Hamed and Abdulraouf B. Allamandani:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fhemp-xr.com\u002F in September 2023 and has determined that you take orders there for various products, which you represent as containing Delta-8 tetrahydrocannabinol (THC) or cannabidiol (CBD).\u003C\u002Fp>\n\n\u003Cp>FDA has determined that your Far Out Candy 500MG Delta 8 Cookies, Not Ya Son’s Weed Bakedies Delta 8 THC 600MG Crispy Bites, Hemp XR Delta 8 Stoner Candy Gummies (including Crawlers, Fruit Smashers, Magic Marbles, and Stoney Headz Sour), Lava Rocks 250 MG Delta 8, Delta 8 Rainbow Rope, Pharma Delta 8 Gummies, Hemp XR Delta 8 Honey 500 MG, and Hemp XR CBD Honey 500 MG products are adulterated under section 402(a)(2)(C)(i) of the Federal Food, Drug, and Cosmetic Act (the FD&amp;C Act), 21 U.S.C. 342(a)(2)(C)(i), because they bear or contain an unsafe food additive. It is a prohibited act to introduce adulterated food into interstate commerce under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a). Furthermore, it is a prohibited act to introduce your Hemp XR CBD Honey 500 MG product into interstate commerce under section 301(ll) of the FD&amp;C Act, 21 U.S.C. 331(ll).\u003C\u002Fp>\n\n\u003Cp>As explained further below, introducing or delivering these products for introduction into interstate commerce violates the FD&amp;C Act. You can find the FD&amp;C Act and FDA regulations through links on FDA’s home page at www.fda.gov. You can find specific information about how FDA regulates cannabis-derived products at https:\u002F\u002Fwww.fda.gov\u002Fnews-events\u002Fpublic-health-focus\u002Ffda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd.\u003C\u002Fp>\n\n\u003Cp>Over the past several years, FDA has warned the public on various illegally marketed CBD-containing products. FDA has also observed a proliferation of products containing another cannabinoid, Delta-8 THC, and has recently expressed serious concerns about products containing Delta-8 THC that include: 1) Delta-8 THC products have not been evaluated or approved by FDA for safe use and may be marketed in ways that put the public health at risk; 2) FDA has received adverse event reports involving Delta-8 THC containing products; 3) Delta-8 THC has psychoactive and intoxicating effects; 4) FDA is concerned about the processes used to create the concentrations of Delta-8 THC claimed in the marketplace; and 5) FDA is concerned about Delta-8 THC products that may be consumed by children, as some packaging and labeling may appeal to children. See https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fconsumer-updates\u002F5-things-know-about-delta-8-tetrahydrocannabinol-delta-8-thc. This letter is to inform you that your firm markets Delta-8 THC-containing products that may pose a serious health risk to consumers.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulterated Human Foods\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>According to your product labeling, your Far Out Candy 500MG Delta 8 Cookies, Not Ya Son’s Weed Bakedies Delta 8 THC 600MG Crispy Bites, Hemp XR Delta 8 Stoner Candy Gummies (including Crawlers, Fruit Smashers, Magic Marbles, and Stoney Headz Sour), Lava Rocks 250 MG Delta 8, Delta 8 Rainbow Rope, Pharma Delta 8 Gummies, and Hemp XR Delta 8 Honey 500 MG products are foods to which Delta-8 THC has been added.\u003C\u002Fp>\n\n\u003Cp>As defined in section 201(s) of the FD&amp;C Act, 21 U.S.C. 321(s), the term \"food additive\" refers to any substance the intended use of which results in its becoming a component of any food, unless the substance is generally recognized as safe (GRAS) among qualified experts under the conditions of its intended use, or unless the substance meets a listed exception.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Food additives require premarket approval based on data demonstrating safety. Any food additive that has not been approved for its intended use in food is deemed to be unsafe under section 409(a) of the FD&amp;C Act, 21 U.S.C. 348(a), and causes the food to be adulterated under section 402(a)(2)(C)(i) of the FD&amp;C Act, 21 U.S.C. 342(a)(2)(C)(i). Introduction of an adulterated food into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>There is no food additive regulation that authorizes the use of Delta-8 THC. We are not aware of any information to indicate that Delta-8 THC is the subject of a prior sanction (see 21 CFR Part 181). Furthermore, we are not aware of any basis to conclude that Delta-8 THC is GRAS for use in conventional foods. FDA's regulations in 21 CFR 170.30(a)-(c) describe the criteria for eligibility for classification of a food ingredient as GRAS. The use of a food substance may be GRAS based on either scientific procedures or, for a substance used in food before 1958, through experience based on common use in food (see 21 CFR 170.30).\u003C\u002Fp>\n\n\u003Cp>We know of no basis for general recognition of safety for Delta-8 THC based either on scientific procedures or common use in food prior to January 1, 1958. Based on our review of published, scientific literature, existing data and information do not provide an adequate basis to conclude that the use of Delta-8 THC in food meets the criteria for GRAS status. Some of the available data raise serious concerns about potential harm from Delta-8 THC. Our review of published scientific literature identified potential for adverse effects on the central nervous and cardiopulmonary systems. In addition, studies in animals have suggested that gestational exposure to Delta-8 THC can interfere with neurodevelopment. Therefore, based on our review, the use of Delta-8 THC in your products does not satisfy the criteria for GRAS status under 21 CFR 170.30.\u003C\u002Fp>\n\n\u003Cp>FDA is not aware of any other exception to the food additive definition that would apply to Delta-8 THC for use as an ingredient in a conventional food. Therefore, Delta-8 THC added to a conventional food is a food additive under section 201(s) of the FD&amp;C Act and is subject to the provisions of section 409 of the FD&amp;C Act. Under section 409, a food additive is deemed unsafe unless it is approved by FDA for its intended use prior to marketing. Delta-8 THC is not approved for use in any conventional food. Food containing an unsafe food additive within the meaning of section 409 is adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&amp;C Act. Therefore, your Far Out Candy 500MG Delta 8 Cookies, Not Ya Son’s Weed Bakedies Delta 8 THC 600MG Crispy Bites, Hemp XR Delta 8 Stoner Candy Gummies (including Crawlers, Fruit Smashers, Magic Marbles, and Stoney Headz Sour), Lava Rocks 250 MG Delta 8, Delta 8 Rainbow Rope, Pharma Delta 8 Gummies, and Hemp XR Delta 8 Honey 500 MG are adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&amp;C Act because they bear or contain an unsafe food additive. Introduction of these adulterated foods into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>Furthermore, according to your product labeling, your Hemp XR CBD Honey 500 MG is a food to which CBD has been added.\u003C\u002Fp>\n\n\u003Cp>There is no food additive regulation which authorizes the use of CBD. We are not aware of any information to indicate that CBD is the subject of a prior sanction (see 21 CFR Part 181). Furthermore, we are not aware of any basis to conclude that CBD is GRAS for use in conventional foods. FDA's regulations in 21 CFR 170.30(a)-(c) describe the criteria for eligibility for classification of a food ingredient as GRAS. The use of a food substance may be GRAS based on either scientific procedures or, for a substance used in food before 1958, through experience based on common use in food (see 21 CFR 170.30).\u003C\u002Fp>\n\n\u003Cp>We know of no basis for general recognition of safety for CBD based either on scientific procedures or common use in food prior to January 1, 1958. Based on our review of published, scientific literature, existing data and information do not provide an adequate basis to conclude that the use of CBD in food meets the criteria for GRAS status. Some of the available data raise serious concerns about potential harm from CBD. Our review of publicly available data associated with the one FDA-approved CBD drug, as well as our review of published scientific literature, identified potential for liver injury from CBD and potentially harmful interactions with certain drugs. In addition, studies in animals have shown that CBD can interfere with the development and function of testes and sperm, decrease testosterone levels, and impair sexual behavior in males. Therefore, based on our review, the use of CBD in your products does not satisfy the criteria for GRAS status under 21 CFR 170.30.\u003C\u002Fp>\n\n\u003Cp>FDA is not aware of any other exception to the food additive definition that would apply to CBD for use as an ingredient in a conventional food. Therefore, CBD added to a conventional food is a food additive under section 201(s) of the FD&amp;C Act and is subject to the provisions of section 409 of the FD&amp;C Act. Under section 409, a food additive is deemed unsafe unless it is approved by FDA for its intended use prior to marketing. CBD is not approved for use in any conventional food. Food containing an unsafe food additive within the meaning of section 409 is adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&amp;C Act. Therefore, your Hemp XR CBD Honey 500 MG product is adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&amp;C Act because it bears or contains an unsafe food additive. Introduction of this adulterated food into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>In addition, it is a prohibited act under section 301(ll) of the FD&amp;C Act, 21 U.S.C. 331(ll), to introduce or deliver for introduction into interstate commerce any food, including animal food, to which has been added a drug approved under section 505 of the FD&amp;C Act or for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public. Based on available evidence, FDA has concluded that the prohibition in section 301(ll) applies to CBD.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> There is an exception if the substance was marketed in food before the drug was approved or before the substantial clinical investigations involving the drug had been instituted. However, based on the available evidence, FDA has concluded that this is not the case for CBD. FDA is not aware of any evidence that would call into question its current conclusion that section 301(ll) of the FD&amp;C Act, 21 U.S.C. 331(ll), prohibits the introduction into interstate commerce of any food to which CBD has been added, but you may present FDA with any evidence bearing on this issue.\u003C\u002Fp>\n\n\u003Cp>As stated above, according to your product labeling, your Hemp XR CBD Honey 500 MG product is a food to which CBD has been added. Therefore, the introduction or delivery for introduction into interstate commerce of this product is a prohibited act under section 301(ll) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to the United States Food and Drug Administration at CFSANResponse@fda.hhs.gov. Please include “CMS 656057” in the subject line of your email.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann M. Oxenham, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Food Safety and Applied Nutrition\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>\u003Csup>\u003Cem>\u003Cstrong>___________________\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Under section 201(s) of the FD&amp;C Act (21 U.S.C. 321(s)), the following types of substances are excluded from the food additive definition: (1) pesticide chemical residues in or on a raw agricultural commodity or processed food, (2) pesticide chemicals, (3) color additives, (4) substances used in accordance with a “prior sanction” (i.e., a sanction or approval granted prior to the enactment of the Food Additives Amendment of 1958 under the FD&amp;C Act, the Poultry Products Inspection Act, or the Meat Inspection Act), (5) new animal drugs, and (6) dietary ingredients in or intended for use in a dietary supplement.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> CBD is the active ingredient in the approved drug product Epidiolex. Furthermore, the existence of substantial clinical investigations regarding CBD has been made public. For example, two such substantial clinical investigations include GW Pharmaceuticals’ investigations regarding Sativex and Epidiolex. (See GW Pharmaceuticals Receives Investigational New Drug (IND) from FDA for Phase 2\u002F3 Clinical Trial of Epidiolex in the Treatment of Dravet Syndrome). FDA considers a substance to be “authorized for investigation as a new drug” if it is the subject of an Investigational New Drug application (IND) that has gone into effect. Under 21 CFR 312.2, unless a clinical investigation meets the limited criteria in that regulation, an IND is required for all clinical investigations of products that are subject to section 505 of the FD&amp;C Act.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Overnight Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nAlaa Odeh Mahmoud Hamed and Abdulraouf B. Allamandani\n\nRecipient Title\n\nRegistered Agents\n\nGCHNC LLC dba Hemp XR\u002FGate City Hemp dba Hemp XR\u002FAllaziya Enterprises, LLC dba Hemp XR\n\n2138-B Lawndale Dr.\n\nGreensboro, NC 27408\n\nUnited States\n\nhempxr@gmail.com\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition (CFSAN)\n\nUnited States\n\nWARNING LETTER\n\nSeptember 28, 2023\n\n3741 Battleground Ave Ste C\n\nGreensboro, NC 27410\n\nRE: # 656057\n\nDear Alaa Odeh Mahmoud Hamed and Abdulraouf B. Allamandani:\n\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fhemp-xr.com\u002F in September 2023 and has determined that you take orders there for various products, which you represent as containing Delta-8 tetrahydrocannabinol (THC) or cannabidiol (CBD).\n\nFDA has determined that your Far Out Candy 500MG Delta 8 Cookies, Not Ya Son’s Weed Bakedies Delta 8 THC 600MG Crispy Bites, Hemp XR Delta 8 Stoner Candy Gummies (including Crawlers, Fruit Smashers, Magic Marbles, and Stoney Headz Sour), Lava Rocks 250 MG Delta 8, Delta 8 Rainbow Rope, Pharma Delta 8 Gummies, Hemp XR Delta 8 Honey 500 MG, and Hemp XR CBD Honey 500 MG products are adulterated under section 402(a)(2)(C)(i) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act), 21 U.S.C. 342(a)(2)(C)(i), because they bear or contain an unsafe food additive. It is a prohibited act to introduce adulterated food into interstate commerce under section 301(a) of the FD&C Act, 21 U.S.C. 331(a). Furthermore, it is a prohibited act to introduce your Hemp XR CBD Honey 500 MG product into interstate commerce under section 301(ll) of the FD&C Act, 21 U.S.C. 331(ll).\n\nAs explained further below, introducing or delivering these products for introduction into interstate commerce violates the FD&C Act. You can find the FD&C Act and FDA regulations through links on FDA’s home page at www.fda.gov. You can find specific information about how FDA regulates cannabis-derived products at https:\u002F\u002Fwww.fda.gov\u002Fnews-events\u002Fpublic-health-focus\u002Ffda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd.\n\nOver the past several years, FDA has warned the public on various illegally marketed CBD-containing products. FDA has also observed a proliferation of products containing another cannabinoid, Delta-8 THC, and has recently expressed serious concerns about products containing Delta-8 THC that include: 1) Delta-8 THC products have not been evaluated or approved by FDA for safe use and may be marketed in ways that put the public health at risk; 2) FDA has received adverse event reports involving Delta-8 THC containing products; 3) Delta-8 THC has psychoactive and intoxicating effects; 4) FDA is concerned about the processes used to create the concentrations of Delta-8 THC claimed in the marketplace; and 5) FDA is concerned about Delta-8 THC products that may be consumed by children, as some packaging and labeling may appeal to children. See https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fconsumer-updates\u002F5-things-know-about-delta-8-tetrahydrocannabinol-delta-8-thc. This letter is to inform you that your firm markets Delta-8 THC-containing products that may pose a serious health risk to consumers.\n\nAdulterated Human Foods\n\nAccording to your product labeling, your Far Out Candy 500MG Delta 8 Cookies, Not Ya Son’s Weed Bakedies Delta 8 THC 600MG Crispy Bites, Hemp XR Delta 8 Stoner Candy Gummies (including Crawlers, Fruit Smashers, Magic Marbles, and Stoney Headz Sour), Lava Rocks 250 MG Delta 8, Delta 8 Rainbow Rope, Pharma Delta 8 Gummies, and Hemp XR Delta 8 Honey 500 MG products are foods to which Delta-8 THC has been added.\n\nAs defined in section 201(s) of the FD&C Act, 21 U.S.C. 321(s), the term \"food additive\" refers to any substance the intended use of which results in its becoming a component of any food, unless the substance is generally recognized as safe (GRAS) among qualified experts under the conditions of its intended use, or unless the substance meets a listed exception.1\n\nFood additives require premarket approval based on data demonstrating safety. Any food additive that has not been approved for its intended use in food is deemed to be unsafe under section 409(a) of the FD&C Act, 21 U.S.C. 348(a), and causes the food to be adulterated under section 402(a)(2)(C)(i) of the FD&C Act, 21 U.S.C. 342(a)(2)(C)(i). Introduction of an adulterated food into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nThere is no food additive regulation that authorizes the use of Delta-8 THC. We are not aware of any information to indicate that Delta-8 THC is the subject of a prior sanction (see 21 CFR Part 181). Furthermore, we are not aware of any basis to conclude that Delta-8 THC is GRAS for use in conventional foods. FDA's regulations in 21 CFR 170.30(a)-(c) describe the criteria for eligibility for classification of a food ingredient as GRAS. The use of a food substance may be GRAS based on either scientific procedures or, for a substance used in food before 1958, through experience based on common use in food (see 21 CFR 170.30).\n\nWe know of no basis for general recognition of safety for Delta-8 THC based either on scientific procedures or common use in food prior to January 1, 1958. Based on our review of published, scientific literature, existing data and information do not provide an adequate basis to conclude that the use of Delta-8 THC in food meets the criteria for GRAS status. Some of the available data raise serious concerns about potential harm from Delta-8 THC. Our review of published scientific literature identified potential for adverse effects on the central nervous and cardiopulmonary systems. In addition, studies in animals have suggested that gestational exposure to Delta-8 THC can interfere with neurodevelopment. Therefore, based on our review, the use of Delta-8 THC in your products does not satisfy the criteria for GRAS status under 21 CFR 170.30.\n\nFDA is not aware of any other exception to the food additive definition that would apply to Delta-8 THC for use as an ingredient in a conventional food. Therefore, Delta-8 THC added to a conventional food is a food additive under section 201(s) of the FD&C Act and is subject to the provisions of section 409 of the FD&C Act. Under section 409, a food additive is deemed unsafe unless it is approved by FDA for its intended use prior to marketing. Delta-8 THC is not approved for use in any conventional food. Food containing an unsafe food additive within the meaning of section 409 is adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&C Act. Therefore, your Far Out Candy 500MG Delta 8 Cookies, Not Ya Son’s Weed Bakedies Delta 8 THC 600MG Crispy Bites, Hemp XR Delta 8 Stoner Candy Gummies (including Crawlers, Fruit Smashers, Magic Marbles, and Stoney Headz Sour), Lava Rocks 250 MG Delta 8, Delta 8 Rainbow Rope, Pharma Delta 8 Gummies, and Hemp XR Delta 8 Honey 500 MG are adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&C Act because they bear or contain an unsafe food additive. Introduction of these adulterated foods into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nFurthermore, according to your product labeling, your Hemp XR CBD Honey 500 MG is a food to which CBD has been added.\n\nThere is no food additive regulation which authorizes the use of CBD. We are not aware of any information to indicate that CBD is the subject of a prior sanction (see 21 CFR Part 181). Furthermore, we are not aware of any basis to conclude that CBD is GRAS for use in conventional foods. FDA's regulations in 21 CFR 170.30(a)-(c) describe the criteria for eligibility for classification of a food ingredient as GRAS. The use of a food substance may be GRAS based on either scientific procedures or, for a substance used in food before 1958, through experience based on common use in food (see 21 CFR 170.30).\n\nWe know of no basis for general recognition of safety for CBD based either on scientific procedures or common use in food prior to January 1, 1958. Based on our review of published, scientific literature, existing data and information do not provide an adequate basis to conclude that the use of CBD in food meets the criteria for GRAS status. Some of the available data raise serious concerns about potential harm from CBD. Our review of publicly available data associated with the one FDA-approved CBD drug, as well as our review of published scientific literature, identified potential for liver injury from CBD and potentially harmful interactions with certain drugs. In addition, studies in animals have shown that CBD can interfere with the development and function of testes and sperm, decrease testosterone levels, and impair sexual behavior in males. Therefore, based on our review, the use of CBD in your products does not satisfy the criteria for GRAS status under 21 CFR 170.30.\n\nFDA is not aware of any other exception to the food additive definition that would apply to CBD for use as an ingredient in a conventional food. Therefore, CBD added to a conventional food is a food additive under section 201(s) of the FD&C Act and is subject to the provisions of section 409 of the FD&C Act. Under section 409, a food additive is deemed unsafe unless it is approved by FDA for its intended use prior to marketing. CBD is not approved for use in any conventional food. Food containing an unsafe food additive within the meaning of section 409 is adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&C Act. Therefore, your Hemp XR CBD Honey 500 MG product is adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&C Act because it bears or contains an unsafe food additive. Introduction of this adulterated food into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nIn addition, it is a prohibited act under section 301(ll) of the FD&C Act, 21 U.S.C. 331(ll), to introduce or deliver for introduction into interstate commerce any food, including animal food, to which has been added a drug approved under section 505 of the FD&C Act or for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public. Based on available evidence, FDA has concluded that the prohibition in section 301(ll) applies to CBD.2 There is an exception if the substance was marketed in food before the drug was approved or before the substantial clinical investigations involving the drug had been instituted. However, based on the available evidence, FDA has concluded that this is not the case for CBD. FDA is not aware of any evidence that would call into question its current conclusion that section 301(ll) of the FD&C Act, 21 U.S.C. 331(ll), prohibits the introduction into interstate commerce of any food to which CBD has been added, but you may present FDA with any evidence bearing on this issue.\n\nAs stated above, according to your product labeling, your Hemp XR CBD Honey 500 MG product is a food to which CBD has been added. Therefore, the introduction or delivery for introduction into interstate commerce of this product is a prohibited act under section 301(ll) of the FD&C Act.\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nYour response should be sent to the United States Food and Drug Administration at CFSANResponse@fda.hhs.gov. Please include “CMS 656057” in the subject line of your email.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn M. Oxenham, J.D.\n\nDirector\n\nOffice of Compliance\n\nCenter for Food Safety and Applied Nutrition\n\nFood and Drug Administration\n\n___________________\n\n1 Under section 201(s) of the FD&C Act (21 U.S.C. 321(s)), the following types of substances are excluded from the food additive definition: (1) pesticide chemical residues in or on a raw agricultural commodity or processed food, (2) pesticide chemicals, (3) color additives, (4) substances used in accordance with a “prior sanction” (i.e., a sanction or approval granted prior to the enactment of the Food Additives Amendment of 1958 under the FD&C Act, the Poultry Products Inspection Act, or the Meat Inspection Act), (5) new animal drugs, and (6) dietary ingredients in or intended for use in a dietary supplement.\n\n2 CBD is the active ingredient in the approved drug product Epidiolex. Furthermore, the existence of substantial clinical investigations regarding CBD has been made public. For example, two such substantial clinical investigations include GW Pharmaceuticals’ investigations regarding Sativex and Epidiolex. (See GW Pharmaceuticals Receives Investigational New Drug (IND) from FDA for Phase 2\u002F3 Clinical Trial of Epidiolex in the Treatment of Dravet Syndrome). FDA considers a substance to be “authorized for investigation as a new drug” if it is the subject of an Investigational New Drug application (IND) that has gone into effect. Under 21 CFR 312.2, unless a clinical investigation meets the limited criteria in that regulation, an IND is required for all clinical investigations of products that are subject to section 505 of the FD&C Act.","GCHNC LLC dba Hemp XR\u002FGate City Hemp dba Hemp XR\u002FAllaziya Enterprises, LLC dba Hemp XR","gchnc-llc-dba-hemp-xrgate-city-hemp-dba-hemp-xrallaziya-enterprises-llc-dba-hemp-xr-656057-09282023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgchnc-llc-dba-hemp-xrgate-city-hemp-dba-hemp-xrallaziya-enterprises-llc-dba-hemp-xr-656057-09282023","2026-10-26T08:08:44.869428+00:00","2023-12-05","656057","Alaa Odeh Mahmoud Hamed and Abdulraouf B. Allamandani","2026-08-20T00:28:28.105+00:00","2023-09-28",19,{"510k":387,"classification":388,"enforcement":389,"event":390,"event_backfill":391,"pma":392,"warning_letter":393},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]